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            Selective inhibition of the human A3 adenosine receptor (hA3AR) by potent 
antagonists has been shown to be useful pharmacologically in the treatment of several 
pathological conditions, including glaucoma, inflammatory diseases and cancer. Among 
the heterocyclic structures identified as potent hA3AR antagonists, the pyrazolo[4,3-e]-
1,2,4-triazolo-[1,5-c]pyrimidine (PTP) tricyclic scaffold has demonstrated good affinity 
towards the hA3 receptor subtype with a broad range of selectivity profile. In this project, 
a new series of [2(para-(un)substituted)-phenyl]-pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-
c]pyrimidines (40-90) bearing an aryl group in replacement of the C
2
-furyl ring, together 




-positions, was rationally designed and 





-positions of PTP, in conjunction with a different aromatic moiety other 
than furan ring at C
2
-position on the affinity at hA3 adenosine receptor and selectivity 
over other adenosine receptor subtypes (hA1, hA2A, hA2B).             
           Based on the binding affinity results, the new series of 2-aryl-8-ar(alkyl)-PTPs 
bearing the N
5
-amino, (bis)benzamide and phenylacetamide (40-47, 49-51, 53-78) not 
only showed good hA3 affinity profile (up to 15-fold increment), but also remarkably 
enhanced the selectivity (of about 2-3 order of magnitude) against other adenosine 
receptor subtypes relative to the 2-furyl-PTP counterparts. In addition to the structural 
benefit on hA3 affinity and selectivity, such bioisosteric replacement with 2-aryl rings 
could also pharmacokinetically overcome the metabolic transformation of the existing 2-





arylcarbamide (79-90) were also synthesized and evaluated pharmacologically, in order 
to explicitly examine the significance of the arylcarbamoyl chain at the N
5
-position that 
had been previously reported to be crucial towards the hA3 affinity. In spite of the good 
hA3 affinity of compounds in the range of 1.3 to 5.9 nM, the concurrent bioisosteric 
replacement of existing 2-furyl ring with a 2-aryl ring and incorporation of a N
5
-
arylcarbamoyl chain has resulted in significant decrease (7 to 37-fold) of hA3 affinity 
relative to the 2-furyl analogues. Nevertheless, the selectivity over other adenosine 
receptor subtypes of such 2-aryl-PTP derivatives was still found to be greatly improved.  
            Generally, all the synthesized [2-(para-(un)substituted)phenyl]-pyrazolo[4,3-e]-
1,2,4-triazolo-[1,5-c]pyrimidine derivatives possessed hA3 affinity in the low nanomolar 
range. In particular, the most potent derivative of the series presented improved hA3 
affinity and selectivity profile (compound 69, KihA3 = 0.108 nM; hA1/hA3 = 5,204; 
hA2A/hA3 = 7,204) in comparison to its C
2
-furyl counterpart (compound 154, KihA3= 0.81 
nM; hA1/hA3 = 867; hA2A/hA3 = 522). Besides that, compound 73 represented the new 2-
aryl-PTP derivative that possessed the best combined hA3 affinity and selectivity profile 
in the series, with Ki hA3 = 0.241 nM; hA1/hA3 > 124,000; and hA2A/hA3 > 415,000. 
Additional adenylyl cyclase activity assays, aimed to determine the effect on the hA3 
agonist-inhibited cyclic adenosine monophosphate (cAMP) production, were also 
conducted for some selected compounds. The results from such functional assays further 
confirmed that these 2-aryl-PTPs were functional antagonists and their hA3 potencies 
correlated well with the hA3 affinities from binding assays.  
            Apart from the pharmacological evaluations, molecular modeling investigations 
were also performed on the newly synthesized 2-aryl-PTPs in order to further rationalize 
xv 
 
the experimental hA3 affinity and selectivity profiles of such derivatives. Through 
CoMFA (Comparative Molecular Field Analysis)-based QSAR (quantitative structure-






-positions of the 
tricyclic nucleus were investigated to quantitatively distinguish the essential structural 
basis of the PTP derivatives for recognition at the hA3AR, with emphasis given to the 
unprecedentedly explored C
2
-position. The resulting CoMFA model demonstrated good 
correlation and predictability (r
2
 = 0.935; q
2
 = 0.707; r
2
pred = 0.690). From the model, it 
was found that the steric effects (rather than electrostatic effects) were relatively more 
predominant for the optimal interaction of these antagonists with the hA3 receptor.  
            Subsequently, molecular docking simulations were also conducted on the new 2-
aryl-PTPs to depict new insights on the hypothetical binding modes and interactions of 
such derivatives. The docking studies were based on a newly constructed hA3 homology 
model, which was built as ‘hybrid’ between the human A2A adenosine receptor and the 





and 2-aryl ring, as well as electron acceptor at N
5
-amide group were deemed crucial for 
hA3 affinity. Other interactions including π-π stacking and van der Waals interactions 
were also observed between the ligands and the residues. Residues Val169 and Tyr265 
especially were speculated to play an important role on the hA3 affinity, suggesting that a 
site-directed mutagenesis study for these residues could disclose interesting insights on 
the hA3AR’s binding site. Additionally, the binding modes and interactions of some 2-
aryl-PTP derivatives and the corresponding 2-furyl-PTP analogues in the hA2A receptors 
were also examined. It was deduced that the loss of H-bonding as well as steric hindrance 
imposed by the 2-aryl ring within the small binding pocket surrounded by TM2 and TM3 
xvi 
 
could account for the decrease in hA2A affinity and subsequent increase of selectivity 
against this particular receptor subtype as observed for the new 2-aryl-PTPs. 
            In summary, the rational design and synthesis of this new series of 2-[(para-
(un)substituted)-phenyl]-pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidines has given rise 
to a class of potent and highly selective hA3AR antagonists. The integration of 
experimental and theoretical methods employed in our study provides a useful approach 
for the better understanding of important structural features and binding interactions 
responsible for hA3 affinity in the new series of 2-aryl-PTP derivatives, which will be 
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hA3 model-ligand complex for compound (A) 56; (B) 60; (C) 69; (D) 25 and (E) 70. hA3 
‘hybrid’ model is coloured blue and hA2AAR-based hA3 model is coloured red. Ligands 
docked in hA3 ‘hybrid’ model and hA2AAR-based hA3 model are both coloured light blue 
and pink, respectively. RMSD values for each pair of hA3 models are shown on top of 
each subfigure. 
Figure 22. General topology of the hA3 ‘hybrid’ homology model. Compounds 40 
(yellow), 60 (cyan) and 69 (magenta) are docked inside the transmembrane recognition 
site. TM7 is omitted for ease of viewing.  
Figure 23. Hypothetical binding interactions of (A) compound 155 and (B) compound 40 
within the binding cavity of hA3 ‘hybrid’ homology model. Side chains of some amino 
acids important for ligand recognition are highlighted. Non-polar hydrogen atoms are not 
displayed. Hydrogen bond is represented in dashed line. 
Figure 24. Hypothetical binding interactions of (A) compound 25 and (B) compound 69 
within the binding cavity of hA3 ‘hybrid’ homology model. Side chains of some amino 
acids important for ligand recognition are highlighted. Non-polar hydrogen atoms are not 
displayed. Hydrogen bond is represented in dashed line.  
Figure 25. Hypothetical binding interactions of compound 60 within the binding cavity 
of hA3 ‘hybrid’ homology model. Side chains of some amino acids important for ligand 
recognition are highlighted. Non-polar hydrogen atoms are not displayed. Hydrogen bond 
is represented in dashed line.  
Figure 26. Hypothetical binding interactions of new series of 2-aryl-PTPs 40-47, 49-51, 
53-61, 64-74 with respective residues in hA3 ‘hybrid’ homology model.  
Figure 27. (A) Binding pose of compound 87 inside the binding cavity of hA3 ‘hybrid’ 
homology model. TM7 is omitted for ease of viewing. Hypothetical binding interactions 
of (B) compound 158 and (C) compound 87 within the binding cavity of hA3 ‘hybrid’ 
homology model. Side chains of some amino acids important for ligand recognition are 
highlighted. Non-polar hydrogen atoms are not displayed. Possible hydrogen bonds are 
represented in dashed lines. 
Figure 28. Hypothetical binding interactions of new series of 2-aryl-PTPs 79-90 with 
respective residues in hA3 ‘hybrid’ homology model.  
Figure 29. (A) Binding pose of compound 75 inside the binding cavity of hA3 ‘hybrid’ 
homology model. TM7 is omitted for ease of viewing. Hypothetical binding interactions 
of (B) compound 157 and (C) compound 75 within the binding cavity of hA3 ‘hybrid’ 
homology model. Side chains of some amino acids important for ligand recognition are 
highlighted. Non-polar hydrogen atoms are not displayed. Hydrogen bond is represented 
in dashed line. 
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Figure 30. Hypothetical binding interactions of new series of 2-aryl-PTPs 75-78 with 
respective residues in hA3 ‘hybrid’ homology model.  
Figure 31. (A) Binding poses of compound 155 (purple) and 40 (yellow) inside the 
binding cavity of hA2A receptor. TM7 is omitted for ease of viewing. Hypothetical 
binding interactions of (B) compound 155 and (C) compound 40 within the binding 
cavity of hA2A receptor. Side chains of some amino acids important for ligand 
recognition are highlighted. Non-polar hydrogen atoms are not displayed. Hydrogen bond 
is represented in dashed line. 
Figure 32. (A) Binding poses of compound 25 (orange) and 69 (magenta) inside the 
binding cavity of hA2A receptor. TM7 is omitted for ease of viewing. Hypothetical 
binding interactions of (B) compound 25 and (C) compound 69 within the binding cavity 
of hA2A receptor. Side chains of some amino acids important for ligand recognition are 
highlighted. Non-polar hydrogen atoms are not displayed. Hydrogen bond is represented 
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Chapter 1 General Introduction 
 
The information contained in this chapter has been collated in the following review 
articles:  
 Cheong, S. L.; Federico, S.; Venkatesan, G.; Moro, S.; Spalluto, G.; Pastorin, G. 
Human A3 adenosine receptor as multifaceted therapeutic target: pharmacology, 
medicinal chemistry and in silico approach. Med. Res. Rev. 2011, In Press, 
doi:10.1002/med.20254. 
 
 Cheong, S. L.; Venkatesan, G.; Paira, P.; Jothibasu, R.; Mandel, A. L.; Federico, 
S.; Spalluto
,
 G.; Pastorin, G. Pyrazolo derivatives as potent adenosine receptor 
antagonists: An overview on the structure-activity relationships. Int. J. Med. 
Chem. 2011, In Press, doi:10.1155/2011/480652. 
 
1.1       Introduction 
            In our body, adenosine acts as an endogenous modulator that regulates many 
physiological processes through activation of specific human adenosine receptors 
(hARs). These receptors, which consist of 7 transmembrane domains, are one of the 
members of the G protein-coupled receptor (GPCR) superfamily. They can be 
categorized into four different subtypes, namely A1, A2A, A2B and A3 adenosine receptors 
(Figure 1).
1
 Each of these adenosine receptors has its own distinct tissue localization, 
biochemical pathways and pharmacological profiles.  
Among the four hAR subtypes, the hA3AR is the latest to be cloned and 
pharmacologically characterized 1. The amino acid sequence of the hA3AR is 49.5%, 
43.2% and 39.9% identical in sequence to hA1AR, hA2AAR and hA2BAR subtypes, 
respectively. 
2
 Amid various species, the hA3AR shows homology of about 74% with rat 
A3AR, whereas sheep A3AR shares closer relationship to the hA3AR with 85% of 
identical homology. 
3
 Besides that, distribution of A3AR is also noted to be species-
dependent.  In  sheep,  they  are  mostly  distributed  in  the  spleen,  while in human, the  
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Figure 1. Different receptor subtypes for endogenous adenosine and subsequent 
interaction with second messenger, the adenylyl cyclase through coupling of Gi or Gs. 
 
A3ARs are highly expressed in the lung, liver and primary cells (e.g. macrophages, 
monocytes, eosinophils) involved in inflammation. 
4, 5
 
                In terms of signaling transduction pathway  (Figure 2),  activation  of the A3ARs 
results in the (i) inhibitory G-protein (Gi protein)-mediated inhibition of adenylyl cyclase 
with following decrease in cyclic adenosine monophosphate (cAMP) level, (ii) rise in the 
Gq protein-mediated phospholipase C (PLC) activity and (iii) calcium ion mobilization. 
6, 
7
 Other secondary pathways related to A3AR have also been reported, such as (iv) ATP-
sensitive potassium channel activation (designated as KATP) in the heart, or (v) A3AR-
mediated activation of RhoA with consequent stimulation of phospholipase D (PLD) and 
Endogenous  
adenosine  














protein kinase C (PKC). Both of these signaling pathways are evidenced to play a role in 
the cardioprotective function. 
8
 On top of that, A3AR also seems to influence (vi) 
phosphoinositide 3-kinase (PI3K) or extracellular signal-regulated kinase (ERK1/2) 
activities through the activation of Ras. 
9
 The phosphoinositide 3-kinase/phospholipase B 
(PI3K/PKB) and mitogen-activated protein kinase/extracellular signal-regulated kinase 
(MEK1/ERK1/2) pathways found to be involved in cell survival, have been associated 
with A3AR-induced preconditioning in cardiomyocytes from newborn rats during 
hypoxia or reoxygenation. 
10
 
Through the above-mentioned signalling pathways, the modulation of such 
receptor is thus implicated in cardioprotective and cerebroprotective functions, as well as 
modulation of cellular growth upon its selective activation. 
11-13
 On the other hand, its 
inhibition by selective antagonists has been reported to be potentially useful in treatment 
of pathological conditions including glaucoma, inflammatory diseases and cancer. 
14, 15
 
As such, the A3ARs are deemed promising therapeutic targets that propel the research on 
the development of potential A3AR ligands targeting at this particular receptor. 
            In fact, a large number of A3 ligands i.e. agonists and antagonists have been 
investigated, and several classes of derivatives showing good A3 affinity with broad 
ranges of selectivity against other adenosine receptor subtypes have been successfully 
synthesized and tested as A3AR ligands. In the next section, pertinent therapeutic 
applications associated with the modulation of A3AR by some of the corresponding 
ligands are discussed in more details. In the context of this project, the PTP derivatives 
will also be reviewed in the subsequent sections, mainly on their structure-affinity    
relationship     (SAR)     profiles     as     potent     adenosine     receptor    antagonists,   as 











































Figure 2. Schematic representation of main biochemical pathways involved in the 
modulation of A3 adenosine receptor.  
 
well as the molecular modeling studies previously performed on such derivatives and 
homology modeling of hA3 receptor.  
 
1.2       Pharmacology and Therapeutic Potential of A3 Adenosine Receptor  
            Many selective hA3 agonist and antagonists have been synthesized and evaluated 
for their hA3 binding affinities; such ligand development has rendered characterization of 
the pharmacological role of A3 adenosine receptor relatively more feasible and effective. 
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To-date, there are increasing studies that indicate the A3 receptor could be involved in 
several pathophysiological conditions that occur especially in the central nervous and 
cardiovascular systems, as well as the inflammatory disorders and cancer. 
 
1.2.1    Role of A3 receptor in central nervous system  
Studies have shown that chronic pre-treatment with an A3AR agonist has resulted 
in remarkable neuroprotection in ischemic gerbils, 
16
 whereas the acute administration of 
the same agent determined a worsening of neuronal damage. 
17
 Some contrasting 
evidence was also observed in the astroglia, in which nanomolar concentrations of A3AR 
agonist, Cl-IB-MECA (1) (Figure 3) conferred neuroprotection, while micromolar doses 
induced cell death. 
18
 Besides that, further experiments conducted with mice deprived of 
A3AR indicated the role of this receptor not only in neuroprotection, but also in 
nociception and locomotion. 
19
 In fact, such potential neuroprotection was substantiated 
by the A3AR-mediated synthesis of neuroprotective chemokine or suppression of TNF- 
production, which implied an important role of this receptor in brain inflammation. 
20, 21
  
In addition, adenosine is also indicated to exhibit anti-convulsant properties, on 
the basis of which the ARs ligands have been extensively investigated on their potential 
role in epilepsy. 
22, 23
 In mice models, the chronic administration of A3AR agonist, IB-
MECA (2) (Figure 3) resulted in significant protection against chemically-induced 
seizures, and postepileptic mortality was remarkably reduced. 
24
 Apart from that, it was 
also observed a 10-fold upregulation of the A3AR’s mRNA in patients’ eyes with 
glaucoma versus the healthy eyes, as reported by Schlötzer-Schrehardt et al.. 
25
 Such 
observation was suggested to be due to hypoxia and oxidative stress rather than the 
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disease itself. Studies have reported that A3 agonists were able to open the chloride 
channels and increase ocular hypertension in ciliary epithelial cells, while the A3 
antagonists could reduce aqueous humor secretion and thus the intraocular pressure 
typically seen in glaucoma. 
26
 In fact, the A3AR antagonist, OT7999 (3) (Figure 3) found 
to significantly decrease the intraocular pressure in the animal model, is expected to enter 
the clinical trials soon for the treatment of glaucoma. 
27
 



































                  1                                        2                                               3 
Figure 3.  Structures of (1) A3 agonist, Cl-IB-MECA (2) A3 agonist, IB-MECA and (3) 
A3 antagonist, OT7999. 
 
1.2.2    Role of A3 receptor in cardiovascular system  
It is perceived that, when there is increased oxygen consumption (e.g. during 
exercise), adenosine is liberated and transported out of the cardiac myocytes. It then 
diffuses across
 
the interstitial space and transmits information about the status of 
cardiomyocytes
 
to arteriolar smooth muscle to effect dilatation, until condition is restored 
to normal ranges. 
28, 29
 Some studies have indicated that A3 receptor could be involved in 
ischemic preconditioning (IPC), a form of internal protective mechanism, particularly in 
early ischemia (about 5 minutes before exposure to ischemia) 
30, 31
 and late IPC (in which 
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adenosine treatment occurs 24 hours before the induction of ischemia). 
32, 33
 The 
mechanism responsible for such pre-ischemic phenomenon seems to rely on the 
activation of PKC and especially the A3-mediated opening of the KATP channels. 
34
 On 
top of that, overexpression of A3AR has also been correlated with decreased cardiac rate 
and contractility, and lower postischemic dysfunction. 
35-37
 Coherently, experimental 
studies in different species and models also indicated that activation of ARs prior to 
ischemia was associated with a cardioprotective role despite the fact that there could be 




           Interestingly, A3AR activation by the agonists, Cl-IB-MECA (1) and IB-MECA 
(2) (Figure 3), during acute myocardial ischemia and reperfusion was reported to be 
associated with cardioprotection. Such beneficial effect, which has been observed either 
prior to ischemia or during reperfusion, could be blocked by the A3 antagonists. 
38
 
Nevertheless, very few reports are available on (pre)clinical studies examining the 
beneficial effects upon administration of adenosine or in the presence of an AR agonist in 




1.2.3    A3 receptor in inflammation and related pathological conditions 
Adenosine has shown to be implicated in the pathophysiology of inflammation, 







 and mast cells. 
44
 Controversial results have been obtained 
with stimulation of A3ARs on neutrophils, ranging from pro- or anti-inflammatory effects 
via neutrophil production or blockade of degranulation and oxidative stress. 
45
 Monocytes 
and macrophages represent an abundant source of pro-inflammatory cytokines such as 
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tumor necrosis factor alpha (TNF-). Even though there is no direct effect on the A3AR-
mediated production of TNF-, 43 the activation of such receptor was shown to cause 
TNF- release via lipopolysaccharide (LPS) and Ca2+-dependent activation of nuclear 
factor kappa-B (NF-kB). 
46
 On the other hand, in some studies, the stimulation of A3AR 
on human monocytes was found to decrease synthesis of a pro-inflammatory cytokine, 
interlukin-12 (IL-12) usually produced in response to parasitic and bacterial infections. 
47
  
In some experiments aimed to evaluate the role of ARs in inflammatory diseases, 
for instance in asthma, it was observed that mast cells required A3AR in their 





Besides, the A3ARs density on eosinophils of patients suffering from asthmatic 
conditions was also found elevated. 
49
 On the other hand, in a rabbit model, it was 
reported that the bronchoconstriction induced by adenosine was counterbalanced by 
theophylline, which was a natural adenosine receptors’ antagonist. 50, 51 Such 
observations inferred the potential role of A3AR antagonists in the treatment of asthma. 
In fact, a dual A2BAR and A3AR antagonist developed by the pharmaceutical company 
Novartis as QAF 805 (an aminothiazole derivative), has been proposed as a successful 
antiasthmatic agent. 
52




In the case of rheumatoid arthritis, it was recently noted that TNF-α inhibition 
involved also the A3AR; 
54, 55
 in particular, the A3AR agonists were observed to provide 
protective effects via inhibition of macrophage inflammatory protein alpha (MIP-) and 
TNF- production, 56 or suppression of pro-inflammatory cytokine secretion through 
PI3K-NFkB pathway. 
57
 On top of that, A3ARs have also demonstrated a protective role 
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in vivo in lung injury following ischemia and reperfusion, 
58, 59
 most probably through 
upregulation of phosphorylated ERK 
58 




1.2.4    Significance of A3 receptor in cancer 
A3AR agonists have been indicated for their potential use in the treatment of 
cancer, which are able to induce apoptosis and tumour growth inhibition in the cancer 
cells. Such anticancer activity of an A3AR agonist is proposed to occur through both NF-
kB and Wnt signaling. 
61, 62
 The A3AR agonists, IB-MECA and Cl-IB-MECA, have been 
extensively tested to investigate their effect on the proliferation of various tumour cells. 
Interestingly such agonists, especially if co-administered with 5-fluorouracil, 
63
 were 
responsible for a cytostatic effect towards cancer cells, as shown by arrest of cell cycle at 
the G0/G1 phase. 
64, 65
 The cancer cell function was completely recuperated after 




 In in vivo 
experiments, IB-MECA and Cl-IB-MECA were found to exclusively activate A3ARs and 
inhibit the growth of primary murine melanoma tumors, 
66
 colon cancers, 
65
 or human 
prostate cancers. 
67
 In addition, these compounds showed an added value in cancer 
treatment, since they also promoted (i) chemoprotective effect (by re-establishing normal 
levels of white blood cells and neutrophil count); 
68
 (ii) natural killer cell activity; 
69
 (iii) 
up-regulation of IL-12 both in melanoma- and human-colon carcinoma-bearing mice.
 65
  
           On the contrary, Gessi and co-workers demonstrated that low concentrations (100 
nM) of Cl-IB-MECA instead favoured proliferation of cancer cells. 
70
 These results were 
substantiated by Abbracchio and collaborators, who observed an increased expression of 
Rho 
71
 and an enhanced production of anti-apoptotic protein Bcl-XL. 
72
 They suggested 
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that stimulation of A3AR by agonists might determine different effects on the basis of cell 
type and experimental conditions (e.g. concentrations). In fact, high concentrations (10-
60 µM) of the above-mentioned A3AR agonists 
73
 or cordycepin (i.e. 3’-deoxyadenosine, 
5) 
74
 (Figure 4) determined both a receptor-dependent or -independent inhibitory effect 
towards cancer cell proliferation through arrest at the G0/G1 phase. Recently, a newly 
synthesized A3AR antagonist (pyrazolo[3,4-d]pyrimidine, 6) (Figure 4) was shown to 
counteract the A3AR agonists Cl-IB-MECA- and IB-MECA-mediated proliferation of the 
glioma cells through the inhibition of A3AR agonist-mediated ERK 1/2 activation. 
75
 This 
observation was in agreement with the studies which demonstrated that ERK 1/2, p38 and 
Akt could be the phosphorylative pathways responsible for A3AR-mediated cell 
proliferation in glioblastoma. These findings implied that A3AR antagonists could 
represent promising adjuvant agents in the glioma chemotherapy. 
 























                             4                                       5                                      6  
Figure 4. Structures of (4) A3 antagonist, MRS1523 (5) cordycepin (6) A3 antagonist, 
pyrazolo[3,4-d]pyrimidine. 
 




Overexpression of A3 in several tumour cell
lines → biological markers.
• A3 Agonists promote cytostatic effect
towards cancer cells, while avoiding
neutropenia.
• Conversely, in some studies low
concentrations (100 nM) of A3 Agonists
favor proliferation of cancer cells.




• Significantly lower intraocular pressure in 
A3 knockout mice
• OT-7999 reduced intraocular pressure in
monkeys
INFLAMMATION
• A3 agonist-mediated anti- and pro-inflammatory
effects of inflammatory cells
Asthma
• A3 antagonists inhibit release of allergic
mediators in mast cells, counterbalance
bronchoconstriction, and decrease eosinophilia.
MRS 1523 prevented mucus production.
Ischemia 
• Acute administration of A3 agonists:  
- before ischemia (20’ before)
→ damage
- after ischemia    →  protection
• Chronic administration of A3 agonists: 
protection
Epilepsy
• A3 agonists provide protection against
chemically-induced seizures, postepileptic
mortality remarkably reduced
• A3 agonists cause vasoconstriction in
both the coronary and aortic vasculature
via Gi.
Ischemia
• Early IPC (5’ before) and late IPC (24hrs
before)
• A3 agonists determine cardioprotection
Reperfusion
• A3 agonists determine cardioprotection
Rheumatoid arthritis
• A3 agonists provide protection via
inhibition of MIP- and TNF- production,
or suppression of pro-inflammatory cytokine
secretion.




              On the whole, A3AR ligands are a class of therapeutically relevant agents that 
could play an important role in the neuro- and cardio-protection, as well as inflammatory 
diseases and cancer (Figure 5). Nevertheless, issues on peculiar physiological role of 
A3AR activation, which may produce effects that are species-dependent, or produce 
opposite effects depending on duration and level of activation as well as concentration of 
A3 agonist used, have not yet been satisfactorily explained. In spite of these enigmatic 
observations, some promising A3AR ligands have still thrived into the clinical trials, 
Figure 5. Therapeutic potentials of A3 adenosine receptor ligands in several 
pathophysiological conditions.  
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particularly a) adenosine itself (Adenocard), used to treat arrhythmias and 
supraventricular tachycardia; b) IB-MECA and Cl-IB-MECA (A3 agonists) in Phase II 
clinical studies for arthritis, psoriasis and liver cancer and c) OT-7999 (A3 antagonist), 
27
 
which is soon to enter clinical trials for the treatment of glaucoma. 
 
1.3      Overview on SAR Profiles of PTPs as Potent Adenosine Receptor Antagonists 
           Among several diverse structures that have demonstrated affinity at the adenosine 
receptors, our group has particularly focused on the development of compounds bearing a 
pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidine (PTP) nucleus. It represents a class of 
polyheterocyclic derivatives that has been identified as potent adenosine receptor 
antagonists, particularly towards the A2A, A2B and A3 receptor subtypes, with relatively 









-positions of the tricyclic nucleus, these differently substituted PTP derivatives 
can be selective against these different subtypes of adenosine receptors. In the following 
sections, the SAR profiles of corresponding PTP derivatives as potent A2A, A2B and A3 
adenosine receptor antagonists have been reported.  
 
1.3.1    PTPs as A2A adenosine receptor antagonists 
            The pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidine derivatives were first 
described as adenosine receptor antagonists by Gatta and co-workers, 
76
 who identified a 
compound named 8FB-PTP (7) (Figure 6), which demonstrated good binding to the A2A 
receptor but lacked selectivity towards the A1 receptor subtype. Structure-affinity 
relationship studies showed that the free amino group at N
5
-position and the effect of 
substituent on the pyrazole ring seemed important for both high affinity and selectivity 
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for the A2A receptor subtype. From further studies, substitutions at N
7
-position were 
shown to improve the selectivity for the A2A receptor, while the same substitutions at N
8
-
position increased the affinity to the A1 and A2A receptors with low levels of selectivity, 
as indicated by the N
7
-n-butyl (8) and the N
8
-n-butyl (9) derivatives. 
77, 78
 This again 
indicated that the presence of a chain (preferably a long (ar)alkyl one) at the N
7
-position 
seemed essential for both affinity and selectivity for the A2A receptors.  
            In fact, two selected compounds, named SCH 63390 (10) and SCH 58261 (11) 
proved to be the most potent and selective A2A receptor antagonists ever reported, both in 
rat and human models. 
78-80a
 The latter was further developed into an A2A antagonist 
radioligand, [
3
H]SCH 58261 (12) with a KD value of about 1 nM 
80b
.  Nevertheless, this 
class of compounds presented a significant problem because of poor water solubility. To 
overcome this drawback, several polar moieties on the side chain of the pyrazole nucleus 
have been introduced. In particular, the introduction of a hydroxyl function at the para- 
position of the phenyl ring of compounds (10) and (11) led to derivatives (5-amino-7-[3-
(4-hydroxyphenyl)propyl]-2-(2-furyl)pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine) 
(13) and (5-amino-7-[β-(4-hydroxyphenyl)ethyl]-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-
triazolo[1,5-c]pyrimidine) (14), which not only showed a better hydrophilic character but 
also a significant increase of both affinity and selectivity for the A2A receptor subtype, 
suggesting that most probably, a hydrogen bond was involved in the receptor recognition 
via this part of the ligand. 
79
  
            To understand the nature of such hypothetical hydrogen bond, compound SCH 
442416 (15) was synthesized.  This derivative showed even higher affinity and selectivity 
for  the  A2A  receptor,   thus   representing   a   suitable  candidate  for  positron  emission 
Chapter 1 General Introduction 
14 
 




















                                           7                                                                     8 
 














































                                                       
 





















                                      14                                                                  15 
Figure 6. Structures of pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidines as A2A 
adenosine receptor antagonists. 
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Figure 6 (cont.). Structures of pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidines as A2A 
adenosine receptor antagonists  
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 Moreover, it was developed into a 
novel fluorescent tracer (MRS 5346) (16), which was conjugated to a fluorescent dye 
Alexa Fluor-488. It has the KD value of 16.5 +/- 4.7 nM and could be used in the 
fluorescence polarization competition binding experiments as well as high-throughput 
screening. 
82
 On top of that, such derivative also confirmed the role of a hydrogen bond 
via the pyrazolo side chain. Nonetheless, the introduction of oxygenated groups could not 
be considered sufficient to confer water solubility. Hence, carboxylic (17) and sulfonic 
(18) moieties were introduced, and such structural modifications (the sulfonic moiety in 
particular) improved water solubility. However, in some cases, a loss of affinity with 
respect to reference compounds (13, 14) for the A2A receptor was observed. On the other 
hand, the introduction of an amino group at the para-position of the phenyl ring (19) 
improved both affinity and selectivity towards the A2A receptor, although with low water 
solubility. 
80a
 Despite these observations, it was found that the N
7
 derivative (such as 
compound 11) was totally inactive to the human A2B and A3 receptors. The N
8
 




            A recent series of pyrazolo-triazolo-pyrimidine derivatives was obtained by 
modifying the phenylethyl substituent in 11 with substituted phenylpiperazinethyl groups. 
85
 Introduction of fluorine atoms in the phenyl ring (21) enhanced the affinity up to 
subnanomolar values and the compounds displayed potent oral activity, but their 
solubility still remained poor. Further introduction of ether substituents led to derivatives 
with   high   affinity  and  selectivity  for   A2A  receptors  and  an  improvement  of  water  
solubility.  In   particular,  one  of   these   compounds  (SCH  420814,   Privadenant,  22) 
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exhibited  high  affinity   for  both  rat  and   human  A2A  receptors,   with  Ki  values  of  
2.5 and 1.1 nM, respectively. In addition, the compound was very selective for human 
A2A receptors over A1, A2B, and A3 receptors. Interestingly, the compound did not show 
significant binding against a panel of 59 unrelated receptors, enzymes, and ion channels.  
Privadenant is now in Phase II Clinical Trials for dyskinesia in Parkinson's disease. 
    
1.3.2    PTPs as A2B adenosine receptor antagonists 
            The binding data obtained from parallel studies on A2A receptor antagonists have 
indicated that the N
5
-unsubstituted pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidine 
derivatives (20, 23) possessed high affinity at the human A2B receptors but completely 
lacked selectivity. Subsequently, introduction of a polar γ-amino-butyryl amide (24) 
(Figure 7) at N
5
-position decreased affinity towards the A2B receptors but it was found to 
be slightly selective against the A2A subtype. 
86
 An improvement of this class of 





-positions. In fact, in parallel studies on human A3 adenosine antagonists (to be 
elaborated in the following section), it was observed that the replacement of the 
phenylcarbamoyl moiety at the N
5
-position with a phenylacetyl group (25) produced a 
decrease in affinity to the human A3 receptor affinity and a retention or improvement 
towards the A2B subtype. A combination of a naphthyl acetyl moiety at the N
5
-position 
and a phenylpropyl group (characteristic of A2A antagonists) at the N
8
-position led to a 
compound (26), which was found to be quite potent and selective towards the A2B 
receptors. 
87





positions could lead to potent and selective A2B receptor antagonists. 
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Figure 7. Structures of pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidines as A2B 
adenosine receptor antagonist.  
 
1.3.3    PTPs as A3 adenosine receptor antagonists 
            The optimization approach to obtain potent A3 receptor antagonists in the series of 
pyrazolo-triazolo-pyrimidines derived from a hybrid molecule between a human A2A 
receptor antagonist 
78, 79
 and an agonist of the A3 subtype. 
88, 89
 The tricyclic scaffold of a 
known human A2A antagonist was substituted at the N
5
-position with an arylcarbamoyl 
moiety. Specifically, the para-methoxyphenylcarbamoyl chain was demonstrated to be 
optimal for A3 affinity when introduced at the N
6
-position of the A3 agonist NECA (as 
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represented by compound 27) (Figure 8(A)). Such rational design led to compound 28 
(Figure 8(B)), which was one of the most potent and selective human A3AR antagonists. 
83
 Subsequent collation of binding data and molecular modeling studies indicated that 
small substituents, such as a methyl group at the N
8
-position, the phenyl ring on the N
5
-
carbamoyl moiety and a furyl ring at C
2
-position, were important for A3 affinity (e.g. 
compound 29). 
84, 90-92
 Only small substituents at the para-position of the N
5
-phenyl ring, 
including fluoro (F), chloro (Cl), and methoxy (OCH3) were tolerated. At the meta-
position, only hydrogen was tolerated, while the ortho-position could be substituted by a 
chlorine atom. Introduction of an allyl chain at N
8
-position, followed by reduction with 
tritium afforded [
3
H]MRE-3008-F20 (30), which was the first selective and tritiated hA3 
receptor antagonist radioligand with a KD value of 0.8 nM. 
93
 Since its discovery, it has 
been used for the identification of A3 receptors on various cells, including Jurkat T cells, 
HL60 cells and human neutrophils. 
94, 95
 Later, the N
5
-phenyl ring of the tricyclic scaffold 
was substituted with a pyridinium salt, as represented by compound 31, which not only 
showed good solubility (15mM) but also significantly improved hA3 affinity. 
96
 In 
previous studies, substitution of the N
5
-pyridine moiety with various N
5
-heteroaryl rings 
resulted in a general loss of hA3 affinity and selectivity. 
92
 
            Substitution at position C
2
 of the tricyclic system has not been deeply explored, 
being essentially limited to the introduction of a furyl group. The furan ring has been 
considered as an essential structural requirement for the binding of antagonists at all the 
adenosine receptor subtypes, while its removal from the tricyclic system was always 
associated with an irreversible loss of affinity and selectivity. 
97
 Besides that, 
modification  was  also  performed  concurrently  at   the   C
9
-position,   and  it  has  been   
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Figure 8. Structures of (A) NECA as A3 adenosine receptor agonist; (B) pyrazolo[4,3-e]-
1,2,4-triazolo-[1,5-c]pyrimidines as A3 adenosine receptor antagonists. 
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observed that the introduction of a substituent on such position, such as NHCH2CH3 (32) 
and SCH3 (33) has induced a loss of both affinity and selectivity towards A3 receptor.  
The introduction of such substituents was postulated to impose repulsive effect due to the 




            All the above-mentioned SAR profiles of PTPs at each of the A2A, A2B and A3 
receptor were summarized in Figure 9. In addition, the binding affinities data of these 
reported PTP derivatives (7-26, 28-33) at the A1, A2A, A2B and A3 receptors were 























Figure 9. Structure-affinity relationships (SAR) profiles of PTP derivatives at each of the 
A2A, A2B and A3 receptors. 
 A2A affinity and selectivity: R1 = long 
and bulky (ar)alkyl chain at N
7
 
 A2B affinity: R1 = long and bulky 
(ar)alkyl chain at N
8
 
 A3 affinity and selectivity: R1 = small 
alkyl chain at N
8
 
2-furyl moiety is essential for 
affinity at all the adenosine 
receptor subtypes 
 
 A2A affinity: R = NH2 
 A2B affinity: R = bulky amide group e.g. naphthyl acetyl moiety 
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1.4       Molecular Modeling on PTP derivatives (hA3AR antagonists) 
            Besides the conventional medicinal chemistry research, in silico approach has 
been increasingly gaining its role in the drug discovery arena. Such empirical approach 
and semi-rational strategies such as molecular modeling are frequently employed in 
tandem for the design of potent and selective ligands of hA3AR nowadays. To-date, many 
molecular modeling studies have been performed on the hA3AR ligands, including 
quantitative structure-activity relationship (QSAR), molecular docking simulations and in 
silico simulations of hA3 adenosine receptor activation. Among these modeling studies, 
the molecular docking simulations and QSAR studies performed on the PTP derivatives 
as hA3AR antagonists have been discussed in the following sections.  
 
1.4.1 Molecular docking simulations 
            A structure-based drug design approach, such as molecular docking simulations 
relies mainly on the interactions of molecules with the biological target in a three 
dimensional environment. For hA3AR, the affinity of the hA3 ligands to such a receptor is 
a result of structural and chemical complementarities, which can be determined through 
identification of binding modes and interactions of ligands inside the receptor cavity.  All 
the docking studies are performed on a hA3 receptor homology model, since the high-
resolution crystal structure of hA3 receptor has still not yet been resolved. Through the 
hA3 models, the hypothetical binding modes and interactions of different chemical 
scaffolds of hA3 ligands are depicted and experimental hA3 binding affinities of these 
ligands are therefore rationalized. The majority of these hA3 models are based on the 
bovine rhodopsin as template in homology modeling,  with increasing number of  models  
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constructed from the recently resolved hA2A receptor crystal structure (see Section 1.5). 
            In Baraldi et al. 
90
 (Figure 10), the PTP derivatives were hypothesized to be 
involved in interactions with residues on TMs 3, 5, 6 and 7 of the hA3AR model. The C
2
-
furan ring was found facing the extracellular side and interacting with Asn250 (TM6) via 
π-π interaction. The arylcarbamoyl moiety at the N5-position was oriented in the middle 
of TM6 and TM7, and residue Ser275 (TM7) was able to form a H-bond with the 
carbamoyl group. The binding pocket around N
5
-substituents was encompassed by non-
polar residues like Val235 (TM6), Leu236 (TM6) and Asn278 (TM7). Apparently, 
stringent steric control seemed to take place at the para and meta positions of the N
5
-
phenyl ring. The N
8
-alkyl group was located within another hydrophobic pocket confined 
by Leu90 (TM3), Phe182 (TM5), Ile186 (TM5) and Leu190 (TM5).  
            In Moro et al. 
91
 (Figure 10), the furan ring interacted with Phe168 (ECL2) and 
Phe182 (TM5) through π-π interaction, while the carbamoyl group interacted with His95 
(TM3) and Ser247 (TM6) through H-bonding. The N
5
-substituents were situated in a 
hydrophobic region characterized by three non-polar residues, including Ile98 (TM3), 
Ile186 (TM5) and Leu244 (TM6). It was also noticed the strong electrostatic interaction 
between the pyridinium moiety at the N
5
-position of compound 31 (the presence of which 
was shown to have increased the hA3 affinity remarkably) and the side chain carbonyl 
oxygen atoms of Asn274 (TM7) and Asn278 (TM7). Besides that, the alkyl group at N
8
-
position was found surrounded by non-polar residues such as Leu90 (TM3), Leu246 
(TM6) and Ile268 (TM7) and N
4
 of the triazole ring formed a H-bond with the Asn250 
(TM6).  
            Conversely, Tafi et al. 
98
  (Figure 10) proposed that the tricyclic core nucleus was 










































-positions of PTP 
derivatives with specific residues in hA3AR and 3D-pharmacophores derived from QSAR 
studies. 
a
Model from Baraldi et al. 
b
Model from Moro et al. 
c
Model from Tafi et al. 
Coloured polyhedra: QSAR model from Moro et al. Dotted circles and triangle: QSAR 
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stabilized by the π-π interaction with Trp243 (TM6) and the carbonyl group of ureidic 
group at N
5




-alkyl group and N
5
-
phenyl ring were delimited by three hydophobic pockets, constituted by Phe239, Trp243, 
His272 (HYD1), Leu102, Phe239, Trp243 (HYD2) and His95, Phe182, Trp185, Tyr254 
(HYD3), respectively. In addition, it was suggested that the involvement of the non-
conserved residue Tyr254 (TM6) in a H-bond with the N
5
-pyridyl ring was important for 
the hA3 affinity and selectivity. 
 
1.4.2  Quantitative structure-activity relationship studies  
                In this computational approach, appropriate representations of molecular 
structures for the drug compounds, or the so-called ‘molecular descriptors’ are chosen to 
construct a theoretical model, which provides structural basis for a particular class of 
hA3AR antagonists that are deemed crucial in molecular recognition to the hA3 receptor. 
These include for example, the topological and electrostatic potential descriptors 
represented in numbers that contain pertinent information specific to each individual 
compound. 
99
 In another words, the activity of the compounds is a cumulative influence 
of different structural features identified in terms of individual descriptors, which are 
important in molecular recognition to the hA3 receptor. 
             An interesting integrated approach of receptor-based and ligand-based drug 
design was proposed by Moro et al. 
91
 to define a pharmacophore map for the series of 
pyrazolo-triazolo-pyrimidine derivatives as hA3AR antagonists. In this study, docking-
based structure superimposition was used to perform a QSAR study for the PTPs through 
Comparative Molecular Field Analysis (CoMFA). The steric and electrostatic contour 
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plots derived from the resulting CoMFA model were consistent with the hypothetical 
binding interactions of ligands as described in the molecular docking studies (Section 
1.4.1). From the CoMFA contour maps (Figure 10), a green polyhedron was observed at 
the neighbouring N
5
-arylcarbamoyl moiety, suggesting that sterically bulky substituents 
at this position were favoured for hA3 affinity. Such steric bulk-favoured region nicely 
fitted into the receptor region, which was surrounded by non-polar residues such as Ile98, 
Ile186 and Leu244. A blue polyhedron was also observed in proximity to the N
5
-phenyl 
ring and it was complementary to the same non-polar residues mentioned above. Besides 
that, the presence of two red polyhedra around the N
8
-substituents and the N
5
-carbamoyl 
moiety indicated that electrostatic effects on hA3 affinity were considerable at these 
regions, which were surrounded by polar residues like His95, Ser247, Ser175 and 
His272. 
           On the other hand, a reciprocal approach of such integrated strategy was reported 
by Tafi et al.. 
98
 In this case, the ligand-based structural alignment was applied to define 
the pharmacophore map for the known hA3 antagonists through the Catalyst program. 
The docking simulation for the PTP derivatives was later performed based on the best 
Catalyst-predicted pharmacophoric framework. The best model superposed to the 







- positions, an H-bond acceptor at the ureidic group and an aromatic 
feature at the tricyclic core were important for the hA3 receptor antagonism (Figure 10).  
            Despite the fact that the structural alignment of molecules is crucial to establish a 
reliable CoMFA model, the conformational superimposition of the molecules is 
considered difficult and time-consuming. An alternative descriptor, namely the 
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autocorrelation vector, has been introduced in the conventional partial least-squares 
(PLS) analysis applied in CoMFA. Such autocorrelation allows the comparison of 
molecules with different structures and spatial orientation without any prior alignment. 
This concept was recently applied to the Molecular Electrostatic Potential (MEP) on a 
molecular surface, a molecular descriptor with magnitude and spatial distribution deemed 





PLS approach was used to generate a ligand-based 3D-QSAR model for the same group 
of pyrazolo-triazolo-pyrimidines selected in previous CoMFA-PLS study reported by 
Moro et al.. 
100, 101
 The results obtained showed that the application of such methodology 
reproduced a remarkable quantitative model, with a prediction of the model derived from 
MEP-PLS analysis comparable to that of the CoMFA-PLS derived model. Thus, it 
indicated that the autocorrelation MEP-PLS model was a robust and efficient alternative 
to the classical CoMFA approach for generating a 3D-QSAR model. This type of 
approach is expected to serve as a useful tool to process a large molecular database in the 
virtual screening applications. 
 
1.5  Homology modeling of hA3 receptor 
            Due to technical difficulties that hamper experimental X-ray crystallography and 
NMR characterization of GPCRs, the 3D structure of most GPCRs, such as the hA3 
adenosine receptor, have not been elucidated yet. Even so, many studies have been 
carried out to construct the hA3 receptor model through various computational methods. 
The resulting hA3 receptor model is beneficial in the prediction of the novel putative 
binding pocket for the hA3 receptor ligands through  molecular  docking  simulations and  
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serves as a mainstay for structure-based drug design. 
 
1.5.1     Progress of hA3AR homology modeling   
             Initially, the human A3 adenosine receptor models were constructed based on the 
information derived from low resolution electron density maps (EDM) of rhodopsin, via 
the “cross-docking” methodology as proposed by Moro et al.. 103, 104 Only in 2000, the 
crystal structure of high resolution bovine rhodopsin (PDB Code: 1F88) at 2.8 Å was 
successfully discovered. 
105
 Since then, the homology modeling studies for human A3 
adenosine receptor have been mainly based on such template. 
106-108 
Although presenting 
the typical seven-transmembrane architecture as that of adenosine receptors, the bovine 
rhodopsin displays very limited sequence identity with A3 receptors (less than 20% 
sequence identity). 
109 
Recently, the other two structures of human GPCR, such as the 
crystallographic structure of human beta2 (β2)-adrenergic G-protein coupled receptor 
(PDB Code: 2RH1)
 110-112 





2.6 Å, respectively, have been resolved, and they have served as alternative templates for 




 Among these available 
GPCRs, the hA2A receptor is considered an optimal template for homology modeling of 




             Apart from conventional homology modeling, a novel strategy known as ligand-
assisted homology modeling has been firstly introduced by Evers et al., 
115
 who modelled 
GPCRs by homology, together with the incorporation of bound ligand molecules inside 
the binding sites. In such approach, the ligand molecules bound to the models act as 
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restraints and more accurate geometries regarding the protein binding sites are obtained 
as a result. 
116 
Recently, a similar strategy, namely ligand-based homology modeling 
(LBHM), has been carried out by Moro and his co-workers on the hA3AR. 
117 
The study 
enabled the exploration of multi-conformational space of the antagonists and the possible 
receptor reorganization induced by the ligand binding. Notably, such a refined model 
took into account the presence of the ligand in terms of specific molecular volume, as 
well as steric and chemical requirements. This methodology has been validated through 
analysis of more than 200 known hA3AR antagonists in the corresponding putative ligand 
binding site. Through this multi-conformational states approach, a consensus binding 
motif among all known antagonists has been found, and a novel ‘Y-shaped’ 3D-
pharmacophore has been derived. Such a receptor-based pharmacophore is useful in 
guiding screening of potential hits from the available compound database.   
 
1.5.2    hA3AR models   
            In general, the TM regions of GPCRs possess the same overall topology and the 
sequence alignment is guided by the most conserved residues in each helix. 
107
 
Nonetheless, the loops constitute the most variable regions. Particularly, the extracellular 
loop 2 (ECL2) is of particular interest in homology modeling of adenosine receptors due 
to its important role in ligand recognition, with special caution given to the presence of 
the highly conserved disulfide bond formed between the cysteine 166 (ECL2) and 
cysteine 83 (TM3). The formation of such a disulfide bond is deemed critical in 
determining the conformation of the binding pocket for the ligands. To-date, a number of 
A3AR models have been reported describing the hypothetical modes and interactions 
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with known A3AR ligands of different chemical scaffolds. Most of these models were 
built based on the bovine rhodopsin template (Figure 11 (A)). 
108 
On the other hand, the 
A3AR models based on the human β2-adrenergic receptor (Figure 11 (B)) and the 
hA2AAR receptor (Figure 11 (C)) have also been recently published. 
75,
 
108, 114a, 114b 
The 
main differences among these models were observed at the ECL2, ICL3 and extracellular 
end of TM1. 
108 
As the ECL2 plays an important role in ligand recognition, the structure-
based drug design is mainly affected by differences in ECL2.  
             The bovine rhodopsin-based homology model consists of a seven-helical bundle 
with a central cavity surrounded by helices 3, 5, 6 and 7. The access of the ligands into 
the central cavity is governed by the ECL2, which possesses a β-sheet secondary 
structure. As mentioned earlier, this model has been widely used to identify putative 
ligand-receptor interactions and rationalize the structure-affinity relationship of known 
hA3AR antagonists and agonists. For the human β2-adrenergic receptor-based homology 
model, the location of the hA3AR antagonist is found similar between the models 
obtained from the rhodopsin and the β2-adrenergic receptor, despite the fact that there are 
structural differences in the ligand binding sites between the two models. The presence of 
a α-helix on ECL2 in this model enables the accessibility of ligands into the central 
binding sites. In the hA2AAR-based homology model, the helical arrangement is similar 
to other homology models. Nevertheless, the helices are shifted, and the differences 
among their relative positions result in an RMSD around 2.5 Å. 
108, 114
 The binding 
pocket of ligands for such a model shifted closer to the TM6 and TM7 and open to the 
extracellular side. With regards to the volume of binding site, both the A3AR models built 
from  human  β2-adrenergic  receptor  and hA2AAR have the binding sites that are open to   
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Figure 11. Topology of (A) bovine rhodopsin-based hA3 homology model (B) human β2 
adrenergic receptor-based hA3 homology model (C) hA2A adenosine receptor-based hA3 
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the extracellular side, which has rendered the measurement of the volume difficult. They 
are estimated as 1620 Å
3
 and 1930 Å
3
, respectively. However, they are not comparable to 
that of the bovine rhodopsin-based model, in which the binding site is enclosed, and the 




1.5.3     Evaluations of hA3AR model 
             Evaluation of hA3 receptor model is an important component in confirming the 
accuracy of a system in homology modeling. The commonly employed strategies include:  
(i) computational evaluation tool to check for protein stereochemistry or fitness of 




(ii) the concordance with available experimental data from site-directed mutagenesis of 
hA3AR; the residues that mutagenesis studies have been identified to play a 




(iii) the models should be able to rationalize the affinity and selectivity profile of newly 
synthesized derivatives through analysis of the hypothetical binding interaction 
between the ligand and the respective residues in the docking studies. 
107
 Based on 
such receptor-based structural information, new compounds are rationally designed 
and synthesized;  
(iv) the model should also be able to suggest the mutation of residues that the model 
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Chapter 2 Statement of Purpose 
 





-positions of the tricyclic scaffold, has given rise to a group of adenosine 
receptor antagonists with good affinity and moderate selectivity especially towards the 
hA2A, hA2B and hA3 receptors. Instead, the substitution at position C
2
 of the tricyclic 
nucleus has not been deeply explored yet, essentially being limited to a 2-furyl group, 
which is recognized to be important for binding of antagonists at all the adenosine 
receptor subtypes. Nevertheless, metabolic instability due to the furan ring of the tricyclic 
nucleus could result in the production of toxic metabolites, which have been reported to 
cause in vivo hepatotoxicity in treated mice. 
119
 As such, these observations have 
suggested the need to further investigate the significance of the existing furan ring at the 
C
2
-position towards the affinity and selectivity at the adenosine receptors, possibly 
through its replacement with other similar aromatic moieties.  
            Through comprehensive literature searches, it was found that several 
polyheterocycles acting as hA3AR antagonists 
120-124
 had similar tricyclic scaffolds as that 
of the PTPs. In fact, those scaffolds presented a 2-aryl ring at the equivalent position of 
the 2-furyl of PTPs. 
120-124
 In those derivatives, the 2-aryl ring was identified as one of the 
crucial structural requirements for the affinity and selectivity at the hA3 receptor. From 
the biotransformation aspect, the metabolites of the 2-phenyl ring are relatively less 
reactive than those from the furan ring. In addition, the typical oxidation targeted at the 
para-position of the phenyl ring can be bypassed through the synthesis of [2(para-
substituted)-phenyl]-PTP derivatives, thus improving bioavailability of bioactive 
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compounds in the blood circulation to eventually exert its pharmacological action at the 
target site. These findings have served as the basis for the design and synthesis of the new 
series of PTP derivatives in this project, which mainly target at the hA3AR (to be 
elaborated in detail under Section 3.2).  
            Additionally, the advances in molecular modeling studies, such as the quantitative 
structure-activity relationship analysis, molecular docking simulations and homology 
modeling of the hA3AR have indeed caused a great impact towards the rational design of 
new hA3AR antagonists, as well as construction of reliable and predictive hA3AR 
homology models to define crucial ligand-receptor interactions. Together with traditional 
medicinal chemistry research, such theoretical studies are definitely deemed necessary to 
develop a refined pharmacophore map for the new series of 2-aryl-PTPs, particularly at 
the C
2
-position, and also to provide new insights on the hypothetical binding mode and 
interactions of new ligands inside the binding site of a hA3AR homology model 
constructed from appropriate templates.  
 
Hypothesis 1:  
Based on the above-mentioned structural and metabolic benefits of the 2-aryl ring, it is 
therefore hypothesized that the bioisosteric replacement of the existing 2-furyl ring with a 





-positions of the tricyclic nucleus will ultimately (i) maintain or improve 
the affinity at hA3AR; (ii) ameliorate the selectivity against other adenosine receptor 
subtypes; (iii) potentially overcome the metabolic instability due to the 2-furyl ring, and 
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also bypass the typical oxidation which occurs at the para-position of the phenyl ring (for 
those para-substituted PTPs), with subsequent improvement in plasma bioavailability. 
 
Hypothesis 2: 
It is also hypothesized that pertinent molecular modeling investigations can be used to 
rationalize the experimental data obtained from the pharmacological characterization of 
new 2-aryl-PTP derivatives by providing new insights on (i) essential structural features 
associated with their selective inhibition of hA3AR (via QSAR analysis) and (ii) 
important binding interactions between ligands and specific residues responsible for the 
hA3 affinity (through molecular docking simulations on the hA3AR homology model), 
particularly at the C
2
-position of the tricyclic nucleus. 
 
Main Objectives: 
            To test these two hypotheses, the following investigations were planned and 
carried out: 
(1) Design, synthesize and characterize a new series of pyrazolo-triazolo-pyrimidines 
bearing an aryl ring at the C
2





-positions of the tricyclic scaffold (Chapter 3).  







) of the PTP tricyclic nucleus towards the affinity and 
selectivity profile at the hA3AR through binding affinity assay at the hA1, hA2A 
and hA3 receptors, as well as functional assays at the hA2B and hA3 receptors 
(Chapter 4). 
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(3) Detailed analysis of structure-affinity relationship for the new series of 2-aryl-
PTPs towards hA3AR subtypes (Chapter 4). 
(4) Rationalization of the experimental binding affinity data through molecular 
modeling investigations, including quantitative structure-activity relationship 
analysis (Chapter 5), hA3AR homology modeling (Chapter 6) and molecular 
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Chapter 3 Design and Synthesis of a New Series of Pyrazolo-Triazolo-
Pyrimidine Derivatives 
 
The information related to the rationale and the synthesis of the new series of 2-aryl-
PTPs in this chapter has been reported in the following research articles:  
 Cheong, S. L.; Dolzhenko, Ann.; Kachler, S.; Paoletta, S.; Federico, S.; Cacciari, 
B.; Dolzhenko, Ant.; Klotz, K-N.; Moro, S.; Spalluto, G.; Pastorin, G. The 
significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a 
new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA3 
adenosine receptor’s antagonists: New insights into structure-affinity-relationship 
and receptor-antagonist recognition. J. Med. Chem. 2010, 53, 3361-3375  
 
 Cheong, S. L.; Dolzhenko, Ant. V.; Paoletta, S.; Lee, E. P. R.; Kachler, S; 
Federico, S.; Klotz, K-N.; Dolzhenko, Ann. V; Moro, S.; Spalluto, G.; Pastorin, G. 






 positions of 
the pyrazolo-triazolo-pyrimidine scaffold guarantee a selective modulation of the 
human A3 adenosine receptors? Bioorg. Med. Chem. 2011, 19, 6120-6134  
 
 
3.1       Introduction 
            This section describes the rationale for the design of a new series of pyrazolo[4,3-
e]-1,2,4-triazolo-[1,5-c]pyrimidines bearing an aryl ring at the C
2
-position (based on the 
hypothesized structural and metabolic merits as mentioned in Chapter 2 Statement of 





-positions of the tricyclic nucleus. The discussion will first elaborate on the 
factors influencing the design of the library, and this is followed by chemical 
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3.2       Rationale of Drug Design 
                Among the several diverse structures that have demonstrated affinity at the hA3 
adenosine receptor, this project has particularly focused on the development of 
compounds bearing a pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidine nucleus (35) 
(Chart 1). 
125, 126
 The PTP tricyclic nucleus resembles the triazoloquinoline core of the 
non-selective adenosine receptor antagonist CGS15943 (34), 
127
 except for the fused 
phenyl ring being replaced by a fused pyrazole, which has resulted in increase of 
selectivity against other adenosine receptor subtypes. 
84
 Further exploitation of 




 of such structure, 
84, 90
 has given rise to 
highly potent and moderately selective hA3AR antagonists (as summarized in Section 
1.3.3). In particular, the combination of a methyl group at N
8
 and a 4-pyridyl carbamoyl 
chain at N
5
 has led to the most potent hA3 antagonist (31) ever synthesized. 
96
 
Conversely, structural modification at position C
2
 of the tricyclic system has not been 
thoroughly examined, being always restricted to the substitution with a furyl group. As 
mentioned earlier, such a 2-furan ring has been considered as an indispensable structural 
requirement for the binding of antagonists at all the adenosine receptor subtypes, while its 
removal from the tricyclic system is associated with an irreversible loss of affinity and 
selectivity, regardless of the receptor under investigation. 
            To reiterate, Baraldi and co-workers 
97
 have found that the substitution of the 
furan ring in PTPs with phenyl or alkoxyphenyl rings led to a loss of affinity at A2A, A2B, 
and A3 receptors, while at the A1 subtype in some cases displayed a high nanomolar 
binding profile. Similarly, the functionalization of the furan ring with polar substituents 
also led to complete inactive derivatives, clearly indicating that an un-substituted furan 
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ring at the C
2
-position played a fundamental role in ligand-receptor recognition. 
Nonetheless, it was noted that in most cases, substitution at the pyrazole ring occurred at 
the N
7
- rather than at the N
8
-position. Apparently, these compounds might not reflect the 
same binding profile as their N
8 
analogs. This observation has triggered our interest to 
further investigate the effect of concurrent substitution of an alkyl group at N
8
-position 
and different moieties other than a furan ring at C
2
-position of PTPs on the affinity at the 
hA3 receptor and selectivity over other adenosine receptor subtypes. Interestingly, several 
reported hA3AR antagonists bearing the tricyclic scaffolds (which also bear structural 





 triazolopyrazinones (38) 
123
 and triazolobenzotriazinones 
(39) (Chart 1), 
124
 comprise a substituted phenyl moiety at the position equivalent to that 
of furan ring in PTP derivatives. From the structure-affinity relationship (SAR) studies of 
these derivatives, the presence of the phenyl ring seemed crucial to maintain good affinity 
and selectivity at hA3 receptor. In light of the beneficial effect of this phenyl ring towards 
the hA3 affinity and selectivity, the substitution of the C
2
-furyl ring with an aryl group is 
therefore deemed feasible for the design and synthesis of new series of PTPs.       
            From the pharmacokinetics aspect, several studies have reported that drugs 
containing a furan in their chemical structure (e.g. prazosin and frusemide) were 
subjected to a metabolic cleavage of the furyl ring by the Cytochrome P450 enzymes in 
the liver, 
119, 128, 129
 resulting in marked hepato-toxicity in treated mice. 
119
 Some of these 
intermediate metabolites, for examples epoxide groups and γ-keto-α,β-unsaturated 
aldehydes (Figure 12), were shown to be reactive and able to form adducts with cellular 
proteins  or  DNA,  therefore  causing   unpredictable   effects.  Although   these   reactive  
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R = NH2, NH-CO-Ph, NH-CO-CH2-Ph, N(CO-Ph)2,
NH-CO-NH-Ph, NH-CO-NH-(4-F)Ph, NH-CO-NH-(4-OCH3)Ph
R1 = H, 4-Cl, 4-F, 4-Br, 4-NO2, 4-OCH3, 4-CF3, 4-Ph







































x = N; x1 = C=O;x2 = N; x3 = C; x4 = C
PYRAZOLOQUINOLINES, 38:
x = N; x1 = C-H; x2 = C; x3 = C; x4 = C
TRIAZOLOPYRAZINONES, 39:
x = N; x1 = C=O; x2 = N; x3 = C; x4 = N
TRIAZOLOBENZOTRIAZINONES, 40:




Chart 1. Rationale for the design of 2-(para-(un)substituted)phenyl pyrazolo[4,3-e]- 
1,2,4-triazolo--[1,5-c]pyrimidines. 
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metabolites can be detoxified by several enzymes in the body,  this still poses some 
threatof toxicity and should be regarded as a safety issue. On the other hand, metabolites 
derived from biotransformation of the phenyl ring through oxidation by CYP450 
enzymes, are expected to be relatively less reactive than those found in the metabolism of 
furan ring. Furthermore, the typical oxidation targeted at the para-position of the phenyl 
ring can be bypassed through the synthesis of para-substituted derivatives, leading to 
improvement of bioavailability of the new bioactive compounds. In fact, the 
incorporation of different groups (e.g. F, Cl, Br, OCH3, NO2) at the 4’-position of the 
benzene ring represents a strategy often adopted by pharmaceutical companies to prevent 
the metabolic oxidation of drugs bearing aromatic groups. An example is illustrated by 
Diclofenac
®
, usually processed by cytochrome P450 monooxygenase through an arene 
oxide (epoxide) intermediate; this molecule has been improved in terms of bioavailability 






















Figure 12. Metabolic pathway for P450-mediated ring opening of the furan ring. 
Epoxide intermediate γ-keto-α,β-unsaturated aldehyde 
γ-ketocarboxylic acid 
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             On the basis of the potential structural and metabolic benefits of the C
2
-aryl 
group in PTP derivatives, a novel structure-affinity relationship evaluation was conducted 
through the rational design and synthesis of a new series of pyrazolo[4,3-e]-1,2,4-
triazolo-[1,5-c]pyrimidines (compounds 40-90) (Chart 1 and Table 1). At the C
2
-
position, an unsubstituted 2-phenyl ring or a 2-(para-substituted)phenyl ring was 
introduced. Para-substituents with different electronic effects, for examples those with 
electron-withdrawing effect (e.g. 4-nitro, 4-halogens, 4-trifluoromethyl and 4-phenyl) as 





-position, alkyl groups with different steric effects, ranging from a small methyl and 
ethyl to a long and bulky group like phenylethyl chain, were incorporated. At the N
5
, a 
free amine or different lengths of amide moieties, for instances (bis-)benzamide, 
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Compounds Substituents at R Substituents at R1 Substituents at R2 
40 NH2 H N
8
-CH3 
41 NH2 F N
8
-CH3 
42 NH2 Cl N
8
-CH3 
43 NH2 Br N
8
-CH3 
44 NH2 OCH3 N
8
-CH3 
45 NH2 NO2 N
8
-CH3 
46 NH2 CF3 N
8
-CH3 
47 NH2 Ph N
8
-CH3 
48 NH2 Cl N
7
-CH2CH3 
49 NH2 Cl N
8
-CH2CH3 
50 NH2 H N
8
-CH2CH2-Ph 
51 NH2 F N
8
-CH2CH2-Ph 
52 NH2 Cl N
7
-CH2CH2-Ph 
53 NH2 Cl N
8
-CH2CH2-Ph 
54 NH2 Br N
8
-CH2CH2-Ph 
55 NH2 OCH3 N
8
-CH2CH2-Ph 
56 NH-CO-Ph H N
8
-CH3 
57 NH-CO-Ph F N
8
-CH3 
58 NH-CO-Ph Cl N
8
-CH3 
59 NH-CO-Ph Br N
8
-CH3 
60 NH-CO-Ph OCH3 N
8
-CH3 
61 NH-CO-Ph NO2 N
8
-CH3 
62 N(CO-Ph)2 OCH3 N
8
-CH3 
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Compounds Substituents at R Substituents at R1 Substituents at R2 
63 N(CO-Ph)2 Cl N
8
-CH3 
64 NH-CO-Ph H N
8
-CH2CH2-Ph 
65 NH-CO-Ph F N
8
-CH2CH2-Ph 
66 NH-CO-Ph Cl N
8
-CH2CH2-Ph 
67 NH-CO-Ph Br N
8
-CH2CH2-Ph 
68 NH-CO-Ph OCH3 N
8
-CH2CH2-Ph 
69 NH-CO-CH2-Ph H N
8
-CH3 
70 NH-CO-CH2-Ph F N
8
-CH3 
71 NH-CO-CH2-Ph Cl N
8
-CH3 
72 NH-CO-CH2-Ph Br N
8
-CH3 
73 NH-CO-CH2-Ph OCH3 N
8
-CH3 
74 NH-CO-CH2-Ph NO2 N
8
-CH3 
75 NH-CO-CH2-Ph H N
8
-CH2CH2-Ph 
76 NH-CO-CH2-Ph F N
8
-CH2CH2-Ph 
77 NH-CO-CH2-Ph Cl N
8
-CH2CH2-Ph 
78 NH-CO-CH2-Ph Br N
8
-CH2CH2-Ph 
79 NH-CO-NH-Ph Cl N
8
-CH3 
80 NH-CO-NH-Ph Br N
8
-CH3 
81 NH-CO-NH-Ph CF3 N
8
-CH3 
82 NH-CO-NH-Ph Ph N
8
-CH3 
83 NH-CO-NH-(4-F)Ph Cl N
8
-CH3 
84 NH-CO-NH-(4-F)Ph Br N
8
-CH3 
85 NH-CO-NH-(4-F)Ph CF3 N
8
-CH3 
86 NH-CO-NH-(4-F)Ph Ph N
8
-CH3 
87 NH-CO-NH-(4-OCH3)Ph Cl N
8
-CH3 
88 NH-CO-NH-(4-OCH3)Ph Br N
8
-CH3 
89 NH-CO-NH-(4-OCH3)Ph CF3 N
8
-CH3 
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3.3       Chemical Considerations 
            The detailed synthetic pathways for the new series of 2-(para-substituted)phenyl-
pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives 40-90 (Table 1) are 
elaborated in the following sections, as well as depicted in Schemes 1, 2 and 3.  
 
3.3.1 Synthesis of 2-aryl-7- or -8-(ar)alkyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-  
c]pyrimidin- 5-amines (40-45, 48-55), N-(2-aryl-8-(ar)alkyl-pyrazolo[4,3-e]-1,2,4-
triazolo[1,5-c]pyrimidin-5-yl)benzamides (56-68) and N-(2-aryl-8-(ar)alkyl-
pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl)phenylacetamides (69-78) 
            The 2-aryl-7- or -8-(ar)alkyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
amines (40-45, 48-55), N-(2-aryl-8-(ar)alkyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-
c]pyrimidin-5-yl)benzamides (56-68) and N-(2-aryl-8-(ar)alkyl-pyrazolo[4,3-e]-1,2,4-
triazolo[1,5-c]pyrimidin-5-yl)phenylacetamides (69-78) were prepared following similar 
procedures as already described elsewhere for the synthesis of the pyrazolo-[4,3-e]-1,2,4-
triazolo[1,5-c]pyrimidines (Scheme 1). 
76, 84, 130
 




 regioisomers for alkylated 3(5)-amino-4-
cyano-pyrazoles (96-99) in both the ethyl and phenylethyl series were synthesized as 
described in refs. 76 and 84. Briefly, the 3(5)-amino-4-cyano-pyrazole (95), once 
dissolved in dimethylformamide (DMF), was alkylated through a reaction with 
iodoalkane and sodium hydride (NaH) under ice bath condition. The NaH, which is a 
strong base, promotes deprotonation of the acidic proton on the nitrogen atom of the 
pyrazole ring. As a result, the electron rich nitrogen atom readily attacks the electron 
deficient alkyl group on the iodoalkane with ensuing alkylation. Such  alkylation  process   






























Reagents: (i) 2-methylhydrazine, absolute EtOH; (ii) ethoxymethylene-malono nitrile, benzene; (iii) conc. HCl,
NaOH; (iv) NaH, R2X, dimethylformamide; (v) HC(OEt)3, reflux; (vi); 2-(4-substituted)benzoic hydrazide,
MeO(CH2)2OH; (vii) Ph2O, 260 °C, flash chromatography; (viii) HCl, reflux; (ix) NH2CN, 1-methyl-2-pyrrolidinone,
pTsOH




































R2 = Me, (94)



























      R1 R2  R1 R2  R1 R2 
40 H N
8-Me 45 NO2 N
8-Me 52 Cl N
7-PhEt 
41 F N
8-Me 48 Cl N
7-Et 53 Cl N
8-PhEt 
42 Cl N
8-Me 49 Cl N
8-Et 54 Br N
8-PhEt 
43 Br N
8-Me 50 H N
8-PhEt 55 OCH3 N
8-PhEt 
44 OCH3 N
8-Me 51 F N
8-PhEt    
 
Scheme 1. Synthetic scheme for 2-aryl-PTP derivatives 40-45, 48-55. 
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 regioisomers in a 
1:4 ratio in favour of the isomer of interest. On the other hand, for preparation of 




 regioisomers was 
obtained, thus decreasing the yields remarkably. For that reason, an alternative procedure 
was followed to obtain only the 3-amino-4-cyano-1-methyl-pyrazole isomer (94) in good 
yield.
 130
 In this case, benzaldehyde (91) was reacted with methylhydrazine in ethanol 
under reflux to form 2-benzylidene-1-methyl-hydrazone (92), together with elimination 
of water. The formation of the benzylidene group was to protect the terminal NH2 of 
methylhydrazine from attack by other reagents in the subsequent steps. Next, the 
hydrazone and the reactant, ethoxymethylenemalononitrile were both dissolved in 
benzene followed by reflux in order to obtain the {[(2Z)-2-benzylidene-1-
methylhydrazino]methylene}malononitrile (93). The latter was then suspended in 
benzene and mixed with concentrated HCl, after which the mixture was heated under 
reflux and the resultant residue recrystallized from boiling diethyl ether to afford the 
hydrochloride of 3-amino-4-cyano-1-methyl-pyrazole (94). The HCl cleaved off the 
benzylidene and allowed the re-formation of the terminal hydrazine-NH2 (deprotection), 
with subsequent ring closure with the malononitrile group. The HCl salt was then 
neutralized with 5N NaOH and the pure isomer of 3-amino-4-cyano-1-methyl-pyrazole 
(94) was afforded after liquid-liquid extraction.  
            The intermediates (94, 96-99) were then directly refluxed in triethyl orthoformate 
that reacted with the free amino group on the pyrazole ring to give the corresponding 
imidates (100-104), which were subsequently reacted with the appropriate (para-
(un)substituted)benzoic hydrazide in refluxing 2-methoxy-ethanol to afford the 
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pyrazolo[3,4-d]pyrimidines (105-118). Following that, these compounds were subjected 
to a thermally-induced cyclization in diphenyl ether at 260°C. After the chromatographic 
separation of N
7
 (minor product) and N
8 
(major product) regioisomers (this last step was 
necessary only for derivatives with N
8
-substituents other than the methyl group), the 
tricyclic compounds (119-132) were provided in acceptable yields (about 50-60% for N
8
 
derivatives and 20-30% for N
7
 derivatives). Hydrolysis of the tricyclic compounds in 
20% HCl gave rise to the corresponding intermediates (133-146), which were  
subsequently converted into the 5-amino-8-(substituted)-2-[(para-
substituted)phenyl]pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives (40-45, 
48-55). In this step, an excess of cyanamide (H2NCN) in N-methylpyrrolidinone and p-
toluene sulfonic acid (p-TsOH) were refluxed at 160C, resulting in ring closure and re-
formation of tricyclic system with an additional free amino group at the N
5
-position. 
Concurrently, ammonia was liberated from the reaction. The p-TsOH added into the 
reaction mixture acted as a catalyst to increase the rate of reaction.   
Later, some of the compounds bearing either a methyl group (40-45) or a 
phenylethyl group (50, 51, 53-55) at N
8
 were dispersed in toluene and treated with either 
benzoic anhydride or phenylacetyl chloride (Scheme 2). The mixture was heated under 
reflux and stirred for 6-24h. The solvent was removed under reduced pressure and the 
residue was crystallized from an appropriate solvent or subjected to chromatographic 
purification, to afford the desired acylated compounds (56-61, 64-78). In addition, two 
further compounds, obtained from the reaction of the compounds 42 and 44 with benzoyl 
chloride, were isolated from the alcoholic mixtures of methanol or ethanol: they included 
the bis-acylated products 62 and 63.  





























Reagents: (i) benzoic anhydride, toluene (in synthesis of 56-61, 64-68) or benzoyl chloride with DIPEA/TEA in
toluene/dioxan (in synthesis of 62, 63), reflux; (ii) phenylacetyl chloride, DIPEA, toluene, reflux
i
ii



















    R1  R2  R1 R2 
40 H Me 50 H PhEt 
41 F Me 51 Br PhEt 
42 Cl Me 53 F PhEt 
43 Br Me 54 Cl PhEt 
44 OCH3 Me 55 OMe PhEt 
45 NO2 Me    
 
 
  R1 R2     R1 R2  R1 R2 
56 H Me 61 NO2 Me 66 Cl PhEt 
57 F Me 62 OCH3 Me 67 Br PhEt 
58 Cl Me 63 Cl Me 68 OMe PhEt 
59 Br Me 64 H PhEt    
60 OCH3 Me 65 F PhEt    
  
    R1  R2 
69 H Me 
70 F   Me 
71 Cl Me 
72 Br Me 
73 OCH3 Me 
74 NO2 Me 
75 H PhEt 
76 F PhEt 
77 Cl PhEt 
78 Br PhEt 
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3.3.2  Synthesis of 2-aryl-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
amines (42, 43, 46, 47) and N-[aryl-N’-(2-aryl-8-methyl-pyrazolo[4,3-e]-1,2,4-
triazolo[1,5-c]pyrimidin-5-yl)]carbamides (79-90) 
 
* Compounds reported in this section were synthesized by the undergraduate student, Ms. 
Lee Evelyn Pei Rong during her Final Year Project, who was supervised and mentored 
by Asst. Prof. Pastorin Giorgia, postdoctoral fellow, Dr. Dolzhenko Anton and PhD 
student, Ms. Cheong Siew Lee (author of this thesis). 
 
            The N-[aryl-N’-(2-aryl-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-
5-yl)]carbamide derivatives 79-90 and the corresponding pyrazolo[4,3-e]-1,2,4-
triazolo[1,5-c]pyrimidin-5-amines 42, 43, 46, 47 were synthesized through a combination 
of new steps as well as known procedures as described above (Scheme 3). The 
preparation of intermediate 94 has been considered as a critical step in the synthesis of 
PTP derivatives bearing a methyl group at N
8
-position. To-date, several methods have 
been reported, but all with their limitations. In a procedure described by Gatta and co-
workers, 3-amino-4-cyano-1-methyl-pyrazole 94 was prepared by the alkylation of 3(5)-
amino-4-cyano-pyrazole under typical conditions (NaH, in dry DMF) using a small 
alkylating agent. 
76





regioisomers which required separation by flash chromatography, with a consequent 
reduction in yield (see step iv in Scheme 1). An alternative method of preparation 
involved the use of methyl hydrazine as the starting reactant either by (1) direct 
condensation with ethoxymethylene malononitrile  followed  by ring closure, affording 
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only the regioisomer 5-amino-4-cyano-1-methyl-pyrazole, 
131
 or (2) introducing a 
protecting group prior to the condensation reaction,
 132
 with subsequent ring closure to 
obtain 3-amino-4-cyano-1-methyl-pyrazole 94. Nevertheless, method (2) is less 
favourable since methylhydrazine is a controlled compound that is more commonly used 
as rocket fuel. 
133
 
            Therefore, a new regioselective synthetic procedure was devised in this part of the 
project that allowed for the preparation of 3-amino-4-cyano-1-methyl-pyrazole 94 
through a more practical and chromatographic-free process, as illustrated in Scheme 3. 
The condensation reaction between hydrazine (147) and benzaldehyde gave the 
intermediate benzohydrazone 148 with the benzylidene group serving as a protecting 
group. Subsequent reaction with ethoxymethylene malononitrile, selective methylation 
with methyl iodide and deprotection with ring closure provided only 3-amino-4-cyano-1-
methyl-pyrazole 94 in good yield of about 81%. 
3-amino-4-cyano-1-methyl-pyrazole 94 was then reacted with triethyl 
orthoformate using the procedure mentioned above to afford imidate 100. 
76
 A novel 
method that has been recently reported by our group 
134
 was employed for the synthesis 
of 150 in which imidate 100 was reacted with hydrazine in ethanol at 0-20˚C for 5 hours 
to isolate pure 150 (Scheme 3). Previously, intermediates 121 and 122 were prepared by 
cyclocondensation of hydrazides with imidate 100. 
76
 This method required harsh 
conditions (260˚C) and chromatographic purification of the products. The poor solubility 
of such intermediates, particularly when C
2
-moiety is a substituted phenyl group, made 
chromatographic purification a time- and solvent-consuming process. Hence, we adopted 
a more practical process 
35
 with mild reaction conditions,  as  shown  in steps  vi  and  vii.  












































































































Reagents: (i) PhCHO; (ii) (NC)2C=CH(OEt); (iii) MeI, NaOH; (iv) conc.HCl, reflux; (v) HC(OEt)3; (vi) H2NNH2;
(vii) 1) R1PhCHO, Et3N, 2) PhI(OAc)2; (viii) conc. HCl, reflux; (ix) H2NCN, TsOH; (x) R'N=C=O
147





















 R1  R’  R’  R’ 
Cl 79 Ph 83 4-F-Ph 87  4-OCH3-Ph 
Br 80 Ph 84 4-F-Ph 88 4-OCH3-Ph 
CF3 81 Ph 85 4-F-Ph 89 4-OCH3-Ph 
Ph 82 Ph 86 4-F-Ph 90 4-OCH3-Ph 
       
 
 
Reagents: (i) NaH, PhCH2CH2I, dimethylformamide; 
(ii) HC(OEt)3, reflux; (iii); 2-(4-substituted)benzoic 
hydrazide, MeO(CH2)2OH; (iv) Ph2O, 260 °C, flash 
chromatography; (v) HCl, reflux; (vi) NH2CN, 1-
methyl-2-pyrrolidinone, pTsOH, reflux 
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The isolated intermediate 150 subsequently reacted with respective para-substituted 
benzaldehyde, followed by an oxidation step with iodobenzene diacetate to afford 121, 
122, 151, 152 with good purity and reasonable yields in the range of 68-92%. 
Subsequent steps of the synthetic scheme were performed using established 
procedures. 
76, 84, 90
 Treatment of 121, 122, 151, 152 with dilute HCl under reflux induced 
pyrimidine ring-opening to furnish the 1-methyl-4-(3(5)-aryl-1,2,4-triazol-5(3)-yl)-
pyrazol-3-ylamines 135, 136, 153, 154  in good yield. These derivatives 135, 136, 153, 
154 were converted to 2-aryl-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
yl amines 42, 43, 46, 47 by cyclocondensation with an excess of cyanamide in 1-methyl-
2-pyrrolidinone at 160˚C. Substituted ureas 79-90 were obtained by reaction of the 




Nevertheless, it was noticed that the substituted ureas 79-90 were unstable during 
recrystallization with polar solvents. Some compounds, such as 79 and 80 degraded to 
their respective substituted amines 42 and 43 upon attempting recrystallization with polar 
solvents like DMSO and DMF. The inherent poor solubility of the substituted ureas 79-
90 in solvents with low boiling points like ethanol and methanol rendered them 
unsuitable candidates for chromatographic purification methods. Therefore, we deduced 
that as the final nucleophilic addition reaction with the respective isocyanates was a clean 
procedure, which allowed for isolation of the substituted ureas as a single product, 
washing of the product with hot ethanol would be sufficient to obtain a pure sample. The 
purity of each compound in this library was later further confirmed with elemental 
analysis. 
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3.4         Experimental Methods 
3.4.1      General experimental methods 
                   Reactions were routinely monitored by thin-layer chromatography (TLC) on 
silica gel plate (precoated 60 F254 Merck plate). Column chromatographies were 
performed using silica gel 60 (Merck, 70-230 mesh). Reagents and solvents were of 
synthetic grade or better. Melting points were determined in open glass capillary tubes on 
a Gallenkamp instrument and were uncorrected. Compounds were dissolved in HPLC 
(high performance liquid chromatography)-grade methanol for determination of mass to 
charge ratio (m/z) via the LCQ Finnigan MAT mass spectrometer (source of ionization: 
atmospheric pressure chemical ionization (APCI) probe). Combustion analyses were 
performed at the laboratory of microanalysis of the Department of Chemistry, University 
of Ferrara (Italy), and were within +/- 0.6% of the theoretical values for C, H and N. 
1
H 
spectra were determined in deuterated chloroform (CDCl3) or deuterated 
dimethylsulfoxide (DMSO-d6) through a  Bruker DPX 300 MHz spectrometer, with 
chemical shifts given in parts per million (δ) downfield relative to the central peak of the 
solvents, and J values (coupling constants) given in hertz. The following abbreviations 
were used: s, singlet; bs, broad singlet; d, doublet; dd, double doublet; bd, broad doublet; 
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3.4.2   General procedure for the synthesis of 2-aryl-7- or -8-(ar)alkyl-pyrazolo[4,3-
e]-1,2,4-triazolo[1,5-c]pyrimidin-5-amines (40-55) 
 
3.4.2.1 Synthesis of 2-aryl-7- or -8-(ar)alkyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-
c]pyrimidin-5-amines (40-45, 48-55) 
               The 3-amino-4-cyano-1-methyl-pyrazole isomer (94) in the methyl series, 




 regioisomers of alkylated 3(5)-amino-4-cyano-
pyrazoles in the ethyl and phenylethyl series (96-99), as well as the corresponding 
imidates (100-104) (discussed under Section 3.3.1) were prepared as previously described 
in refs. 76, 84 and 130.   
               The obtained imidates (10 mmol) (100-104) were then dissolved in 2-
methoxyethanol (50 mL), and respective (4-substituted)-benzoic hydrazide (13 mmol) 
was added. The mixture was refluxed for 12 h at 150°C to afford the pyrazolo[3,4-
d]pyrimidines (105-118); after cooling, the solvent was removed under reduced pressure 
and the dark oily residue was cyclized further in diphenyl ether (50 mL) at 260°C. After 
3h, the mixture was poured onto cold petroleum ether (300 mL). In the ethyl and 
phenylethyl series, the precipitate was filtered off and purified by column 
chromatography (AcOEt: Petroleum ether in different ratios). The major product, N
8
-
substituted compound was obtained in reasonable yield (~50%). As in the methyl series, 
the corresponding precipitate was filtered and washed with petroleum ether and AcOEt to 
afford the N
8
-regioisomer with yield of ~60%.  
               The purified N
8
-regiosiomers (10 mmol) (compounds 119-132) were suspended 
in 20 mL of 1,4-dioxane, followed by addition of 5 mL of concentrated hydrochloric 
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acid, 37%w/w into the solution (with final concentration of HCl ~ 20%v/v). The mixture 
was refluxed for 2 h at 120°C, and after cooling, the solvent was removed under reduced 
pressure. The mixture was further basified with saturated sodium bicarbonate, and 
extracted with EtOAc (3 x 50 mL). The organic layers were dried over anhydrous 
Na2SO4 and evaporated under reduced pressure. The residue obtained was crystallized 
from EtOAc to afford the hydrolyzed compound as solid (133-146, for which the 
formation of desired regioisomer of the hydrolysed compound was determined and 
confirmed through the 2D-NOESY analysis (data not shown)). It was subjected to next 
step of reaction without further purification.  
               Such hydrolyzed derivatives (133-146) (1 mmol) were subsequently solubilized 
in 10 mL of 1-methyl-2-pyrrolidinone and cyanamide (12 mmol) was added into the 
solution, followed by p-toluene sulfonic acid monohydrate (3 mmol). The mixture was 
refluxed for 12 h at 160°C. The excess of cyanamide was precipitated out by addition of 
80 mL of EtOAc, followed by filtration and solvent from the filtrate was removed under 
reduced pressure. A brown colour residue consisting of pyrazolo-triazolo-pyrimidine 
derivatives was obtained. The residue was further purified by column chromatography 
(AcOEt: Petroleum Ether in different ratios) to obtain the pure 2-aryl-7- or -8-(aryl)alkyl-
pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-amines (40-45, 48-55).  
 
2-(phenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-amine (40): 
Yield 52%, pale yellow solid, mp 242-244°C (AcOEt-Petroleum ether) 
1
H NMR 
(300MHz, DMSO-d6) δ: 4.03 (3H, s, Me), 7.56-7.63 (5H, m, NH2 and aromatic 3H), 8.23 
(2H, d, aromatic H, 
3
JHH = 7.5 Hz), 8.59 (1H, s, pyrazolo-H). MS-APCI (methanol) m/z: 





. Anal. Calcd for C13H11N7: C, 58.86; H, 4.18; N, 36.96. Found: C, 58.80; H, 
4.33; N, 36.75. 
2-(4-fluorophenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-amine 
(41): Yield 54%, pale yellow solid, mp >300 dec°C (AcOEt-Petroleum ether) 
1
H NMR 
(300MHz, DMSO-d6) δ: 4.02 (3H, s, Me), 7.40 (2H, dd, aromatic H, 
3
JHH = 8.7 Hz, 
3
JHF 
= 8.7 Hz), 7.61 (2H, s, NH2),  8.25 (2H, dd, aromatic H, 
3
JHH = 8.7 Hz, 
4
JHF = 5.7 Hz), 
8.59 (1H, s, pyrazolo-H). MS-APCI (methanol) m/z: 284.3 [M+H]
+
. Anal. Calcd for 
C13H10N7F: C, 55.12; H, 3.56; N, 34.61. Found: C, 55.36; H, 3.37; N, 34.53. 
2-(4-chlorophenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-amine 
(42): Yield 25%, brown solid, mp 177-179°C (AcOEt-Petroleum ether) 
1
H NMR 
(300MHz, DMSO-d6) δ: 4.19 (3H, s, Me), 7.62 (2H, s, NH2), 7.66 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.23 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.58 (1H, s, pyrazolo-H). MS-
APCI (methanol) m/z: 299.5 [M]
+
. Anal. Calcd for C13H10N7Cl: C, 52.10; H, 3.36; N, 
32.71. Found: C, 52.19; H, 3.15; N, 32.79. 
2-(4-bromophenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-amine 
(43): Yield 47%, brown solid, mp >300 dec°C (AcOEt-Petroleum ether) 
1
H NMR 
(300MHz, DMSO-d6) δ: 4.21 (3H, s, Me), 7.62 (2H, s, NH2), 7.89 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.12 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.29 (1H, s, pyrazolo-H). MS-
APCI (methanol) m/z: 345.4 [M+H]
+
. Anal. Calcd for C13H10N7Br: C, 45.37; H, 2.93; N, 
28.49. Found: C, 45.66; H, 2.47; N, 28.32. 
2-(4-methoxyphenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
amine (44): Yield 54%, pale yellow solid, mp 313-314°C (DMF-EtOH) 
1
H NMR (300 
MHz, DMSO-d6): δ 3.85 (3H, s, OMe), 4.03 (3H, s, Me), 7.11 (2H, d, aromatic H,
 3
JHH = 
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8.7 Hz), 7.57 (2H, s, NH2), 8.16 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.57 (1H, s, 
pyrazolo-H). MS-APCI (methanol) m/z: 296.3 [M+H]
+
. Anal. Calcd for C14H13N7O: C, 
56.94; H, 4.44; N, 33.20. Found: C, 57.20; H, 4.39; N, 33.10. 
2-(4-nitrophenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-amine 
(45): Yield 53%, yellow solid, mp >300 dec°C (DMF-EtOH) 
1
H NMR (300 MHz, 
DMSO-d6): δ 4.04 (3H, s, Me), 7.72 (2H, s, NH2), 8.43 (2H, d, aromatic H, 
3
JHH = 9.0 
Hz), 8.47 (2H, d, aromatic H, 
3
JHH = 9.0 Hz), 8.63 (1H, s, pyrazolo-H). MS-APCI 
(methanol) m/z: 311.4 [M+H]
+
 Anal. Calcd for C13H10N8O2: C, 50.32; H, 3.25; N, 36.11. 
Found: C, 50.44; H, 3.18; N, 36.25. 
2-(4-chlorophenyl)-7-ethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-amine 
(48): Yield 35%, pale yellow solid, mp >300 dec°C (AcOEt-Petroleum ether) 
1
H NMR 
(300MHz, CDCl3) δ: 1.59 (3H, t, CH3, 
3




JHH = 7.2 
Hz), 7.49 (2H, d, aromatic H, 
3
JHH = 8.4 Hz), 8.00 (2H, s, NH2), 8.21-8.31 (3H, m, 
aromatic 2H and pyrazolo-H). MS-APCI (methanol) m/z: 314.2 [M]
+
. Anal. Calcd for 
C14H12N7Cl: C, 53.59; H, 3.86; N, 31.25. Found: C, 54.00; H, 3.74; N, 31.13. 
2-(4-chlorophenyl)-8-ethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-amine 
(49): Yield 18%, brown solid, mp >300 dec°C (AcOEt-Petroleum ether) 
1
H NMR 
(300MHz, DMSO-d6) δ: 1.47 (3H, t, CH3, 
3





7.2 Hz),  7.61 (2H, s, NH2), 7.67 (2H, d, aromatic H, 
3
JHH = 8.4 Hz), 8.22 (2H, d, 
aromatic H, 
3
JHH = 8.4 Hz), 8.61 (1H, s, pyrazolo-H). MS-APCI (methanol) m/z: 314.4 
[M]
+
. Anal. Calcd for C14H12N7Cl: C, 53.59; H, 3.86; N, 31.25. Found: C, 53.76; H, 3.91; 
N, 31.67. 




(50): Yield 17%, yellow solid, mp 137-139°C (AcOEt-Petroleum ether) 
1
H NMR 
(300MHz, DMSO-d6) δ: 3.22 (2H, t, Ph-CH2, 
3





7.2 Hz), 7.16-7.28 (5H, m, aromatic H), 7.55-7.62 (5H, m, NH2 and aromatic 3H), 8.25 
(2H, d, aromatic H 
3





Anal. Calcd for C20H17N7: C, 67.59; H, 4.82; N, 27.59. Found: C, 67.64; 
H, 4.86; N, 27.76. 
2-(4-fluorophenyl)-8-phenylethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
amine (51): Yield 21%, pale yellow solid, mp 261-263°C (AcOEt-Petroleum ether) 
1
H 
NMR (300MHz, DMSO-d6) δ: 3.22 (2H, t, Ph-CH2, 
3




JHH = 7.2 Hz), 7.12-7.28 (5H, m, aromatic H), 7.39 (2H, dd, aromatic H, 
3
JHH = 9.0 Hz, 
3
JHF = 8.7 Hz), 7.61 (2H, s, NH2), 8.24 (2H, dd, aromatic H, 
3
JHH = 8.7 Hz, 
4
JHF = 5.7 
Hz), 8.47 (1H, s, pyrazolo-H). MS-APCI (methanol) m/z: 374.8 [M+H]
+
. Anal. Calcd for 
C20H16N7F: C, 64.33; H, 4.32; N, 26.26. Found: C, 64.36; H, 4.34; N, 26.36. 
2-(4-chlorophenyl)-7-phenylethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
amine (52): Yield 25%, dark yellow solid, mp 277-279°C. (AcOEt-Petroleum ether) 
1
H 
NMR (300MHz, DMSO-d6) δ: 3.18 (2H, t, Ph-CH2, 
3




JHH = 7.2 Hz), 7.18-7.26 (5H, m, aromatic H), 7.60 (2H (d, aromatic H, 
3
JHH = 8.4 Hz), 
8.01 (2H, s, NH2), 8.14-8.24 (3H, m, aromatic 2H, and pyrazolo-H). MS-APCI 
(methanol) m/z: 390.4 [M]
+
. Anal. Calcd for C20H16N7Cl: C, 61.62; H, 4.14; N, 25.15. 
Found: C, 61.69; H, 4.16; N, 25.23. 
2-(4-chlorophenyl)-8-phenylethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
amine (53): Yield 17%, orange solid, mp 287-289°C (AcOEt-Petroleum ether) 
1
H NMR 
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(300MHz, DMSO-d6) δ: 3.22 (2H, t, Ph-CH2, 
3





7.2 Hz), 7.18-7.29 (5H, m, aromatic H), 7.62-7.65 (4H, m, NH2 and aromatic 2H), 8.21 
(2H, d, aromatic H, 
3
JHH = 8.4 Hz), 8.49 (1H, s, pyrazolo-H). MS-APCI (methanol) m/z: 
390.7 [M]
+
 Anal. Calcd for C20H16N7Cl: C, 61.62; H, 4.14; N, 25.15. Found: C, 61.75; H, 
4.12; N, 25.34. 
2-(4-bromophenyl)-8-phenylethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
amine (54): Yield 20%, beige solid, mp 295-297°C (AcOEt-Petroleum ether) 
1
H NMR 
(300MHz, DMSO-d6) δ: 3.22 (2H, t, Ph-CH2, 
3





7.2 Hz), 7.18-7.29 (5H, m, aromatic H), 7.65 (2H, s, NH2), 7.77 (2H, d, aromatic H, 
3
JHH 
= 8.4 Hz); 8.14 (2H, d, aromatic H, 
3
JHH = 8.4 Hz), 8.48 (1H, s, pyrazolo-H). MS-APCI 
(methanol) m/z: 434.6 [M]
+
. Anal. Calcd for C20H16N7Br: C, 55.31; H, 3.71; N, 22.58. 
Found: C, 55.40; H, 3.76; N, 22.76. 
2-(4-methoxyphenyl)-8-phenylethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
amine (55): Yield 15%, pale yellow solid, mp 217-219°C (AcOEt-Petroleum ether) 
1
H 
NMR (300MHz, DMSO-d6) δ: 3.22 (2H, t, Ph-CH2, 
3
JHH = 7.2 Hz), 3.84 (3H, s, CH3), 




JHH = 7.2 Hz), 7.10 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 7.13-7.26 
(5H, m, aromatic H), 7.58 (2H, s, NH2), 8.14 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.46 
(1H, s, pyrazolo-H). MS-APCI (methanol) m/z: 386.8 [M+H]
+
. Anal. Calcd for 
C21H19N7O: C, 65.44; H, 4.97; N, 25.44. Found: C, 64.49; H, 4.53; N, 25.36. 
 
3.4.2.2  Synthesis of 2-aryl-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-
5-amines (42, 43, 46, 47) 
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               The preparation of 2-aryl-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-
c]pyrimidin-5-amines 42, 43, 46 and 47 involved in the subsequent synthesis of N-[aryl-
N’-(2-aryl-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl)]carbamide 
derivatives 79-90 (discussed under Section 3.3.2) were carried out through the devised 
procedures. Firstly, to the solution of hydrazine hydrate (147) (9.7 mL, 200 mmol) in 
absolute EtOH (350 mL) at 0°C, benzaldehyde (21.2 mL, 200 mmol) was added. After 
1.5 h, ethoxymethylenemalononitrile (200 mmol) was added and the resulting solution 
was stirred for 1 h at room temperature. After cooling overnight, the yellowish 
precipitate, the {[2-benzylidenehydrazino]methylene}malononitrile (149) was collected, 
washed with cold EtOH and recrystallized from CHCl3.    
               Next, to solution of {[2-benzylidenehydrazino]methylene}malononitrile, 149 
(100 mmol) in absolute EtOH (200 mL) and 1M aqueous NaOH (110 mmol), methyl 
iodide (12.5 mL, 200 mmol) was added and the resulting solution was stirred at room 
temperature for 24 h. After cooling overnight, the yellowish product was filtered, washed 
with cold EtOH and recrystallized from EtOH. A mixture of {[(2Z)-2-benzylidene-1-
methylhydrazino]methylene}malononitrile (93) (100 mmol), 9 ml of concentrated HCl, 
37%w/w in EtOH (60 mL) was refluxed for 30 min. Solvent was removed under reduced 
pressure and the obtained solid was heated under reflux for 10 min in Et2O (30 mL). 
After cooling, the resulting precipitate was filtered and neutralized with 5M NaOH, 
followed by extraction with CHCl3. The organic layer was collected, dried over Na2SO4 
and evaporated under reduced pressure. The 3-amino-4-cyano-1-methyl-pyrazole (94) 
was obtained in good yield of 81%.  
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              After that, a mixture of 3-amino-4-cyano-1-methyl-pyrazole 94 (20 mmol) and 
triethyl orthoformate (30 mL) was heated under reflux for 8 h. Excess of triethyl 
orthoformate was removed under reduced pressure and the residue was crystallized from 
AcOEt/Hexane. To a solution of 4-cyano-3-[(ethoxymethylene)amino]-1-methylpyrazole 
(100) (6 mmol) in EtOH (20 ml) at 0°C, hydrazine hydrate (1.2 mL, 24 mmol) was 
added. 
134
 The mixture was stirred at room temperature for 5h. The resulting precipitate 
was filtered and washed with EtOH to provide 150. After that, a mixture of 150 (10 
mmol), the appropriate benzaldehyde (10 mmol) and TEA (0.42 mL, 3 mmol) in EtOH 
(30 ml) was heated under reflux overnight. After cooling, the resulting precipitate was 
filtered, washed with cold EtOH and mixed with AcOH (10 mL). To the resulting 
mixture was added an equimolar quantity of iodobenzene diacetate. After stirring at room 
temperature for 1 h, the precipitate was filtered and washed with EtOH to afford the 
desired compounds 121, 122, 151, 152 as solids.  
              Later, the mixture of 121, 122, 151, 152 (10 mmol) in 10% HCl (50 mL) was 
refluxed for 4-8 h depending on the substituent. Then, the solution was cooled and 
basified with concentrated ammonium hydroxide. The resulting precipitate was filtered 
and washed with H2O to afford the desired compounds 135, 136, 153, 154 as solids. The 
pyrazole derivatives 135, 136, 153, 154 (10 mmol) were then solubilized in 1-methyl-2-
pyrrolidinone (40 mL), followed by addition of cyanamide (60 mmol) and p-
toluenesulfonic acid (15 mmol). The mixture was heated at 160˚C for 4 h. Then, 
cyanamide (60 mmol) was added again and the solution was heated overnight. 
Subsequently, the solution was diluted with EtOAc (80 mL) and the precipitate (excess of 
cyanamide) was filtered off. The organic phase was concentrated and washed with hot 
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water (3 x 30 mL) to remove the excess of 1-methyl-2-pyrrolidinone. Then, the organic 
phase was dried with Na2SO4. The solvent was removed under reduced pressure and the 
sample was purified via chromatographic separation (EtOAc/Petroleum ether 2:1) to give 
the desired compounds. 
 
2-(4-chlorophenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-amine 
(42): Yield 25%, brown solid, mp 177-179°C (AcOEt-Petroleum ether) 
1
H NMR 
(300MHz, DMSO-d6) δ: 4.19 (3H, s, Me), 7.62 (2H, s, NH2), 7.66 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.23 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.58 (1H, s, pyrazolo-H). MS-
APCI (methanol) m/z: 299.5 [M]
+
. Anal. Calcd for C13H10N7Cl: C, 52.10; H, 3.36; N, 
32.71. Found: C, 52.19; H, 3.15; N, 32.79. 
2-(4-bromophenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-amine 
(43): Yield 47%, brown solid, mp >300 dec°C. (AcOEt-Petroleum ether) 
1
H NMR 
(300MHz, DMSO-d6) δ: 4.21 (3H, s, Me), 7.62 (2H, s,NH2), 7.89 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.12 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.29 (1H, s, pyrazolo-H). MS-
APCI (methanol) m/z: 345.4 [M+H]
+
. Anal. Calcd for C13H10N7Br: C, 45.37; H, 2.93; N, 
28.49. Found: C, 45.66; H, 2.47; N, 28.32. 
2-(4-trifluoromethylphenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-
5-amine (46): Yield 63%, pale yellow solid, mp 299-300°C (MeOH). 
1
H NMR (300 
MHz, DMSO-d6): δ 4.04 (3H, s, Me), 7.70 (2H, s, NH2), 7.95 (2H, d, aromatic H, 
3
JHH = 
8.3 Hz), 8.43 (2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.61 (1H, s). MS-APCI (methanol) m/z: 
334.2 [M+H]
+
. Anal. Calcd for C14H10N7F3: C, 50.45; H, 3.02; N, 29.42. Found: C, 
50.63; H, 3.00; N, 29.80. 




Yield 85%, pale yellow solid, mp >300°C (EtOH) 
1
H NMR (300 MHz, DMSO-d6): δ 
4.04 (3H, s, Me), 7.42 (1H, t, aromatic H, 
3
JHH = 7.2 Hz), 7.52 (2H, t, aromatic H, 
3
JHH = 
7.3 Hz), 7.65 (2H, s, NH2), 7.78 (2H, d, aromatic H, 
3
JHH = 7.5 Hz), 7.88 (2H, d, aromatic 
H, 
3
JHH = 8.3 Hz), 8.32 (2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.61 (1H, s). MS-APCI 
(methanol) m/z: 342.4 [M+H]
+
. Anal. Calcd for C19H15N7: C, 66.85; H, 4.43; N, 28.72. 
Found: C, 66.94; H, 4.18; N, 28.94. 
 
3.4.3   General procedure for the synthesis of N-(2-aryl-8-methyl-pyrazolo[4,3-e]-
1,2,4-triazolo[1,5-c]pyrimidin-5-yl)benzamides (56-61) 
               To a suspension of 0.3 mmol of 2-aryl-8-methyl-pyrazolo[4,3-e]-1,2,4-
triazolo[1,5-c]pyrimidin-5-amines (40-45) in 10 mL of toluene, 0.27g (1.2 mmol) of 
benzoic anhydride was added. The mixture was heated under reflux and stirred for 6-12 
h. The solvent was removed under reduced pressure and the residue was crystallized from 
an appropriate solvent.  
 
N-[2-(phenyl)-8-methylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
yl]benzamide (56): Yield 53%, pale yellow solid, mp 265-267°C. (AcOEt-Petroleum 
ether) 
1
H NMR (300MHz, CDCl3) δ 4.21 (3H, s, Me); 7.43-7.72 (6H, m, aromatic H), 
8.08-8.15 (2H, bd, aromatic H), 8.25 (1H, s, pyrazolo-H), 8.27-8.38 (2H, bd, aromatic H), 
9.84 (1H, s, NH). MS-APCI (methanol) m/z: 370.2 [M+H]
+
. Anal. Calcd for C20H15N7O: 
C, 65.03; H, 4.09; N, 26.54. Found: C, 65.21; H, 4.34; N, 26.61. 




yl]benzamide (57): Yield 77%, mp 270-272°C (EtOH) 
1
H NMR (300 MHz, DMSO-d6): 
δ 4.20 (3H, s, Me), 7.37 (2H, dd, aromatic H, 3JHH = 8.7 Hz, 
3
JHF = 8.7 Hz), 7.62 (2H, t, 
aromatic H, 
3
JHH = 7.3 Hz), 7.71 (1H, t, aromatic H, 
3
JHH = 7.3 Hz), 8.08 (2H, d, aromatic 
H, 
3
JHH = 7.2 Hz), 8.22 (2H, dd, aromatic H, 
3
JHH = 8.7 Hz, 
4
JHF = 5.7 Hz), 8.93 (1H, s, 
pyrazolo-H), 11.48 (1H, s, NH). MS-APCI (methanol) m/z: 388.3 [M+H]
+
. Anal. Calcd 
for C20H14N7OF: C, 62.01; H, 3.64; N, 25.31. Found: C, 61.88; H, 3.59; N, 25.67. 
N-[2-(4-chlorophenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
yl]benzamide (58): Yield 54%, mp 296-297°C (MeOH) 
1
H NMR (300 MHz, DMSO-
d6): δ 4.20 (3H, s, Me), 7.61 (2H, d, aromatic H, 
3




JHH=7.3 Hz), 7.71 (1H, t, aromatic H, 
3
JHH=7.3 Hz), 8.08 (2H, d, aromatic H, 
3
JHH=7.2 
Hz), 8.18 (2H, d, aromatic H, 
3
JHH=8.7 Hz), 8.93 (1H, s, pyrazolo-H), 11.48 (1H, s, NH). 
MS-APCI (methanol) m/z: 404.2 [M]
+
. Anal. Calcd for C20H14N7OCl: C, 59.48; H, 3.49; 
N, 24.28. Found: C, 59.02; H, 3.65; N, 24.35. 
N-[2-(4-bromophenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
yl]benzamide (59): Yield 73%, mp 292-294°C (EtOH) 
1
H NMR (300 MHz, DMSO-d6): 
δ 4.20 (3H, s, Me), 7.62 (2H, t, aromatic H, 3JHH = 7.5 Hz), 7.71 (1H, t, aromatic H, 
3
JHH 
= 7.3 Hz), 7.75 (2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.08 (2H, d, aromatic H, 
3
JHH = 7.2 
Hz), 8.11 (2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.93 (1H, s, pyrazolo-9), 11.50 (1H, s, NH). 
MS-APCI (methanol) m/z: 449.4 [M+H]
+
. Anal. Calcd for C20H14N7OBr: C, 53.59; H, 
3.15; N, 21.87. Found: C, 53.74; H, 3.01; N, 21.47. 
N-[2-(4-methoxyphenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
yl]benzamide (60): Yield 74%, mp 234-235°C (EtOH) 
1
H NMR (300 MHz, DMSO-d6): 
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δ 3.83 (3H, s, OMe), 4.20 (3H, s, Me), 7.09 (2H, d, aromatic H, 3JHH = 8.7 Hz), 7.62 (2H, 
t, aromatic H, 
3
JHH = 7.3 Hz), 7.71 (1H, t, aromatic H, 
3
JHH = 7.5 Hz), 8.08 (2H, d, 
aromatic H, 
3
JHH = 7.2 Hz), 8.11 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.91 (1H, s, 
pyrazolo-H), 11.42 (1H, s, NH). MS-APCI (methanol) m/z: 400.5 [M+H]
+
. Anal. Calcd 
for C21H17N7O2: C, 63.15; H, 4.29; N, 24.55. Found: C, 63.55; H, 4.18; N, 24.32. 
N-[2-(4-nitrophenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
yl]benzamide (61): Yield 47%, mp 295-296°C (EtOH); 
1
H NMR (300 MHz, DMSO-d6): 
δ 4.20 (3H, s, Me), 7.61 (2H, t, aromatic H,  3JHH = 7.5 Hz), 7.70 (1H, t, aromatic H, 
3
JHH 
= 7.3 Hz), 8.10 (2H, d, aromatic H, 
3




JHH = 9.0 
Hz), 8.43 (2H, d, aromatic H, 
3
JHH = 9.0 Hz), 8.94 (1H, s, pyrazolo-H), 11.57 (1H, bs, 
NH2). MS-APCI (methanol) m/z: 414.3 [M]
+
. Anal. Calcd for C20H14N8O3: C, 57.97; H, 
3.41; N, 27.04. Found: C, 58.01; H, 3.68; N, 27.13. 
 
3.4.4  General procedure for the synthesis of N-benzoyl-N-(2-aryl-8-methyl-
pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl)benzamides (62, 63) 
               To a suspension of 0.3 mmol of 2-(4-methoxyphenyl)-8-methyl-pyrazolo[4,3-
e]1,2,4-triazolo[1,5-c]pyrimidin-5-amine (44) in 5ml of toluene, 0.35 mL (3.0 mmol) of 
benzoyl chloride was added followed by DIPEA (0.52 mL, 3.0 mmol). The mixture was 
heated under reflux with stirring for 8 h. The solvent was removed under reduced 
pressure, and the bis-acylated product, 62 was later crystallized from EtOH. For the 
synthesis of 63, the same procedure was followed, with the exceptions that 0.3 mmol of 
2-(4-chloro)phenyl-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-amine (42) 
Chapter 3 Design and Synthesis 
67 
 
was suspended in 5 mL of dioxane in the presence of TEA (0.42 mL, 3.0mmol), and 
finally the bis-acylated product was crystallized from the MeOH.  
 
N-benzoyl-N-[8-methyl-2-(4-methoxyphenyl)-8H-pyrazolo[4,3-e]-1,2,4-triazolo[1,5 
c]pyrimidin-5-yl]benzamide (62): Yield 93%, mp 248-250°C (EtOH) 
1
H NMR (300 





8.7 Hz), 7.52 (4H, t, aromatic H, 
3
JHH = 7.5 Hz), 7.64 (2H, t, aromatic H, 
3
JHH = 7.3 Hz), 
7.88 (4H, d, aromatic H , 
3
JHH = 7.5 Hz), 8.00 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.96 
(1H, s, pyrazolo-H). MS-APCI (methanol) m/z: 504.4 [M]
+
. Anal. Calcd for C28H21N7O3: 
C, 66.79; H, 4.20; N, 19.47. Found: C, 67.01; H, 4.33; N, 19.44. 
N-benzoyl-N-[8-methyl-2-(4-chlorophenyl)-8H-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-
c]pyrimidin-5-yl]benzamide (63): Yield 50%, mp 278-280°C (MeOH) 
1
H NMR (300 
MHz, DMSO-d6): δ 4.15 (3H, s, Me), 7.51 (4H, t, aromatic H, 
3
JHH = 7.3 Hz), 7.58-7.69 
(4H, m, aromatic H), 7.89 (4H, d, aromatic H, 
3
JHH = 7.2 Hz), 8.08 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.99 (1H, s, pyrazolo-H). MS-APCI (methanol) m/z: 508.2 [M]
+
. Anal. 
Calcd for C27H18N7O2Cl: C, 63.85; H, 3.57; N, 19.30. Found: C, 64.00; H, 3.67; N, 19.35. 
 
3.4.5     General procedure for the synthesis of N-(2-aryl-8-phenylethyl-pyrazolo[4,3-
e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl)benzamides (64-68) 
               To a suspension of 1 mmol of 2-aryl-8-phenylethyl-pyrazolo[4,3-e]-1,2,4-
triazolo[1,5-c]pyrimidin-5-amine (50, 51, 53-55) in 10 mL of toluene, 1.81g (8 mmol) of 
benzoic anhydride was added. The mixture was refluxed and stirred for 12 h at 120°C. 
Then, the solvent was removed under reduced pressure and the residue was purified 
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through column chromatography (AcOEt: Petroleum Ether in different ratios), to obtain 
the pure N
5
-substituted pyrazolo-triazolo-pyrimidine derivatives (64-68).  
 
N-[2-(phenyl)-8-phenylethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
yl]benzamide (64): Yield 27%, light yellow solid, mp 122-124°C (AcOEt-Petroleum 
ether) 
1
H NMR (300MHz, CDCl3) δ: 3.34 (2H, t, Ph-CH2, 
3





JHH = 6.8 Hz), 7.07 (2H, d, aromatic H, 
3
JHH = 6.9 Hz), 7.22-7.24 (3H, m, 
aromatic H), 7.52-7.68 (6H, m, aromatic H), 7.96 (1H, s, pyrazolo-H), 8.08 (2H, d, 
aromatic H, 
3
JHH = 7.2 Hz), 8.26-8.27 (2H, bd, aromatic H), 9.85 (1H, s, NH). MS-APCI 
(methanol) m/z: 457.7 [M-2H]
+
. Anal. Calcd for C27H21N7O: C, 70.57; H, 4.61; N, 21.34. 
Found: C, 70.68; H, 4.59; N, 21.50. 
N-[2-(4-fluorophenyl)-8-phenylethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-
5-yl]benzamide (65): Yield 38%, pale yellow solid, mp 109-111°C (AcOEt-Petroleum 
ether) 
1
H NMR (300MHz, CDCl3) δ: 3.34 (2H, t, Ph-CH2, 
3





JHH = 6.8 Hz), 7.07 (2H, d, aromatic H, 
3
JHH = 6.0 Hz), 7.12-7.24 (5H, m, 
aromatic H), 7.54-7.71 (3H, m, aromatic H), 7.95 (1H, s, pyrazolo-H), 8.07 (2H, d, 
aromatic H, 
3
JHH = 6.9 Hz), 8.27 (2H, dd, aromatic H, 
3
JHH = 8.4 Hz, 
4
JHF = 5.7 Hz); 9.81 
(1H, s, NH). MS-APCI (methanol) m/z: 478.8 [M+H]
+
. Anal. Calcd for C27H20N7OF: C, 
67.91; H, 4.22; N, 20.53. Found: C, 68.06; H, 4.38; N, 20.53. 
N-[2-(4-chlorophenyl)-8-phenylethyl-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidin-5-
yl]benzamide (66): Yield 50%, pale yellow solid, mp 112-114°C (AcOEt-Petroleum 
ether) 
1
H NMR (300MHz, CDCl3) δ: 3.33: 2H (t, Ph-CH2, 
3





JHH = 6.6 Hz), 7.07 (2H, d, aromatic H, 
3
JHH = 6.0 Hz), 7.21-7.24 (3H, m, 
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aromatic H), 7.49 (2H, d, aromatic H, 
3
JHH = 8.4 Hz), 7.58-7.68 (3H, m, aromatic H), 
7.95 (1H, s, pyrazolo-H), 8.07 (2H, d, aromatic H, 
3
JHH = 6.6 Hz), 8.27 (2H, d, aromatic 
H, 
3
JHH = 8.1 Hz), 9.80 (1H, s, NH). MS-APCI (methanol) m/z: 494.9 [M]
+
. Anal. Calcd 
for C27H20N7OCl: C, 65.65; H, 4.08; N, 19.85. Found: C, 65.18; H, 4.13; N, 20.02. 
N-[2-(4-bromophenyl)-8-phenylethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-
5-yl]benzamide (67): Yield 62%, light yellow solid, mp 237-239°C (AcOEt-Petroleum 
ether) 
1
H NMR (300MHz, CDCl3) δ: 3.34 (2H, t, Ph-CH2, 
3





JHH = 6.8 Hz), 7.07 (2H, d, aromatic H, 
3
JHH = 6.0 Hz), 7.20-7.24 (3H, m, 
aromatic H), 7.58-7.68 (5H, m, aromatic H),  7.95 (1H, s, pyrazolo-H), 8.08 (2H, d, 
aromatic H, 
3
JHH = 6.3 Hz), 8.14 (2H, d, aromatic H, 
3
JHH = 8.4 Hz), 9.80 (1H, bs, NH). 
MS-APCI (methanol) m/z: 539.0 [M+H]
+
. Anal. Calcd for C27H20N7OBr: C, 60.23; H, 
3.74; N, 18.21. Found: C, 60.44; H, 3.68; N, 18.65. 
N-[2-(4-methoxyphenyl)-8-phenylethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-
c]pyrimidin-5-yl]benzamide (68): Yield 22%,  pale yellow solid, mp 113-115°C 
(AcOEt-Petroleum ether)
 1
H NMR (300MHz, CDCl3) δ: 3.34 (2H, t, Ph-CH2, 
3
JHH = 6.5 




JHH = 6.8 Hz), 7.03 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 7.07 (2H, d, aromatic H, 
3
JHH = 6.9 Hz), 7.22-7.24 (3H, m, aromatic H), 
7.58-7.68 (3H, m, aromatic H),  7.95 (1H, s, pyrazolo-H), 8.07 (2H, d, aromatic H, 
3
JHH = 
7.8 Hz), 8.21 (2H, d, aromatic H, 
3
JHH = 8.4 Hz), 9.84 (1H, s, NH) MS-APCI (methanol) 
m/z: 491.2 [M+2H]
+
. Anal. Calcd for C28H23N7O2: C, 68.70; H, 4.74; N, 20.03. Found: C, 
68.42; H, 4.55; N, 20.18. 
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3.4.6   General procedure for the synthesis of N-(2-aryl-8-methyl-pyrazolo[4,3-e]-
1,2,4-triazolo[1,5-c]pyrimidin-5-yl)phenylacetamides (69-74) 
               To a suspension of 0.3 mmol of 2-aryl-8-methyl-pyrazolo[4,3-e]-1,2,4-
triazolo[1,5-c]pyrimidin-5-amines (40-45) in  15 mL of toluene, 0.16 mL (1.2 mmol) of 
phenylacetyl chloride was added followed by 0.2-0.5 mL (1.2-3 mmol) of DIPEA. The 
mixture was heated under reflux with stirring for 6-12 h. The solvent was removed under 
reduced pressure and the residue was crystallized from an appropriate solvent.  
N-[2-(phenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
yl]phenylacetamide (69): Yield 50%, pale yellow solid, mp 283-285°C. (AcOEt-
Petroleum ether)  
1
H NMR (300MHz, DMSO-d6) δ 4.03 (2H, s, CH2), 4.15 (3H, s, Me); 
7.28-7.46 (5H, m, aromatic H), 7.57-7.59 (3H, m, aromatic H), 8.20-8.23 (2H, m, 
aromatic H), 8.83 (1H, s, pyrazolo-H), 10.90 (1H, bs, NH).  MS-APCI (methanol) m/z: 
384.3 [M+H]
+
. Anal. Calcd for C21H17N7O: C, 65.79; H, 4.47; N, 25.57. Found: C, 66.02; 
H, 4.62; N, 25.42. 
N-[2-(4-fluorophenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
yl]phenylacetamide (70): Yield 38%, mp 229-231°C (MeOH) 
1
H NMR (300 MHz, 
DMSO-d6): δ 4.03 (2H, s, CH2), 4.16 (3H, s, Me), 7.03 (1H, t, aromatic H, 
3
JHH = 7.0 
Hz), 7.35-7.49 (6H, m, aromatic H), 8.25 (2H, dd, aromatic H, 
3
JHH = 8.5 Hz, 
4
JHH = 5.5 
Hz), 8.84 (1H, s, pyrazolo-H), 10.90 (1H, s, NH). MS-APCI (methanol) m/z: 402.4 
[M+H]
+
. Anal. Calcd for C21H16N7OF: C, 62.84; H, 4.02; N, 24.43. Found: C, 62.34; H, 
4.17; N, 24.31. 
N-[2-(4-chlorophenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
yl]phenylacetamide (71): Yield 36%, mp 223-225°C (EtOH) 
1
H NMR (300 MHz, 
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DMSO-d6): δ 4.03 (2H, s, CH2), 4.16 (3H, s, Me), 7.31 (1H, t, aromatic H, 
3
JHH = 7.2 
Hz), 7.38 (2H, t, aromatic H, 
3
JHH = 7.3 Hz), 7.45 (2H, d, aromatic H, 
3
JHH = 7.5 Hz), 
7.66 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.21 (2H, d, aromatic H,
 3
JHH = 8.7 Hz), 8.84 
(1H, s, pyrazolo-H), 10.93 (1H, s, NH). MS-APCI (methanol) m/z: 418.4 [M]
+
. Anal. 
Calcd for C21H16N7OCl: C, 60.36; H, 3.86; N, 23.46. Found: C, 60.71; H, 3.49; N, 23.98. 
N-[2-(4-bromophenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
yl]phenylacetamide (72): Yield 63%, mp 217-218°C (MeOH) 
1
H NMR (300 MHz, 
DMSO-d6): δ 4.03 (2H, s, CH2), 4.16 (3H, s, Me), 7.31 (1H, t, aromatic H,
 3
JHH = 7.2 
Hz), 7.38 (2H, t, aromatic H,
 3
JHH = 7.3 Hz), 7.45 (2H, d, aromatic H, 
3
JHH = 7.5 Hz), 
7.80 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.14 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.84 
(1H, s, pyrazolo-H), 10.93 (1H, s, NH). MS-APCI (methanol) m/z: 463.3 [M+H]
+
. Anal. 
Calcd for C21H16N7OBr: C, 54.56; H, 3.49; N, 21.21. Found: C, 54.63; H, 3.57; N, 21.15. 
N-[2-(4-methoxyphenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
yl]phenylacetamide (73): Yield 52%, mp 225-226°C (EtOH) 
1
H NMR (300 MHz, 
DMSO-d6): δ 3.86 (3H, s, OMe), 4.03 (2H, s, CH2), 4.15 (3H, s, Me), 7.13 (2H, d, 
aromatic H,
 3
JHH = 8.7 Hz), 7.31 (1H, t, aromatic H,
 3
JHH = 7.2 Hz), 7.39 (2H, t, aromatic 
H, 
3
JHH = 7.2 Hz), 7.45 (2H, d, aromatic H, 
3
JHH = 7.2 Hz), 8.15 (2H, d, aromatic H, 
3
JHH 
= 8.7 Hz), 8.82 (1H, s, pyrazolo-H), 10.83 (1H, s, NH). MS-APCI (methanol) m/z: 413.2 
[M]
+
. Anal. Calcd for C22H19N7O2: C, 63.91; H, 4.63; N, 23.72. Found: C, 64.02; H, 4.88; 
N, 23.81. 
N-[2-(4-nitrophenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
yl]phenylacetamide (74): Yield 57%, mp 248-249°C (MeOH) 
1
H NMR (300 MHz, 
DMSO-d6): δ 4.04 (2H, s, CH2), 4.17 (3H, s, Me), 7.32 (1H, t, aromatic H, 
3
JHH = 7.0 
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Hz), 7.40 (2H, t, aromatic H, 
3
JHH = 7.3 Hz), 7.45 (2H, d, aromatic H, 
3
JHH = 6.8 Hz), 
8.45 (4H, s, aromatic H), 8.88 (1H, s, pyrazolo-H), 11.02 (1H, s, NH). MS-APCI 
(methanol) m/z: 429.4 [M+H]
+
. Anal. Calcd for C21H16N8O3: C, 58.88; H, 3.76; N, 26.16. 
Found: C, 59.03; H, 3.61; N, 26.10. 
 
3.4.7     General procedure for the synthesis of N-(2-aryl-8-phenylethyl-pyrazolo[4,3-
e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl)phenylacetamides (75-78) 
              To a suspension of 1 mmol of 2-aryl-8-phenylethyl-pyrazolo[4,3-e]-1,2,4-
triazolo[1,5-c]pyrimidin-5-amine (50, 51, 53, 54) in 10 mL of toluene, 1.1 mL (8 mmol) 
of phenylacetyl chloride was added, followed by 1.4 mL (8 mmol) of DIPEA. The 
mixture was refluxed and stirred for 24 h at 120°C. Then, the solvent was removed under 
reduced pressure and the residue was purified via column chromatography (AcOEt: 
Petroleum Ether in different ratios), to obtain the pure N
5
-substituted pyrazolo-triazolo-
pyrimidine derivatives (75-78). 
 
N-[2-(phenyl)-8-phenylethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
yl]phenylacetamide (75): Yield 19%, yellow solid, mp 92-94°C (AcOEt-Petroleum 
ether) 
1
H NMR (300MHz, CDCl3) δ: 3.34 (2H, t, Ph-CH2, 
3
JHH = 6.8 Hz), 4.51 (2H, s, 




JHH = 6.9 Hz), 7.07 (2H, d, aromatic H, 
3
JHH = 7.5 Hz), 
7.18-7.23 (3H, m, aromatic H), 7.32-7.43 (5H, m, aromatic H), 7.49-7.51 (3H, m, 
aromatic H), 7.95 (1H, s, pyrazolo-H), 8.16-8.20 (2H, bd, aromatic H), 9.18 (1H, s, NH). 
MS-APCI (methanol) m/z: 475.2 [M+2H]
+
. Anal. Calcd for C28H23N7O: C, 71.02; H, 
4.90; N, 20.71. Found: C, 71.54; H, 5.26; N, 20.17. 




5-yl]phenylacetamide (76): Yield 26%, yellow solid, mp 107-109°C (AcOEt-Petroleum 
ether) 
1
H NMR (300MHz, CDCl3) δ: 3.33 (2H, t, Ph-CH2, 
3
JHH = 6.8 Hz), 4.50 (2H, s, 




JHH = 6.9 Hz), 7.07 (2H, d, aromatic H, 
3
JHH = 7.5 Hz), 
7.15-7.23 (5H, m, aromatic H), 7.32-7.43 (5H, m, aromatic H), 7.94 (1H, s, pyrazolo-H), 
8.17 (2H, dd, aromatic H, 
3
JHH = 8.7 Hz, 
4
JHF = 5.4 Hz), 9.14 (1H, s, NH). MS-APCI 
(methanol) m/z: 492.6 [M+H]
+
. Anal. Calcd for C28H22N7OF: C, 68.42; H, 4.51; N, 
19.95. Found: C, 69.11; H, 4.94; N, 20.62. 
N-[2-(4-chlorophenyl)-8-phenylethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-
5-yl]phenylacetamide (77): Yield 20%, yellow solid, mp 108-110°C (AcOEt-Petroleum 
ether) 
1
H NMR (300MHz, CDCl3) δ: 3.33 (2H, t, Ph-CH2, 
3
JHH = 6.8 Hz), 4.49 (2H, s, 




JHH = 6.8 Hz), 7.07 (2H, d, aromatic H, 
3
JHH = 7.2 Hz), 
7.17-7.23 (3H, m, aromatic H), 7.33-7.43 (5H, m, aromatic H), 7.47 (2H, d, aromatic H, 
3
JHH = 8.4 Hz), 7.93 (1H, s, pyrazolo-H), 8.11 (2H, d, aromatic H, 
3
JHH = 8.4 Hz), 9.14 
(1H, s, NH). MS-APCI (methanol) m/z: 508.6 [M]
+
. Anal. Calcd for C28H22N7OCl: C, 
66.20; H, 4.37; N, 19.30. Found: C, 66.79; H, 4.52; N, 18.73. 
N-[2-(4-bromophenyl)-8-phenylethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-
5-yl]phenylacetamide (78): Yield 24%, yellow solid, mp 279-281°C (AcOEt-Petroleum 
ether) 
1
H NMR (300MHz, CDCl3) δ: 3.34 (2H, t, Ph-CH2, 
3
JHH = 6.9 Hz), 4.50 (2H, s, 




JHH = 6.9 Hz), 7.07 (2H, d, aromatic H, 
3
JHH = 7.5 Hz), 
7.19-7.23 (3H, m, aromatic H), 7.33-7.45 (5H, m, aromatic H), 7.64 (2H, d, aromatic H, 
3
JHH = 8.4 Hz), 7.93 (1H, s, pyrazolo-H), 8.05 (2H, d, aromatic H, 
3
JHH = 8.4 Hz), 9.13 
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(1H, s, NH). MS-APCI (methanol) m/z: 552.5 [M]
+
. Anal. Calcd for C28H22N7OBr: C, 
60.88; H, 4.01; N, 17.75. Found: C, 61.51; H, 4.39; N, 17.32. 
 
3.4.8  General procedure for the synthesis of N-aryl-N’-(2-aryl-8-methyl-
pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl)carbamides (79-90) 
               A mixture of amino compounds 42, 43, 46, 47 (1 mmol) and the appropriate 
phenylisocyanate (4.5 mmol) in toluene (10 mL) was heated under reflux at 120°C 
overnight. After cooling, the resulting mixture was filtered and washed with EtOH to 
afford the final compounds 79-90. 
 
N-[(2-(4-chlorophenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
yl)-N’-phenyl]carbamide (79): Yield 72%, white solid, mp >300°C (EtOH) 1H NMR 
(300 MHz, DMSO-d6): δ 4.15 (3H, s, Me), 7.13 (1H, t, aromatic H, 
3
JHH = 7.3 Hz), 7.41 
(2H, t, aromatic H, 
3
JHH = 7.7 Hz), 7.60 (2H, d, aromatic H, 
3
JHH = 7.9 Hz), 7.67 (2H, d, 
aromatic H, 
3
JHH = 8.7 Hz), 8.32 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.82 (1H, s, 
pyrazolo H), 9.94 (1H, s, N’H), 10.94 (1H, s, NH). MS-APCI (methanol) m/z: 419.5 
[M+H]
+
. Anal. Calcd for C20H15N8OCl: C, 57.35; H, 3.61; N, 26.75. Found: C, 57.26; H, 
3.40; N, 27.12. 
N-[(2-(4-bromophenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-
yl]-N’-phenyl]carbamide (80): Yield 87%, white solid, mp >300°C (EtOH) 1H NMR 
(300 MHz, DMSO-d6): δ 4.15 (3H, s, Me), 7.13 (1H, t, aromatic H, 
3
JHH = 7.7 Hz), 7.41 
(2H, t, aromatic H, 
3
JHH = 7.9 Hz), 7.60 (2H, d, aromatic H, 
3
JHH = 7.9 Hz), 7.81 (2H, d, 
aromatic H, 
3
JHH = 8.3 Hz), 8.25 (2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.82 (1H, s, 
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pyrazolo H), 9.95 (1H, s, N’H), 10.97 (1H, s, NH). MS-APCI (methanol) m/z: 464.3 
[M+H]
+
. Anal. Calcd for C20H15N8OBr: C, 51.85; H, 3.26; N, 24.19. Found: C, 51.39; H, 
3.14; N, 24.36. 
N-[(8-methyl-2-(4-trifluoromethylphenyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-
c]pyrimidin-5-yl)-N’-phenyl]carbamide (81): Yield 74%, white solid, mp 213-214°C 
(EtOH) 
1
H NMR (300 MHz, DMSO-d6): δ 4.15 (3H, s, Me), 7.14 (1H, t, aromatic H, 
3
JHH = 7.3 Hz), 7.41 (2H, t, aromatic H,  
3
JHH = 7.7 Hz), 7.60 (2H, d, aromatic H, 
3
JHH = 
7.9 Hz), 7.97 (2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.52 (2H, d, aromatic H, 
3
JHH = 8.3 Hz), 
8.84 (1H, s, pyrazolo H), 10.04 (1H, s, N’H), 10.97 (1H, s, NH). MS-APCI (methanol) 
m/z: 453.3 [M+H]
+
. Anal. Calcd for C21H15N8OF3: C, 55.75; H, 3.34; N, 24.77. Found: 
C, 55.71; H, 3.80; N, 24.33. 
N-[(2-(4-biphenyl)-8-methylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl)-N’-
phenyl]carbamide (82): Yield 59%, pale brown solid, mp, >300°C (EtOH) 
1
H NMR 
(300 MHz, DMSO-d6): δ 4.16 (3H, s, Me), 7.14 (1H, t, aromatic H, 
3
JHH = 7.3 Hz), 7.37-
7.47 (3H, m, aromatic H), 7.53 (2H, t, aromatic H, 
3
JHH = 7.5 Hz), 7.61 (2H, d, aromatic 
H, 
3
JHH = 7.9 Hz), 7.80 (2H, d, aromatic H, 
3
JHH = 7.5 Hz), 7.91 (2H, d, aromatic H, 
3
JHH 
= 8.3 Hz), 8.41 (2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.84 (1H, s, pyrazolo H), 9.93 (1H, s, 
N’H), 11.00 (1H, s, NH). MS-APCI (methanol) m/z: 460.4 [M]+. Anal. Calcd for 
C26H20N8O: C, 67.81; H, 4.38; N, 24.33. Found: C, 67.79; H, 4.33; N, 24.26. 
N-[(2-(4-chlorophenyl)-8-methylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl)-
N’-(4-fluorophenyl)]carbamide (83): Yield 73%, white solid, mp >300°C (EtOH) 1H 
NMR (300 MHz, DMSO-d6): δ 4.14 (3H, s, Me), 7.25 (2H, dd, aromatic H, 
3
JHH = 9.0 
Hz, 
3
JHF = 8.7 Hz), 7.61 (2H, dd, aromatic H, 
3
JHH = 9.0 Hz, 
4
JHF = 4.9 Hz), 7.66 (2H, d, 





JHH = 8.7 Hz), 8.31 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.82 (1H, s, 
pyrazolo H), 9.97 (1H, s, N’H), 10.95 (1H, s, NH). MS-APCI (methanol) m/z: 437.6 
[M+H]
+
. Anal. Calcd for C20H14N8OFCl: C, 54.99; H, 3.23; N, 25.65. Found: C, 55.10; 
H, 3.43; N, 25.88.  
N-[(2-(4-bromophenyl)-8-methylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl)-
N’-(4-fluorophenyl)]carbamide (84):  Yield 72%, white solid, mp >300°C (EtOH) 1H 
NMR (300 MHz, DMSO-d6): δ 4.14 (3H, s, Me), 7.25 (2H, dd, aromatic H, 
3
JHH = 9.0 
Hz, 
3
JHF = 8.7 Hz), 7.61 (2H, dd, aromatic H, 
3
JHH = 9.0 Hz, 
4
JHF = 4.9 Hz), 7.80 (2H, d, 
aromatic H, 
3
JHH = 8.3 Hz), 8.24 (2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.82 (1H, s, 
pyrazolo H), 9.98 (1H, s, N’H), 10.94 (1H, s, NH). MS-APCI (methanol) m/z: 481.5 
[M]
+
. Anal. Calcd for C20H14N8OFBr: C, 49.91; H, 2.93; N, 23.28. Found: C, 49.81; H, 
2.49; N, 23.68. 
N-[(8-methyl-2-(4-trifluoromethylphenyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-
c]pyrimidin-5-yl)-N’-(4-fluorophenyl)]carbamide (85):  
Yield 74%, pale yellow solid, mp 298-299°C (EtOH) 
1
H NMR (300 MHz, DMSO-d6): δ 
4.14 (3H, s, Me), 7.24 (2H, dd, aromatic H, 
3
JHH = 9.0 Hz, 
3
JHF = 8.7 Hz), 7.60 (2H, dd, 
aromatic H, 
3
JHH = 9.0 Hz, 
4
JHF = 4.9 Hz), 7.95 (2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.49 
(2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.81 (1H, s, pyrazolo H), 10.02 (1H, s, N’H), 10.94 
(1H, s, NH). MS-APCI (methanol) m/z: 470.5 [M]
+
. Anal. Calcd for C21H14N8OF4: C, 
53.62; H, 3.00; N, 23.82. Found: C, 53.97; H, 2.78; N, 23.86. 
N-[(2-(4-biphenyl)-8-methylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl)-N’-
(4-fluorophenyl)]carbamide (86): Yield 84%, white solid, mp >300°C (EtOH) 
1
H NMR 
(300 MHz, DMSO-d6): δ 4.15 (3H, s, Me), 7.25 (2H, dd, aromatic H, 
3
JHH = 9.0 Hz, 
3
JHF 
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= 8.7 Hz), 7.43 (1H, t, aromatic H, 
3
JHH = 7.2 Hz), 7.52 (2H, t, aromatic H, 
3
JHH = 7.3 
Hz), 7.62 (2H, dd, aromatic H, 
3
JHH = 9.0 Hz, 
4
JHF = 4.9 Hz), 7.79 (2H, d, aromatic H, 
3
JHH = 7.5 Hz), 7.90 (2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.39 (2H, d, aromatic H, 
3
JHH = 
8.3 Hz), 8.83 (1H, s, pyrazolo H), 9.94 (1H, s, N’H), 10.97 (1H, s, NH). MS-APCI 
(methanol) m/z: 479.5 [M+H]
+
. Anal. Calcd for C26H19N8OF: C, 65.26; H, 4.00; N, 
23.42. Found: C, 65.64; H, 3.78; N, 23.11. 
N-[(2-(4-chlorophenyl)-8-methylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl)-
N’-(4-methoxyphenyl)]carbamide (87): Yield 94%, white solid, mp 252-253°C (EtOH) 
1
H NMR (300 MHz, DMSO-d6): δ 3.77 (3H, s, OMe), 4.14 (3H, s, Me), 6.99 (2H, d, 
aromatic H, 
3
JHH = 9.0 Hz), 7.50 (2H, d, aromatic H, 
3
JHH = 9.0 Hz), 7.67 (2H, d, 
aromatic H, 
3
JHH = 8.3 Hz), 8.32 (2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.82 (1H, s, 
pyrazolo H), 9.85 (1H, s, N’H), 10.83 (1H, s, NH). MS-APCI (methanol) m/z: 448.4 
[M]
+
. Anal. Calcd for C21H17N8O2Cl: C, 56.19; H, 3.82; N, 24.96. Found: C, 56.65; H, 
3.51; N, 24.37. 
N-[(2-(4-bromophenyl)-8-methylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl)-
N’-(4-methoxyphenyl]carbamide (88): Yield 84%, white solid, mp >300°C (EtOH) 1H 
NMR (300 MHz, DMSO-d6): δ 3.77 (3H,s, OMe), 4.14 (3H, s, Me), 6.99 (2H, d, 
aromatic H, 
3
JHH = 9.0 Hz), 7.50 (2H, d, aromatic H, 
3
JHH = 9.0 Hz), 7.81 (2H, d, 
aromatic H, 
3
JHH = 8.3 Hz), 8.25 (2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.82 (1H, s, 
pyrazolo H), 9.85 (1H, s, N’H), 10.83 (1H, s, NH). MS-APCI (methanol) m/z: 494.2 
[M+H]
+
. Anal. Calcd for C21H17N8O2Br: C, 51.13; H, 3.47; N, 22.71. Found: C, 51.58; H, 
3.18; N, 22.66. 




c]pyrimidin-5-yl)-N’-(4-methoxyphenyl)]carbamide (89): Yield 59%, white solid, mp 
211-213°C (EtOH) 
1
H NMR (300 MHz, DMSO-d6): δ 3.77 (3H, s, OMe), 4.15 (3H, s, 
Me), 6.98 (2H, d, aromatic H, 
3
JHH = 9.0 Hz), 7.50 (2H, d, aromatic H, 
3
JHH = 9.0 Hz), 
7.96 (2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.51 (2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.82 
(1H, s, pyrazolo H), 9.91 (1H, s, N’H), 10.82 (1H, s, NH). MS-APCI (methanol) m/z: 
483.2 [M+H]
+
. Anal. Calcd for C22H17N8O2F3: C, 54.77; H, 3.55; N, 23.23. Found: C, 
55.10; H, 3.68; N, 23.51. 
N-[(2-(4-biphenyl)-8-methylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidin-5-yl)-N’-
(4-methoxyphenyl)]carbamide (90): Yield 55%, white solid, mp >300°C (EtOH) 
1
H 
NMR (300 MHz, DMSO-d6): δ 3.77 (3H,s, OMe), 4.15 (3H, s, Me), 6.99 (2H, d, 
aromatic H, 
3
JHH = 9.0 Hz), 7.43 (1H, t, aromatic H, 
3
JHH = 7.3 Hz), 7.51 (2H, d, aromatic 
H, 
3
JHH = 9.0 Hz), 7.52 (2H, t, aromatic H, 
3
JHH = 7.3 Hz), 7.79 (2H, d, aromatic H, 
3
JHH 
= 7.5 Hz), 7.90 (2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.40 (2H, d, aromatic H, 
3
JHH = 8.3 
Hz), 8.83 (1H, s, pyrazolo H), 9.81 (1H, s, N’H), 10.85 (1H, s, NH). MS-APCI 
(methanol) m/z: 490.2 [M]
+
. Anal. Calcd for C27H22N8O2: C, 66.11; H, 4.52; N, 22.84. 
Found: C, 66.67; H, 3.84; N, 23.29. 
 
3.5        Summary  
             The synthesis of 51 new 2-aryl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine 
derivatives was successfully achieved using optimized synthetic procedures as described 
above. The formation of the PTP derivatives was confirmed from 
1
H NMR and mass 
spectrometry (nominal mass). The purity of the compounds was determined by 
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combustion analysis (combustion analysis data of newly synthesized compounds 40-90 
were tabulated in Table A2 under Appendix). Compounds that gave the the experimental 
C, H and N values within +/- 0.6% of the theoretical values were considered to be 
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Chapter 4 Pharmacological Evaluation on a New Series of Pyrazolo-
Triazolo-Pyrimidine Derivatives  
 
The information related to the pharmacological evaluation of the synthesized compounds 
in this chapter has been reported in the following research articles:  
 Cheong, S. L.; Dolzhenko, Ann.; Kachler, S.; Paoletta, S.; Federico, S.; Cacciari, 
B.; Dolzhenko, Ant.; Klotz, K-N.; Moro, S.; Spalluto, G.; Pastorin, G. The 
significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a 
new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA3 
adenosine receptor’s antagonists: New insights into structure-affinity-relationship 
and receptor-antagonist recognition. J. Med. Chem. 2010, 53, 3361-3375  
 
 Cheong, S. L.; Dolzhenko, Ant. V.; Paoletta, S.; Lee, E. P. R.; Kachler, S; 
Federico, S.; Klotz, K-N.; Dolzhenko, Ann. V; Moro, S.; Spalluto, G.; Pastorin, G. 






 positions of 
the pyrazolo-triazolo-pyrimidine scaffold guarantee a selective modulation of the 
human A3 adenosine receptors? Bioorg. Med. Chem. 2011, 19, 6120-6134  
 
* Pharmacological assays for the new series of 2-aryl-PTP derivatives were performed by 
our collaborator, Professor Karl-Norbert Klotz, at the Institute for Pharmacology and 
Toxicology, University of Würzburg, Germany. 
 
4.1       Introduction 
            In this chapter, we described the binding affinities of the new series of 2-aryl-
pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidines at the human A1, A2A and A3 adenosine 
receptor subtypes, as well as the adenylyl cyclase activity of the derivatives at the human 
A2B receptor.  The selectivities of these compounds towards the hA3 receptor were also 
assessed by comparing the binding affinity values (Ki) against the hA3 receptor with Ki 
values against the hA1 and hA2A receptors. To further confirm the hA3 binding affinity 
data obtained from the binding assay, 2-aryl-PTPs that possessed both the high hA3 
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binding affinity and selectivity profile were subjected to a functional assay such as an 
adenylyl cyclase activity assay, to determine the effect of the tested compounds on the 
production of cyclic adenosine monophosphate (cAMP) inhibited by a known hA3 
agonist.  
 
4.1.1      Binding at human A1, A2A and A3 adenosine receptors 
              The affinities of tested compounds 40-90 towards respective adenosine receptors 
(expressed in Chinese Hamster Ovary cells (CHO) for hA1, hA2A, hA3 receptors) were 
evaluated through the measurement of displacement of selective radioligands, 
135-138
 
which were previously bound to the receptor expressed at the cell surface. The lower is 
the amount of a tested compound required to displace the radioligands from the 
respective receptor, the higher is the affinity of the compound for the particular receptor 










N-ethylcarboxamido adenosine) binding at both the hA2A and hA3 receptors. The data 
were expressed as Ki (dissociation constant), which was calculated from the Cheng and 
Prusoff equation (Ki = IC50 / (1 + [C*] / KD*), where [C*] is the concentration of the 
radioligand and KD* is the dissociation constant of the radioligand), 
138
 with geometric 
means of at least 3 experiments, including 95% confidence intervals. 
 
4.1.2      Adenylyl cyclase activity at human A2B and A3 adenosine receptors 
              Because of the lack of a suitable radioligand for hA2B receptor in binding assay, 
the potency of compounds 40-90 at the hA2B receptor (expressed in CHO cells) was 
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determined in adenylyl cyclase experiments instead. The experiment procedures were 
carried out as described previously in Klotz et al. with minor modifications. 
135, 136
 In this 
assay, a non-selective adenosine agonist, NECA, at known concentration was subjected 
to inhibitory effect of tested compounds. Different from the hA3 receptor, the activation 
of hA2B receptor led to stimulation of adenylyl cyclase, followed by conversion of ATP 
into cAMP. Upon the binding of tested antagonist to the hA2B receptor, the stimulation of 
adenylyl cyclase induced by the agonist NECA is blocked, with eventual decrease in the 
cAMP production. Different concentrations of tested compound would result in different 
levels of cAMP accumulation. The IC50 for each compound was obtained and 
corresponding Ki was then calculated from the Cheng and Prusoff equation, with 
geometric means of at least 3 experiments, including 95% confidence intervals. In the 
case of the hA3 receptor, a similar adenylyl cyclase assay was also carried out on selected 
compounds to assess the antagonistic potencies of these compounds on the hA3 agonist 
(i.e. Cl-IB-MECA)-inhibition of cAMP production at the hA3 receptor. In such a 
functional assay, the obtained IC50 values of the tested antagonists at the hA3 receptor 
were expected to be correlated with the Ki values observed in the binding assays. 
 
4.2        Experimental Methods 
4.2.1     CHO membrane preparation 
                 All the pharmacological methods involving in membrane preparation for 
radioligand binding experiments followed the procedures as described in Klotz et al..
 135
 
             Membranes for radioligand binding were prepared from cells stably transfected 
with the human adenosine receptor subtypes (hA1, hA2A, hA2B and hA3 expressed on 
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CHO cells) in a two-step procedure. In the first low-speed step (1,000 x g for 4 min), the 
cell fragments and nuclei were removed. After that, the crude membrane fraction was 
sedimented from the supernatant at 100,000 x g for 30 min. The membrane pellet was 
then resuspended in the specific buffer used for the respective binding experiments, 
frozen in liquid nitrogen and stored at -80°C. For the measurement of the adenylyl 
cyclase activity, only one step of centrifugation was used, in which the homogenate was 
sedimented for 30 min at 54,000 x g. The resulting crude membrane pellet was 
resuspended in 50 mM Tris/HCl, pH 7.4 and immediately used for the adenylyl cyclase 
assay. 
 
4.2.2     Human cloned A1, A2A, A3 adenosine receptor binding assay 
             Binding of [
3
H]-CCPA to CHO cells transfected with the human recombinant A1 
adenosine receptors was performed as previously described in Klotz et al. and Lohse et 
al. 
135, 136, 139
. Displacement experiments were performed for 3 h at 25°C in 200 µL of 
buffer containing 1 nM [
3
H] CCPA, 0.2 U/mL adenosine deaminase, 20 µL of diluted 
membranes (50 μg of protein/assay) in 50 mM Tris/HCl, pH 7.4 and tested compound in 




             Binding of [
3
H]-NECA to CHO cells transfected with the human recombinant 
A2A adenosine receptors was performed following the conditions as that described for the 
A1 receptor binding. 
135, 136
 In the displacement experiments, samples containing a protein 
concentration of 50 μg/assay in buffer, 30 nM [3H]-NECA and tested compound in 
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different concentrations were incubated for 3 h at 25°C. Nonspecific binding was 
determined in the presence of 100 μM R-PIA (R-N6-phenylisopropyladenosine). 137 
              Binding of [
3
H]-NECA to CHO cells transfected with the human recombinant A3 
adenosine receptors was carried out as previously described. 
135, 136
 The displacement 
experiments were performed for 3 h at 25°C in buffer solution containing 10 nM [
3
H]-
NECA, 20 μg membrane protein in 50mM Tris-HCl, 1 mM EDTA 
(ethylenediaminotetraacetate), 10 mM MgCl2, pH 8.25 and tested compound in different 






              Bound and free radioactivity was separated by filtering the assay mixture 
through Whatman GF/B glass-fiber filters using a Micro-Mate 196-cell harvester 
(Packard Instrument Company). The filter bound radioactivity was counted on Top Count 
(efficiency of 57%) with Micro-Scint 20. The protein concentration was determined 
according to the Bio-Rad method
 140 
with bovine albumin used as a reference standard. 
 
4.2.3    Adenylyl cyclase activity assay 
            As mentioned earlier, due to the lack of a suitable radioligand for hA2B receptor in 
binding assay, the potency at hA2B receptor (expressed in CHO cells) of antagonists was 
determined in adenylyl cyclase experiments instead. In addition, the corresponding assays 
were also performed at the hA3 receptor in order to determine and confirm the potency of 
tested compounds at this receptor subtype. The procedure was carried out as described 
previously with minor modifications. 
135, 136
  
Chapter 4 Pharmacological Evaluation 
85 
 
            Membranes transfected with hA2B receptor and hA3 receptor were incubated with 
100 nM NECA and 1 μM Cl-IB-MECA, respectively, as well as 150,000 cpm of [α-
32
P]ATP and tested compounds in different concentrations for 20 min in the incubation 
mixture as described 
135, 136
 without EGTA (ethylene glycol tetraacetic acid) and NaCl. 
The IC50 values for concentration-dependent inhibition of NECA/Cl-IB-MECA-mediated 
adenylyl cyclase activity caused by tested antagonists were calculated accordingly.  
 
4.2.4   Data analysis 
           In the binding affinity assay, the concentration of the tested compounds that 




H]-NECA (IC50) was calculated 
using a non-linear curve fitting method implemented in the SCT-FIT program as 
described by De Lean et al. 
137
 with different concentrations of tested compounds, each 
performed in triplicate. The dissociation constant (Ki) values were calculated from IC50 
according to the Cheng and Prusoff equation. 
138 
IC50 values obtained in the adenylyl 
cyclase activity assay were calculated from non-linear regression analysis using the 
equation for a sigmoidal concentration-response curve with different concentrations of 
tested compounds, each performed in triplicate. Similarly, the corresponding Ki values of 
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4.3       Results and Discussion  
4.3.1    Structure-affinity relationships  
                The new series of pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidines was 
subjected to pharmacological evaluation on their binding affinities at all the four 
adenosine receptors. Table 2 summarizes the receptor binding affinities of compounds 
40-90 determined at the human A1, A2A, A3 receptors and the corresponding adenylyl 
cyclase activity in CHO cells which expressed the human A2B receptors. 
            We introduced little modifications at the pyrazole ring, in order to focus our 
investigation on the exploitation at position C
2
. In fact, only 2 compounds (compounds 
48 and 52, bearing a substituent at N
7
 instead of N
8
) were strategically included in the 
library to confirm the necessity to have a small alkyl group at N
8
 for an optimal 
interaction with the hA3 receptor subtype. 
84
 For the rest of the derivatives, we fixed the 
methyl (compounds 40-47), ethyl (compound 58) and phenylethyl (compounds 50, 51, 
53-55) groups at N
8





(compounds 56-90). The binding assay results showed that the new series of 2-
aryl-pyrazolo-triazolo-pyrimidines presented good affinity at hA3 receptors, as indicated 
by low nanomolar range of Ki values and most importantly, considerably improved 
selectivity relative to the other adenosine receptor subtypes (Table 2).  
 
4.3.1.1  Effect of substitution at C
2
-position of PTPs on hA3 affinity and selectivity 
profile  
              To examine the impact of the furan ring substitution with a phenyl ring at C
2
- 
position towards the pharmacological profile, we compared the binding assays results 
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between the new 2-aryl derivatives (e.g. compounds 40, 50, 69 and 75) and 2-furyl 
counterparts (e.g. compounds 25, 155-157)
 
(Table 3). 
84, 87, 90 
In the pairs of 2-aryl-/2-
furyl-PTP derivatives bearing an amino, benzamide or phenyacetamide group at the N
5
-
position, it was observed that the bioisosteric replacement of the furan ring with a phenyl 
ring resulted in a 3-15 fold increase in affinity towards the hA3 receptor and significant 
improvement in selectivity (of 2-3 order of magnitude) over other adenosine receptor 
subtypes, namely hA1, hA2A and hA2B receptors. In other words, those compounds with a 
phenyl ring at C
2
-position have demonstrated better affinity and selectivity profiles 
towards hA3 receptor as compared to their 2-furyl counterparts, indicating that the aryl 
group at the C
2
-position played a more essential role on the hA3 affinity and selectivity 
against other adenosine receptors. 
            Nonetheless, we noticed a different trend of hA3 affinity subsequently in a new 
series of 2-aryl-8-methyl-PTPs bearing an arylcarbamoyl moiety at the N
5
-position (79-
90), despite the fact that these compounds still maintained good hA3 affinity in low 
nanomolar range (in the range of 1.3-5.9 nM). In fact, it was found that the bioisosteric 
replacement of the furan ring with an aryl ring in such a group of compounds caused 7- to 
37-fold decrease of affinity towards the hA3 receptor. Notably, the selectivity over other 
adenosine receptor subtypes of these 2-aryl-PTP derivatives (e.g. compound 81, with 
KihA3 = 3.44 nM; hA1/hA3 = 3,750; hA2A/hA3 = 10,500 and compound 89, with KihA3 = 
2.36 nM; hA1/hA3 > 42,400; hA2A/hA3 > 42,400) was still greatly improved relative to 
that of 2-furyl analogues (e.g. compound 29, 
90 
with KihA3 = 0.16 nM; hA1/hA3= 3,740; 
hA2A/hA3 = 2,380 and compound 158, 
90 
with KihA3 = 0.20 nM; hA1/hA3 = 5,490; 
hA2A/hA3 = 6,950) (Table 3). These findings suggested that the presence of 2-
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Table 2. Binding affinities (Ki) at hA1, hA2A, hA2B and hA3 adenosine receptors and selectivities against hA1 and hA2A 
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> 10,000 565 
(518-615) 
0.21 0.15 







> 10,000 68.7 
(52.9-89.3) 
22.9 12.3 





























> 100,000 5,970 
(4,090-8,720) 
> 10,000 > 30,000 > 3.00 < 0.200 










































































58 NH-COPh Cl N





59 NH-COPh Br N





60 NH-COPh OCH3 N





61 NH-COPh NO2 N





62 N(CO-Ph)2 OCH3 N
8-CH3 > 10,000 > 10,000 > 10,000 6.88 
(3.94-12.0) 
>1,450 >1,450 
63 N(CO-Ph)2 Cl N























































































































73 NH-COCH2Ph OCH3 N









































































80 NH-CO-NH-Ph Br N

































82 NH-CO-NH-Ph Ph N
8-CH3 >30,000 >30,000 >10,000 5.90 
(3.33-10.5) 
>5,090 >5,090 
83 NH-CO-NH-(4-F)Ph Cl N





84 NH-CO-NH-(4-F)Ph Br N





85 NH-CO-NH-(4-F)Ph CF3 N
8-CH3 4,420 
(1,700-11,500) 
>30,000 >10,000 1.91 
(1.01-3.59) 
2,310 >15,700 
86 NH-CO-NH-(4-F)Ph Ph N
8-CH3 >100,000 >100,000 >10,000 4.06 
(3.17-5.19) 
>24,600 >24,600 








88 NH-CO-NH-(4-OCH3)Ph Br N





89 NH-CO-NH-(4-OCH3)Ph CF3 N
8-CH3 >100,000 >100,000 >10,000 2.36 
(1.46-3.80) 
>42,400 >42,400 
90 NH-CO-NH-(4-OCH3)Ph Ph N




Displacement of specific [
3
H]-CCPA binding at human A1 receptors expressed in CHO cells, (n=3). 
b
Displacement of 
specific      [
3
H]-NECA binding at human A2A receptors expressed in CHO cells, (n=3). 
c
Ki values of the inhibition of 
NECA-stimulated adenylyl  cyclase activity in CHO cells, (n=3). 
 d
Displacement of specific [
3
H]-NECA binding at human 
A3 receptors expressed in CHO cells, (n=3). Data are expressed as geometric means, with 95% confidence intervals.
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Table 3. Binding affinities (Ki) at hA3 adenosine receptor and selectivities against hA1 
and hA2A adenosine receptors for compounds 25, 155-158 and 40, 50, 69, 75, 89.  
 



















R2                                
                      25, 155-158               40, 50, 69, 75, 89 
Compd. R R1 R2
 
hA3Ki, (nM) hA1/hA3 hA2A/hA3 







40 H H CH3 75.0 4.52 1.61 







50 H H PhCH2CH2 76.7 0.975 2.56 







69 Ph-CH2CO H CH3 0.108 5,200 7,200 







75 Ph-CH2CO H PhCH2CH2 3.02 63.6 203 







89 NH-CO-NH-(4-OCH3)Ph CF3 CH3 2.36 >42,400 >42,400 
a
Data taken from refs. 84 and 90. 
b
Data taken from ref. 87.
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furyl ring in this group of 8-methyl-PTP-N
5
-arylcarbamides was more favourable than 
the 2-aryl ring to acquire better hA3 affinity profile. Even so, the introduction of an aryl 
ring at the C
2
-position was deemed crucial to confer higher selectivity towards hA3 
receptor in comparison to the 2-furyl ring, while maintaining good affinity at the hA3 
receptor.    
             In addition, we also evaluated the effect of para-substituents on the 2-phenyl ring 
towards the affinity profile at the hA3 receptors. Based on the binding results, the 
substituents (e.g. Cl, F, Br, OCH3, NO2, CF3, Ph) at the para-position of the C
2
-phenyl 
ring were found to modulate the affinity at hA3AR to a certain extent. In particular, 
among the substituents introduced at the para-position of the phenyl ring, both the OCH3 
and F groups have exerted relatively more favourable effect on the affinity at hA3 
receptor in all the N
5
-unsubstituted (e.g. compound 44, with KihA3 = 16.7nM; hA1/hA3 = 
583; hA2A/hA3 = 71.3), N
5
-benzamide-substituted  (e.g. compound 60,  with KihA3 = 
2.1nM;  hA1/hA3 > 14300;  hA2A/hA3 > 47600) and N
5
-phenylacetamide-substituted (e.g. 
compound 73, with KihA3 = 0.241 nM; hA1/hA3 > 124,000; hA2A/hA3 > 415,000) 
derivatives. Additionally, such 4-OCH3 group on the 2-phenyl ring was shown to confer 
good selectivity against the hA1, hA2A and hA2B receptors as well. 
             Interestingly, although all the compounds with a 2-(para-bromo)-phenyl moiety 
in the N
8
-methyl series showed good affinity at the hA3 receptor (e.g. compound 72, with 
KihA3 = 0.345 nM; hA1/hA3 = 70,700; hA2A/hA3 > 290,000), its presence in the N
8
-
phenylethyl-substituted derivatives (e.g. compound 67, with KihA3 = 153 nM; hA1/hA3 = 
1.76; hA2A/hA3 > 654 and compound 78, with KihA3 > 10,000 nM; KihA1, KihA2A > 
binding site, resulting in detrimental effect on the hA3 affinity.  
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              Besides that, it was observed that some N
8
-methyl-substituted compounds 
bearing a 2-(para-nitro)phenyl ring (e.g. compound 45, with KihA3 = 655 nM; hA1/hA3 > 
458; hA2A/hA3 > 15.3) have acquired hA3 affinity in relatively high nanomolar range. 
Consistently, compound 61 (with a 2-(para-nitro) phenyl ring, a methyl at N
8
 and a 
benzamide at N
5
) only demonstrated comparatively moderate affinity at hA3 receptor 
(KihA3 = 56.4 nM) in comparison to the other derivatives with different substituents at 
C
2
-position (compounds 57-60), which have shown better hA3 affinity profiles (2-5 nM). 
These observations could again be attributed to the steric constraint of the relatively 
bigger NO2 group as compared to other para-substituents. This rendered the nitro group 
unable to bind firmly onto the binding cavity, thus affecting the affinity at the hA3 
receptor. In light of the consideration that the nitro group might not be a suitable 
substituent at the C
2
-position, it was therefore excluded from the subsequent series of N
8
-
phenylethyl derivatives. Similarly, the introduction of functional groups with relatively 
high molecular volume, like 4-trifluoromethyl (e.g. compound 46, with KihA3 = 304 nM) 
and 4-phenyl ring (e.g.compound 47, with KihA3 = 147 nM) on the 2-phenyl ring of some 
N
5
-unsubstituted derivatives also seemed intolerable towards the hA3 affinity, as shown 
by their high nanomolar affinity at the hA3 receptor.  From these findings, we could again 
infer that the incorporation of bulky groups at the para-position of C
2
-phenyl ring was 
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4.3.1.2  Effect of substitution at N
5
-position of PTPs on hA3 affinity and selectivity 
profile      
             From the binding assay results, it was noticed that the absence of any substituent 
at N
5
-position (such as in compounds 40-55) of 2-aryl-PTPs did not allow good 
discrimination among the adenosine receptor subtypes, except for the hA2B receptor.  In 
other words, the free amino group at N
5
 not only bound to the hA3 receptor, but it also 
showed good interaction at both hA1 and hA2A receptors. This observation was consistent 





 In fact, further incorporation of substituents at the N
5
- 
position (as shown in compounds 56-90) enabled a shift of affinity towards the hA3 
subtype with a concomitant decrease of affinity at hA1 and hA2A receptors, thus 
improving selectivity in favour of the hA3 subtype. This finding seemed to imply that the 
hA3 binding cavity around the N
5
-position was sufficiently spacious to accommodate the 
extended chains, in this case the benzoyl, phenylacetyl and arylcarbamoyl groups. 
Among these substituents, the relatively flexible phenylacetyl group (e.g. compound 72, 
with KihA3 = 0.345 nM; hA1/hA3 = 70,700; hA2A/hA3 > 290,000) showed relatively 
better binding profile than the shorter benzoyl chain (e.g. compound 59, with KihA3 = 
5.24 nM; hA1/hA3 > 5,730; hA2A/hA3 > 19,100) as well as the rigid arylcarbamoyl chain 
(e.g. compound 80, with KihA3 = 2.50 nM; hA1/hA3 > 4,000; hA2A/hA3 = 944). The 
incorporation of para-substituents such as fluoro and methoxy groups on the phenyl ring 
of arylcarbamoyl moiety seemed tolerable to maintain good affinity at A3 receptor in the 
range of 1.33 to 5.90 nM. 
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               Moreover, the spare H on the nitrogen atom at N
5
 did not seem to be crucial, 
since its replacement with an additional benzoyl chain (as in compounds 62, KihA3 = 6.88 
nM and 63, KihA3 = 6.94 nM), although less favourable than a single chain, still 
maintained affinity at hA3 receptor and good selectivity (> 1,400) against other receptor 
subtypes. This finding again confirmed the postulation that the binding pocket of hA3 
receptor around this N
5
-position was large enough to accommodate the bulky and 
branched bis-benzamidic substituent; at hA1 and hA2A subtypes, there was limited space 
available for such bulky groups and resulted in decrease of affinity with subsequent 
increase of selectivity against these two receptors.  
 
4.3.1.3   Effect of substitution at N
8
-position of PTPs on hA3 affinity and selectivity 
profile             
                It was found that when a small alkyl group, like methyl was present at N
8
, the 
compounds (40-47, 56-63, 69-74 and 79-90) showed a preference for hA3 receptors, 




-positions (e.g. compounds 40 [(with a phenyl 
at C
2
 and a free amino at N
5
), KihA3 = 75.0 nM] and 41 [(with a 4-fluorophenyl at C
2
 and 
a free amino at N
5
), KihA3 = 31.4 nM] versus compounds 56 [(with a phenyl at C
2
 and a 
benzamide at N
5
), KihA3 = 5.0 nM] and 57 [(with a 4-fluorophenyl at C
2
 and a benzamide 
at N
5
), KihA3 = 3.43 nM]. This was further confirmed by the introduction of a slightly 
longer alkyl chain (e.g. an ethyl group in compound 49, with KihA3 = 68.7 nM; hA1/hA3 
= 22.9; hA2A/hA3 = 12.3), which still showed hA3 affinity and moderate selectivity. 




 (as in compounds 
48, with KihA3 = 565 nM and 52, with KihA3 > 30,000 nM), the affinity at hA3 receptors 
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dropped of at least 8 times, with the resulting binding affinity profile inclined towards 
hA2A receptors. This observation was substantiated by the results previously reported on 
the N
7
-substituted PTPs as potent hA2A antagonists. 
78
 
               Conversely, when a group bigger than ethyl was introduced at N
8
 (e.g. 
phenylethyl group in compounds 50, 51, 53-55, 64-68 and 75-78), a decrease of affinity 
at hA3 receptor was observed. In derivatives with free amino group at N
5
-position, the 
substitution of the methyl group (e.g. compound 44, with KihA3 = 16.7 nM) with the long 
and bulky phenylethyl group (e.g. compound 55, with KihA3 = 25.0 nM) showed only a 
slight decrease of the hA3 affinity. When a substituent was introduced at the N
5
-position, 
the presence of the phenylethyl group (e.g. compound 64, with KihA3 = 23.9 nM; 
compound 75, with KihA3 = 3.02 nM) seemed to have resulted in a great decrease of hA3 
affinity in comparison to its N
8
-methyl counterpart (compound 56, with KihA3 = 5.0 nM; 
compound 69, with KihA3 = 0.108 nM). This might be due to reason that in the N
5
-
unsubstituted derivatives, there was still enough space for the bulky phenylethyl group to 
orientate itself inside the binding cavity. Once an additional group was introduced at the 
N
5
-position, there is limited space remaining for anchoring the phenylethyl, thus causing 
a considerable decrease of hA3 affinity. Apparently, an inverse relationship appeared 
between the binding affinity values at the hA3 receptor and the molecular volume (MV) 
of the substituent at position N
8







































Figure 13. Structure-affinity relationship pharmacophore for the new series of 2-aryl-
PTP derivatives 40-90. 
• R = NH2  moderate affinity at hA3 receptor; low selectivity against hA1 and hA2A  
                      receptors, high selectivity against hA2B receptor.  
• R = NH-COPh   high hA3 affinity and selectivity against hA1, hA2A and hA2B  
                                 receptors.  
• R = NH-COCH2Ph  confers the best hA3 affinity and high selectivity against hA1,  
                                       hA2A and hA2B receptors.  
• R = NH-CONH-(4-F/OMe)Ph  high hA3 affinity and selectivity against hA1, hA2A  
                                                        and hA2B receptors; 4-F/OMe on N
5
-Ph is tolerable  
                                                        for hA3 affinity.  
 
* Replacement of 2-furyl ring with 2-aryl ring in derivatives bearing N
5
-NH2, -NH-
COPh and -NH-COCH2Ph  improvement of hA3 affinity and significant increase of 
selectivity against hA1, hA2A and hA2B receptors.  
* Replacement of 2-furyl ring with 2-aryl ring in derivatives with N
5
-NH-CONHPh  
 decrease of hA3 affinity but maintained in low nanomolar range; selectivity against 
hA1, hA2A and hA2B receptors is greatly improved.  
• R1 = (4-F/Cl/Br/OMe/NO2/CF3/Ph)-Ph  
  4-F/Cl/OMe are tolerable in all derivatives; 4-F/OMe gives higher hA3  
         affinity; 4-OMe gives high selectivity against hA1, hA2A and hA2B receptors.  
            4-Br is tolerable in N8-CH3 series, intolerable in N
8
-CH2CH2Ph series.  
            4-NO2 is generally not well tolerated.   
  4-CF3/Ph is tolerable in derivatives with N
5
-arylcarbamide, intolerable in  





• Small alkyl chain (e.g. CH3) gives 
good hA3 affinity and selectivity 
against hA1, hA2A and hA2B 
receptors; longer and bulky alkyl 
chain (e.g. PhCH2CH2) is 
disfavoured for hA3 affinity. 
• N7-alkyl chain is preferred for 
hA2A affinity. 
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4.3.2    Adenylyl cyclase activity assay at hA3 receptor  
            Compounds 60 and 73 which showed both high hA3 receptor affinity and 
selectivity, were selected for the adenylyl cyclase activity assay, in which the inhibition of 
adenylyl cyclase (hence blockade of cAMP generation) by Cl-IB-MECA was measured in 
membranes of CHO cells stably transfected with hA3 receptor. Results from this specific 
functional model confirmed that the newly synthesized 2-aryl-PTPs were indeed functional 
antagonists. Both 2-aryl-PTP derivatives with high binding affinity at the hA3 adenosine 
receptors proved to be full antagonists capable of abolishing the effect of Cl-IB-MECA, 
with potencies corresponded to that observed in the binding assay (as shown in Table 4 and 
concentration-response curves Figures 14 (A) and (B)). In particular, compound 73, with a 
binding affinity at hA3AR of 0.241 nM inhibited the effect of 1μM Cl-IB-MECA at a mean 
IC50 value of 2.46 nM. 
 
Table 4. Ki and IC50 values from binding affinity and adenylyl cyclase activity assay at hA3 








(95% CI) hA1/hA3 hA2A/hA3 
60 2.10 
(1.37-3.24) 




>124,000 >415,000 2.46 
(1.50-4.03) 
a
Ki values obtained from binding affinity assay. 
b
IC50 values obtained from adenylyl 
cyclase assay. Data are expressed as geometric means of at least three experiments, with 
95% confidence intervals. 
 





























Figure 14. Concentration-response curve (for one of the experiments) of cAMP 
accumulation in hA3 adenosine receptor by tested antagonists (A) 60 and (B) 73 blocking 




Log concentration of Compound 60 (M) 
Log concentration of Compound 73 (M) 
Compound 60 
Compound 73 
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4.4       Conclusion  
            All the pertinent structure-affinity relationship (SAR) profiles observed in this new 
series of 2-aryl-PTP derivatives (compounds 40-90) is summarized in Figure 13. On the 
whole, the above-mentioned results confirmed the importance of the contemporary 
introduction, in the PTP system, of a) small substituents (e.g. CH3) at the N
8
-position to 
maintain affinity and selectivity at hA3AR; b) a longer chain such as a phenylacetyl group 
at N
5
-position to confer higher affinity and a better selectivity towards hA1, hA2A and hA2B 
receptors in comparison to both the benzamidic group and the arylcarbamoyl moiety; (c) a 
2-(para-substituted) phenyl ring at C
2
, to improve affinity and selectivity profile at hA3 
receptors (especially in 2-aryl-PTPs with N
5
-NH2, -NH-COPh and -NH-COCH2Ph) relative 
to the 2-furyl counterparts, as well as to protect from enzyme deactivation with subsequent 
higher plasma bioavailability. Moreover, the substitution of 2-furyl with an aryl group in 
the new PTP derivatives was also expected to overcome the metabolic instability and 
toxicity due to the C
2
-furan ring.  
          Among the newly synthesized 2-aryl-PTP derivatives, compound 69, with a phenyl 
at C
2
, a methyl group at N
8
 and a phenylacetamidic chain at N
5
, showed the best hA3 
binding affinity profile (Ki hA3 = 0.108 nM) and good selectivity against the other 
adenosine receptors (hA1/hA3 = 5,200; hA2A/hA3 = 7,200). In addition, compound 73 (with 
4-OCH3-phenyl at C
2
, a methyl group at N
8
 and a phenylacetamidic chain at N
5
) 
represented the new 2-aryl-PTP derivative possessing the best combined potency and 
selectivity profile, with Ki hA3 = 0.241 nM; hA1/hA3 > 124,000; hA2A/hA3 > 415,000. It 
also demonstrated high potency in inhibiting the CI-IB-MECA-mediated cAMP production 
in the adenylyl cyclase activity assay, with the IC50 value of 2.46 nM.  
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Chapter 5 Quantitative Structure-Activity Relationship (QSAR) Study on 
a New Series of Pyrazolo-Triazolo-Pyrimidine Derivatives  
 
The information related to the QSAR study on the new series of 2-aryl-PTPs in this chapter 
has been reported in the following research article:  
 Cheong, S. L.; Federico, S.; Venkatesan, G.; Paira, P.; Shao, Y-M.; Spalluto, G.; 
Yap, C.W.; Pastorin, G. Pharmacophore elucidation for a new series of 2-aryl-
pyrazolo-triazolo-pyrimidines as potent human A3 adenosine receptor antagonists. 
Bioorg. Med. Chem. Lett. 2011, 21, 2898-2905. 
  
5.1       Introduction      
            In this chapter, we aimed to quantitatively elucidate a comprehensive ligand-based 
pharmacophore for the new series of 2-(para-(un)substituted)phenyl-pyrazolo-triazolo-
pyrimidine derivatives and clarify the essential structural basis associated with their 
selective inhibition of hA3AR, particularly at the C
2
-aryl ring of the tricyclic nucleus. The 
proposed QSAR study was performed based on Comparative Molecular Field Analysis 
(CoMFA), which correlated both the steric and electrostatic properties of a derivative’s 
chemical structure to the corresponding biological activitiy.    
           In this study, a total of 83 structurally related compounds 
84, 90, 120-124, 127 
(training 
set, 23, 25, 26, 28, 29, 31, 34, 155-230 in Table 5) were selected and used to generate a 
QSAR model. They consisted of 6 classes of heterocycles, namely pyrazolo-triazolo-
pyrimidines (PTP) (23, 25, 26, 28, 29, 31, 155-201); CGS15943 and its derivatives (34, 
202, 203); triazoloquinoxalinones (TQX) (204-219); pyrazoloquinolines (PQ) (220-222); 
triazolopyrazinones (TP) (223-226) and triazolobenzotriazinones (TBT) (227-230), all of 
which have been reported as potent hA3 receptor antagonists. They were chosen in such a 
way that their hA3Ki were uniformly distributed in the range of values (spanning 4 orders 
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 nM) so that the model’s predictive power could be 
effectively evaluated. 
             The rationale of adopting 5 additional groups of derivatives in our QSAR study, 
apart from the PTPs, is based on 3 main considerations: 1) these groups of compounds 
comprise similar tricyclic scaffolds (highlighted in red circles, Table 5) as that of PTPs, 
which are planar in shape and possess a ‘pseudoaromatic’ character with electrons 
delocalized within the 3-membered-ring core; 2) these derivatives share similar substituents 




-position of the tricyclic nuclei as that of new 2-aryl-PTP 
derivatives, such as amino (NH2), benzamidic (Ph-CONH), phenylacetamidic (Ph-CH2-
CONH) and phenylcarbamidic (Ph-NH-CONH) groups; 3) most importantly, majority of 
these compounds bear a similar (un)substituted-phenyl ring at the position equivalent to 
that of the newly synthesized 2-aryl-PTPs (e.g. 2-phenyl ring found in TQX, PQ, TP, TBT 
derivatives). This last aspect enables evaluation of the relative importance of the aromatic 
ring in the 2-aryl-PTPs towards hA3 affinity, which represents the first attempt to identify 
the structural requirements at the unprecedentedly explored C
2
-position of the PTP tricyclic 
nucleus. Such inclusion of the 2-aryl group-bearing derivatives in the training set of our 
study has allowed investigation of the significance of both steric and electrostatic effects of 
other substituents (besides 2-furyl ring) at the C
2
-position of tricyclic nuclei towards the 
hA3 binding affinity. On the contrary, this is lacking in the CoMFA model previously 
reported by Moro et al. 
91
 that adopted mainly the 2-furyl-PTP derivatives as hA3AR 
antagonists in their study. 
            It is noteworthy that in CoMFA, a correct structural alignment of compounds is 
crucial to the success of constructing a reliable QSAR model. 
141 
The final alignment of all 
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compounds (training and testing set chosen in our study) was subjected to the CoMFA, and 
the so-obtained contour plots derived from the analysis were subsequently used to identify 











positions (in each class of derivatives) towards the hA3 
affinity. Thorough interpretation of the results led to the generation of a 3-D 
pharmacophore map not only for the compounds in the training set, but most importantly, 
also for the new series of 2-aryl-PTPs, which presented a similar tricyclic nucleus and 
substitutents as those in the training set. Furthermore, the predictive power of the CoMFA 
model was validated through evaluation on a number of new 2-aryl-PTPs (testing set, 40-
45, 50, 51, 53-61, 64, 71-73, 77, 80, 87 in Table 5). In addition, to further examine the 
predictability of the model on such testing set, a set of rigorous criteria (including 
coefficient of determination and slope of regression lines when forcing the intercept 
through origin) 
142 
were also determined in this part of the study (see Experimental 
Methods for details).  
 
5.2        Experimental Methods 
5.2.1     Selection and preparation of training set and testing set 
             A total of 83 hA3 receptor antagonists (training set) consisting of 53 pyrazolo- 
triazolo-pyrimidine derivatives, 3 CGS15943 derivatives, 16 triazoloquinoxalinones 
(TQX), 3 pyrazoloquinolines (PQ), 4 triazolopyrazinones (TP), and 4 
triazolobenzotriazinones (TBT) (compounds 23, 25, 26, 28, 29, 31, 34, 155-230), 
84, 90, 120-
124, 127
 were included to generate the CoMFA-based QSAR model. The structures of the 
compounds were drawn using  Sketch  tool  available  in  SYBYL7.3, 
143
 followed  by 1000 
Chapter 5 QSAR study 
106 
 
Table 5. Structures and hA3 binding affinities (Ki) of all reference compounds (training set, 
compounds 23, 25, 26, 28, 29, 31, 34, 155-230) and testing compounds (testing set, 




















Compounds R R1 R2 hA3 (Ki/nM) 
Training Set 
155 H furyl CH3 300 
29 Ph-NHCO furyl CH3 0.16 
159 4-SO3H-Ph-NHCO furyl CH3 25 
160 3,4-OCH2O-Ph-NHCO furyl CH3 0.24 
161 4-NO2-Ph-NHCO furyl CH3 0.43 
162 4-Br-Ph-NHCO furyl CH3 0.46 
158 4-OMe-Ph-NHCO furyl CH3 0.2 
163 3-Cl-Ph-NHCO furyl CH3 0.4 
164 Pyridine-NHCO furyl CH3 0.04 
Pyrazolo-triazolo-pyrimidines 
(PTP) 23, 25, 26, 28, 29, 31, 40-
45, 50, 51, 53-61, 64, 71-73, 77, 






       (TP) 223-226 
 
 Triazolobenzotriazinones  
(TBT) 227-230 
CGS15943 derivatives 
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Compounds R R1 R2 hA3 (Ki/nM) 
31 Pyridinium-NHCO furyl CH3 0.01 
25 Ph-CH2-CO furyl CH3 0.81 
165 H furyl C2H5 331 
166 Ph-NHCO furyl C2H5 0.18 
167 4-SO3H-Ph-NHCO furyl C2H5 40 
168 3,4-OCH2O-Ph-NHCO furyl C2H5 0.27 
169 4-NO2-Ph-NHCO furyl C2H5 0.65 
170 4-Br-Ph-NHCO furyl C2H5 0.37 
28 4-OMe-Ph-NHCO furyl C2H5 0.6 
171 3-Cl-Ph-NHCO furyl C2H5 1.6 
172 Ph-CH2-CO furyl C2H5 1.03 
173 H furyl C3H7 408 
174 Ph-NHCO furyl C3H7 0.15 
175 3,4-OCH2O-Ph-NHCO furyl C3H7 0.3 
176 4-NO2-Ph-NHCO furyl C3H7 0.81 
177 4-Br-Ph-NHCO furyl C3H7 0.45 
178 3-Cl-Ph-NHCO furyl C3H7 0.91 
179 3,4-Cl2-Ph-NHCO furyl C3H7 2.5 
180 Ph-CH2-CO furyl C3H7 1.01 
181 H furyl C4H9 600 
182 Ph-NHCO furyl C4H9 0.21 
183 3,4-OCH2O-Ph-NHCO furyl C4H9 0.5 
184 4-NO2-Ph-NHCO furyl C4H9 0.55 
185 4-Br-Ph-NHCO furyl C4H9 0.91 
186 4-OMe-Ph-NHCO furyl C4H9 0.32 
187 3-Cl-Ph-NHCO furyl C4H9 0.6 
188 3,4-Cl2-Ph-NHCO furyl C4H9 3.7 
189 Ph-CH2-CO furyl C4H9 1.11 
23 H furyl (CH3)2CHCH2CH2 700 
190 Ph-O-CH2-CO furyl (CH3)2CHCH2CH2 50 
191 (CH3)2CH-NHCO furyl (CH3)2CHCH2CH2 65 
156 H furyl PhCH2CH2 280 
157 Ph-CH2-CO furyl PhCH2CH2 45 
192 Ph-O-CH2-CO furyl PhCH2CH2 300 
193 α-napthyl-CH2-CO furyl PhCH2CH2 120 
194 NH3
+
CH2CO furyl PhCH2CH2 163 
195 (CH3)2CH-NHCO furyl PhCH2CH2 9.0 
196 (CH3)3C-NHCO furyl PhCH2CH2 4.9 
197 H furyl PhCH2CH2CH2 430 
198 Ph-CH2-CO furyl PhCH2CH2CH2 121 
199 Ph-O-CH2-CO furyl PhCH2CH2CH2 40 
26 α-napthyl-CH2-CO furyl PhCH2CH2CH2 300 
200 3-Cl-Ph-NHCO furyl PhCH2CH2CH2 60 
201 (CH3)3C-NHCO furyl PhCH2CH2CH2 65 
34 H furyl - 13.8 
202 Ph-CO furyl - 3.03 
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Compounds R R1 R2 hA3 (Ki/nM) 
203 Ph-CH2-CO furyl - 0.65 
204 H 3-CH3-Ph - 28.5 
205 H 4-CH3-Ph - 48.3 
206 H 3-F-Ph - 157 
207 H 4-Cl-Ph - 329 
208 H 4-OCH3-Ph - 45.3 
209 Cyclopentyl Ph - 55.4 
210 Cyclopentyl 3-CH3-Ph - 27.5 
211 Cyclopentyl 3-F-Ph - 173 
212 Cyclohexyl 4-Cl-Ph - 56.1 
213 CH3CH2-CO Ph - 15.8 
214 Ph-NHCO Ph - 276 
215 4-OCH3-Ph-NHCO Ph - 960 
216 Ph-CO Ph - 1.47 
217 Ph-CO 4-OCH3-Ph - 2.9 
218 Ph-CO 4-NO2-Ph - 100 
219 Ph-CH2-CO Ph - 3.75 
220 H 4-OCH3-Ph - 90.2 
221 Ph-CO Ph - 2.1 
222 Ph-CO 4-OCH3-Ph - 3.4 
223 H 4-F-Ph - 490 
224 H 4-OCH3-Ph - 158 
225 Ph-CO Ph - 70.3 
226 Ph-CO 4-OCH3-Ph - 4.54 
227 H Ph - 34.6 
228 H 4-F-Ph - 368.5 
229 H 4-Cl-Ph - 33.2 
230 H 4-OCH3-Ph - 51.0 
Testing Set 
40 H Ph CH3 75.0 
41 H 4-F-Ph CH3 31.4 
42 H 4-Cl-Ph CH3 72.4 
43 H 4-Br-Ph CH3 38.6 
44 H 4-OCH3-Ph CH3 16.7 
45 H 4-NO2-Ph CH3 655 
50 H Ph PhCH2CH2 76.7 
51 H 4-F-Ph PhCH2CH2 50.6 
53 H 4-Cl-Ph PhCH2CH2 79.7 
54 H 4-Br-Ph PhCH2CH2 221 
55 H 4-OCH3-Ph PhCH2CH2 25.0 
56 Ph-CO Ph CH3 5.0 
57 Ph-CO 4-F-Ph CH3 3.43 
58 Ph-CO 4-Cl-Ph CH3 2.82 
59 Ph-CO 4-Br-Ph CH3 5.24 
60 Ph-CO 4-OCH3-Ph CH3 2.1 
61 Ph-CO 4-NO2-Ph CH3 56.4 
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Compounds R R1 R2 hA3 (Ki/nM) 
64 Ph-CO Ph PhCH2CH2 23.9 
71  Ph-CH2-CO  4-Cl-Ph CH3  0.248 
72 Ph-CH2-CO 4-Br-Ph CH3 0.345 
73 Ph-CH2-CO 4-OCH3-Ph CH3 0.241 
77 Ph-CH2-CO 4-Cl-Ph PhCH2CH2 8.48 
80 Ph-NHCO 4-Br-Ph CH3 2.50 
87 4-OCH3-Ph-NHCO  4-Cl-Ph CH3 1.33 
 





Hückel charges were then added to all the molecules. Similarly, the structures of 
compounds in a testing set containing 24 newly synthesized 2-aryl-pyrazolo-triazolo-
pyrimidine derivatives  (compounds  40-45,  50,  51, 53-61,  64,  71-73,  77, 80,  87)  were  
also  built  and minimized as according to the procedures elaborated for the training set. 
This set of compounds was used to evaluate the predictive power of the CoMFA model 
constructed based on the 83 compounds in the training set. 
             All the predicted affinities of compounds in the testing set were calculated using 
the optimized CoMFA model. The experimental affinity obtained from the bioassay was 
compared with the predicted affinity and the correlation between these two parameters 
gave rise to the “predictive” r2 value (r2pred). Besides the r
2





and slope of regression lines when forcing the intercept through origin (K) were also 
determined to assess how far the predicted values deviated from the observed activities in 
the absolute scale. 
142
 For a set of data (xi, yi), the coefficient of determination R0
2
 is 
calculated  as the correlation coefficient R
2
 for a  linear  regression  with  the  Y-intercept  
set  to  0.0  (i.e. Y=KX),  which  is  different  from the conventional R
2
 for Y = KX + b. This 
is because when we compare actual versus predicted activities, an exact fit is required 
instead of just a linear correlation. An intercept will imply additional adjustment for the 
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prediction, thus higher inaccuracy. Coefficients of determination were calculated as R0
2
 for 
predicted versus observed activities, and R0′
2
 for observed versus predicted activities. For 
the slopes of regression lines when forcing the intercept through origin, K was calculated 
for predicted versus observed activities, while K′ for the observed versus predicted 
activities. The so-obtained statistical parameters were then compared with the 




5.2.2     Structural alignment of the molecules  
             The flexible alignment module in the Molecular Operating Environment (MOE) 
Suite 2008.10 
144
 was employed as the alignment tool in this part of the study. The most 
potent compound in each class of tricyclic system (compound 31 (PTP), compound 203 
(CGS15943 derivative), compound 216 (TQX), compound 221 (PQ), compound 226 (TP), 
compound 229 (TBT)) were aligned with each other through the alignment tool. The 
resulting alignment of these 6 compounds was used as a template for the superimposition 
of the remaining compounds in the training set, as well as those in the testing set. The force 
field charges of molecules were calculated prior to the flexible alignment. Depending on 
the structure of the molecules, different iteration limit, failure limit and energy cutoff were 
set in order to obtain the desired conformation of the structure with appropriate alignment 
and superimposition. The stochastic conformational search technique was also applied in 
this alignment study.  
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5.2.3 Comparative Molecular Field Analysis (CoMFA) field calculations and 
regression techniques 
            All the field calculations and regression techniques in the study were performed on 
the SYBYL 7.3 program. 
143
 The electrostatic and steric fields were sampled along a three-
dimensional lattice encompassing all molecules in hA3 antagonist training set. The lattice 
consisted of 2184 sample points based on a 2.0 Å lattice spacing with boundaries extending 
4.0 Å beyond the largest structure in all directions. The probe used to calculate the CoMFA 
fields consisted of a sp
3
 carbon atom with a +1 charge and a Van der Waals radius of 1.52 
Å. The steric and electrostatic fields were calculated separately for each molecule using a 
Lennard-Jones 6-12 potential and a Coulombic potential with a 1/r distance-dependent 
dielectric, respectively. The steric and electrostatic energies were truncated at 30 kcal/mol. 
The field values corresponding to the 2184 sample points for each molecule, together with 
binding affinity data, were stored in a SYBYL Molecular Spreadsheet for statistical 
analysis. Partial-least-squared (PLS) regression analysis 
145
 was performed on the hA3 
antagonist training set using a subset of CoMFA field sample points falling within a 
standard deviation ≤ 2.0 kcal/mol. The initial PLS was performed using cross-validation to 
evaluate the predictive ability of the CoMFA models, in conjunction with the cross-
validation option (leave-one-out method) to obtain the optimal number of components to be 
used in the subsequent analysis of the training set. The optimal number of components was 
designated as that which yielded the highest cross-validated r
2
 values in the non-cross-
validated analysis. The final PLS analysis with the optimal number of components was 
performed on the complete training set. On top of that, the CoMFA coefficient contour 
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maps were generated by interpolation of the pairwise products between the 3D-QSAR 
coefficients and the standard deviations of the associated energy variables. 
 
5.3      Results and Discussion 
5.3.1   CoMFA analysis  
           In this part of investigation, we have performed the structural alignment of 
compounds in the training and the testing set through the flexible alignment tool in MOE 
Suite 2008.10. The final alignment, as shown in Figure 15, was used as input for the 
QSAR investigation through CoMFA. The statistical results of the generated QSAR model 
were reported in Table 6 and the graph showing the correlation between the experimental 
and predicted hA3pKi of compounds in the training set was represented in Figure 16.         
           The cross-validated partial-least-squared (PLS) analysis from CoMFA gave a 




) of 0.707 and an optimum number of components set 
equal to 10, based on the analysis of 83 compounds in the training set. Subsequently, the 
non-cross-validated PLS  analysis  was  repeated  with  the  optimum  number  of  
components to give  a  r
2
  of  0.935 (Figure 16). The q
2
 value of 0.707 indicated that the 
predictability of CoMFA model was considerably high. Moreover, the relatively small 
estimated standard error of 0.331 and a high F-test value of 105.918 (values obtained from 
non-cross-validation analysis of CoMFA) also suggested a high degree of confidence in the 
analysis.  On top of that, the steric and electrostatic field contributions of compounds in the 
training set were shown to be 53.9% and 46.1%, respectively. Such finding indicated that 
the contribution of steric effect was relatively more predominant for the optimal interaction  




Figure 15. Final structural alignment for 83 compounds in the training set and 24 
compounds in the testing set.  
 
Table 6. Statistical results from CoMFA 
Parameters Statistical values 
No. of compounds 83 














Standard error of estimate 0.331 
Steric contribution 0.539 


















 -  R0’
 2│ 0.221 





Figure 16. Graphs showing correlation between the predicted pKi and experimental pKi of 
compounds in the training set.  
 
of these antagonists to the hA3 receptor. 
 
5.3.2   External validation of CoMFA model  
            Although high value of q
2
 (from internal validation via cross-validation) appears to 
be a necessary requisite, it is not sufficient to confirm that the model has high predictive 
power. In fact, external validation is considered fundamental to establish a reliable QSAR 
model. 
146 
Hence, in order to externally validate the predictive power of the CoMFA model  
constructed, 24 derivatives (compounds 40-45, 50, 51, 53-61, 64, 71-73, 77, 80, 87) 
consisting  of the new series of 2-(para-(un)substituted)phenyl-pyrazolo[4,3-e]-1,2,4-
triazolo-[1,5-c]-pyrimidines were included as testing set, which were never used in the 
training set during the model development. The actual and predicted (as calculated from 
optimized CoMFA model) hA3pKi for this external testing set were shown in Table 7, and 
R
2
 = 0.935 
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the corresponding correlation graph for predicted pKi versus actual pKi was illustrated in 
Figure 17. Consistently, the CoMFA model has shown a reasonable external predictability 
of r
2
pred = 0.690, which further supported the reliability of this model. In addition, predicted 
and actual affinities of the testing set were also used to calculate another set of rigorous 




) and the slope of 
regression lines when forcing the intercept through origin (K and K’) (Table 6). The 
obtained statistical values for these parameters satisfied the conditions stipulated by 






pred) < 0.1 and 0.85 ≤ K ≤ 1.15; (b)│R0
2
-R0′
2│< 0.3, 142 
which again substantiated the predictive power of our QSAR model.  Therefore, the so-
obtained QSAR model was deduced to be reliable in predicting the hA3 affinity for the new 
2-aryl-PTP derivatives, and the corresponding pharmacophore map elucidated by the model 
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Observed  Predicted Residual
a
 
40 H Ph CH3 7.125 6.394 -0.731 
41 H 4-F-Ph CH3 7.503 7.003 -0.500 
42 H 4-Cl-Ph CH3 7.140 7.285 0.145 
43 H 4-Br-Ph CH3 7.413 7.511 0.098 
44 H 4-OCH3-Ph CH3 7.777 7.189 -0.588 
45 H 4-NO2-Ph CH3 6.184 5.931 -0.253 
50 H Ph PhCH2CH2 7.115 5.769 -1.346 
51 H 4-F-Ph PhCH2CH2 7.296 5.757 -1.539 
53 H 4-Cl-Ph PhCH2CH2 7.099 6.029 -1.070 
54 H 4-Br-Ph PhCH2CH2 6.656 5.854 -0.802 
55 H 4-OCH3-Ph PhCH2CH2 7.602 6.144 -1.458 
56 Ph-CO Ph CH3 8.301 8.021 -0.280 
57 Ph-CO 4-F-Ph CH3 8.465 8.687 0.222 
58 Ph-CO 4-Cl-Ph CH3 8.55 8.836 0.286 















59 Ph-CO 4-Br-Ph CH3 8.281 8.982 0.701 
60 Ph-CO 4-OCH3-Ph CH3 8.678 8.577 -0.101 
61 Ph-CO 4-NO2-Ph CH3 7.249 7.829 0.580 
64 Ph-CO Ph PhCH2CH2 7.622 7.167 -0.455 
71 Ph-CH2-CO 4-Cl-Ph CH3 9.606 8.539 -1.067 
72 Ph-CH2-CO 4-Br-Ph CH3 9.462 8.559 -0.903 
73 Ph-CH2-CO 4-OCH3-Ph CH3 9.618 8.646 -0.972 
 
77 Ph-CH2-CO 4-Cl-Ph PhCH2CH2 8.072 6.869 -1.203 
80 Ph-NHCO 4-Br-Ph CH3 8.602 8.592 -0.01 
87 4-OCH3-Ph-
NHCO 
4-Cl-Ph CH3 8.876 8.479 -0.397 
a




Figure 17. Graphs showing correlation between the predicted pKi and experimental pKi of 




 = 0.690 
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5.3.3    Contour maps of analysis 
            The overall graphical representations of the analysis comprising both the 
electrostatic and steric contour plots were depicted in Figures 18 (A) and 18 (B), through 
illustration by one of the PTP (compound 158) and TQX (compound 221) derivatives 





- and particularly C
2
-position of the PTP tricyclic nucleus, as well as other 
closely related tricyclic scaffolds as mentioned earlier were elaborated in the next sections. 
For CoMFA steric contour, green colour indicates bulky groups are favoured for hA3 
affinity while yellow indicates bulky groups are disfavoured. In the case of electrostatic 
contour, red colour indicates electronegative groups are favoured for hA3 affinity, while 
blue indicates electropositive groups are favoured.  
 
5.3.3.1 Steric contour plot 
            As shown in Figure 18 (B), a yellow contour was observed at both the ortho- and 
para- positions of the 2-phenyl ring in TQXs, PQs, TPs, and TBTs. The presence of bulky 
groups was not favourable at these two positions. Particularly, the presence of a bulky NO2 
group at para- position of the phenyl ring in some of our newly synthesized 2-(para-
substituted)phenyl-pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidines as well as in TQX 
series 
121
 (e.g. compound 45, hA3Ki = 655 nM;  compound 61, hA3Ki = 56.4 nM; compound 
218, hA3Ki = 100 nM) has resulted in a considerable decrease of hA3 affinity as compared 
to other less bulky para-substituents (e.g. compound 41 (with 4-F), hA3Ki = 31.4 nM; 
compound 58 (with 4-Cl), hA3Ki = 2.82 nM).              
            A green contour  (Figures 18 (A)  and 18 (B))  was seen around the phenyl ring at  
Compound 3 







Figure 18. Combined steric and electrostatic contour plots for (A) compound 159. Green 
color indicates bulky groups are favored, and yellow indicates bulky groups are 
disfavoured; red indicates electronegative groups are favoured, and blue indicates 
electropositive groups are favoured. Contour plot’s color legend threshold: green/yellow 














Figure 18 (cont.). Combined steric and electrostatic contour plots for (B) compound 218. 
Green color indicates bulky groups are favoured, and yellow indicates bulky groups are 
disfavoured; red indicates electronegative groups are favoured, and blue indicates 
electropositive groups are favoured. Contour plot’s color legend threshold: green/yellow 
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both the N5- or N4-positions of the tricyclic nuclei, indicating that bulky groups were 
tolerable around this region.  This  was   in  agreement  with  previous  results  and  our  
recent  findings,  which   have shown that the introduction of longer chains at N5- and N4-
positions imparted additional beneficial effects on the hA3 affinity profile of corresponding 
derivatives. 
84, 90, 120-124, 127,
 
147, 148 
A small patch of yellow contour was found between the 
meta and para-positions of the phenyl ring in PTP derivatives bearing the arylcarbamoyl 
chain, suggesting that only substituents of certain size were acceptable at these two 
positions (Figure 18 (A)). For example, compound 159 in the training set (hA3Ki = 25 nM) 
suffered from tremendous decrease of hA3 affinity due to the presence of a relatively bulky 
SO3H group at the para-position of N
5
-phenyl ring, as compared to other polar 
substitutents. In Moro et al., 
91 
it was also reported that a steric control seemed to take place 
around the para and meta-position of the phenyl ring at N
5
-position of PTPs. 
             A green contour observed around the substituent at N
8
-position of PTPs (Figure 18 
(A)) implied that incorporation of substituents at this position was preferable to provide 
good affinity at hA3 receptors. Nevertheless, a few yellow contours were observed above 
and at the immediate left-hand corner of the green contour, suggesting that the presence of 
bulky groups (such as a phenyl ring) or branched chains, was not suitable at such region. 
This was in concordance to our observation from the new series of 2-aryl PTP derivatives, 
in which the less bulky methyl group (e.g. compound 56, hA3Ki = 5 nM), was more 
favourable at the N
8
-position as compared to the bulky alkyl chains such as phenylethyl 
group (e.g. compound 64, hA3Ki = 23.9 nM). Undeniably, an inverse relationship was 
established between the binding affinity values at hA3 receptor and the molecular volume 




Besides that, a green contour was also found in 
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vicinity of the 6-position of phenyl ring in TQXs (Figure 18 (B)), PQs, and TPs, as well as 
7-position of phenyl ring in CGS derivatives and TBTs. Bulky groups seemed to 
accommodate better at this particular position. As reported in Lenzi et al., 
121 
bulky polar 
substituents such as NO2 groups were introduced at 6-position of the phenyl ring in some of 
the TQX derivatives, which resulted in good affinity towards the hA3 receptors.   
 
5.3.3.2 Electrostatic contour plot 





position of the tricyclic nucleus (Figure 18 (A) and 18 (B)). It was believed that the 
delocalization of electrons towards the pseudoaromatic tricyclic core has exerted its effect 
on the phenyl and furan rings, thus rendering the surrounding region to be more electron-
deficient. According to previously reported results, the presence of either furan ring in 
PTPs and CGS derivatives or phenyl ring in TQXs, PQs, TPs and TBTs seemed essential to 
maintain good affinity at the hA3 receptors. 
84, 90, 120-124, 127, 147
 In the present study, we 
demonstrated that the substitution of existing 2-furyl ring in PTP scaffold with a 2-
(un)substituted-phenyl ring has resulted in better affinity and selectivity profile in 
comparison to the 2-furyl counterparts, explicitly in PTP derivatives bearing the N
5
-amino, 
-benzamidic or phenylacetamidic group. 




-position of the 
tricyclic nucleus, suggesting that the presence of an electronegative group (e.g. carbonyl 
group) was favoured for hA3 affinity (Figures 18 (A) and 18 (B)). This was in accordance 





 and CGS15943 derivatives 
127
 (with arylcarbamoyl group or amidic chain) as 
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 and TPs 
123
 (with amidic chain) presented a 





a blue contour was noticed. Similar to that of C
2
-phenyl ring, the electron-withdrawing 
effect of para-substituents or delocalization of electrons towards the nearby carbamoyl and 
amidic group caused the phenyl ring to be electron-deficient. Consistently, a red contour 
was observed at the para-position of such N
5
-phenyl ring in the PTP derivatives (Figure 18 
(A)). This observation was further substantiated by the good hA3 affinity profile ranging 
from 0.2 to 0.4 nM as illustrated, for examples, by compounds 158, 160-162, which bear 
electronegative groups at the para-position. Similarly, the presence of 4-F (84) or 4-OMe 
(87) on the phenyl ring of N
5
-arylcarbamoyl chain in our newly synthesized 2-aryl-PTPs 
was found favourable for the hA3 affinity as well.  
             A red contour was also observed at the N
7
 of the pyrazole ring in PTPs (Figure 18 
(A)) and 6-position of the phenyl ring in TQXs and PQs (Figure 18 (B)), as well as 7-
position of the phenyl ring in CGS derivatives and TBTs. In fact, electronegative 
substituents (such as NO2 group) were previously introduced at 6-position of phenyl ring in 
TQX series, which resulted in improvement of hA3 affinity. 
121
 Subsequently, the sp
2
 
carbon atom at the 6-position was replaced with a corresponding sp
2
 nitrogen atom, as 
represented by TP derivatives. 
123
 Notably, this series of TP derivatives also showed good 
affinity profile at the hA3 receptors. On the other hand, a small blue contour was found near 
to the substituents at the N
8
-position of PTPs. The electrostatic effect at this position 
seemed negligible; instead, the steric effect at this position was expected to determine a 
more important role towards the hA3 affinity, as elaborated in the previous section. 
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              In general, there are some differences between our CoMFA pharmacophore model 
and the contour maps pertaining to the 2-furyl-PTPs as reported by Moro and co-workers. 
91
 Apart from the additional ability to identify the steric and electrostatic effects at the C
2
-
position of PTPs, our model highlighted the presence of green and yellow contour plots at 
the N
8
-position, as well as the red contour plot at the N
7
-position. Notably, these were not 
elaborated in the latter model. Furthermore, it was also found that the electrostatic effect at 
the N
8
-position seemed negligible in our study, which differed from the findings by Moro 
et al. that described the significance of red polyhedron at such position. In brief, the 
CoMFA model developed in this study has successfully elucidated the detailed 
pharmacophore features at each positions of the PTP scaffold, relative to the one described 
by Moro et al.. 
91
                       
 
5.4       Conclusion 
            The QSAR study based on CoMFA has provided new insights on the steric and 
electrostatic factors that are important in modulating the hA3 affinity for the new series of 
2-aryl-PTP derivatives, particularly at the C
2
-position of the tricyclic nucleus (as illustrated 
by compound 73 in Figure 19). On top of that, a predictive QSAR model was also 
obtained, which was able to predict the hA3 affinities of these new 2-aryl-PTPs with 
appreciable accuracy. On the whole, the distribution of steric and electrostatic effects in the 





well as at the para-position of 2-phenyl ring; bulky groups are unfavourable at both the N
8
-
position and para-position of 2-phenyl ring, while bulky groups are preferable at the N
5
-
position of the tricyclic nucleus. (b) for the electrostatic effect, the presence of 
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electronegative groups seems favourable around the amidic group at N
5
, at the para-
position of N
5




 on pyrazolo ring, whereas 




-positions.  Overall, the 
contribution of the steric effect was found relatively more predominant for the optimal 
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Figure 19. Distribution of steric and electrostatic effects in the 2-aryl-pyrazolo-triazolo-
pyrimidine derivative, compound 73. The distances (Å) among the three pharmacophoric 






-aryl ring are indicated. 
Conformation of the structure is obtained from the final alignment shown in Figure 15. Red 
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Chapter 6 Modeling of Antagonist Binding Site for a New Series of 
Pyrazolo-Triazolo-Pyrimidine Derivatives Through a Human A3 ‘Hybrid’ 
Homology Model 
 
The information related to the ‘hybrid’ homology model of hA3AR and molecular docking 
simulations on the new series of 2-aryl-PTPs in this chapter has been reported in the 
following research article:  
 Cheong, S. L.; Chng, C-P.; Kosaraju, V. K.; Xue, F.; Federico, S.; Spalluto, G.; 
Yap, C.W.; Pastorin, G. Modeling of antagonist binding site through a hA3 ‘hybrid’ 
homology model for a new series of 2-aryl-pyrazolo-triazolo-pyrimidines as potent 
human A3 adenosine receptor antagonists. J. Computer Aided Mol. Des. 2011, 
Manuscript under revision. 
 
* The work has been done in collaboration with Dr Chng Choon-Peng from the A*STAR, 
Institute of High Performance Computing (IHPC), Singapore. 
 
6.1      General Introduction  
           In addition to the QSAR study, we also performed molecular docking simulations on 
the new 2-aryl-PTP derivatives through a hA3 ‘hybrid’ homology model. The derivatives 
were docked into the putative ligand binding site of the hA3 ‘hybrid’ model, with the 
purpose of examining the binding modes and identifying important interactions between 
the ligands and specific amino acid residues.  
 
6.2       Homology Modeling of Human A3 Adenosine Receptor   
6.2.1    Introduction  
           In the past, homology modeling for hA3 adenosine receptor was mainly based on 
bovine rhodopsin, the crystal structure of which was successfully discovered in 2000. 
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Although presenting the typical seven-transmembrane architecture as that of adenosine 
receptors, it displays limited sequence identity of <20% with such receptors. 
105, 109
 
Recently, the 2.6 Å crystal structure of hA2AAR, in complex with a selective and potent 
antagonist (ZM241385) was resolved, 
113 
and it shares better yet moderate sequence 
identity of about 43% with the hA3AR. This structure serves as a new template for the 
construction of hA3 homology model used in docking studies. 
75,
 
108, 114a, 114b 
In the present 
study, differing from the conventional single template-based homology modeling of A3 
receptor, we proposed an alternative hA3 homology model constructed based on a multiple 
template approach. In another words, a hA3 model will be built based on more than one 
appropriate GPCR templates to investigate the accuracy of the model, as well as its 
applicability in predicting ligands’ binding modes and interactions of ligands. 
           Besides the bovine rhodopsin and hA2AAR that are available, at the the time of 
writing there are two additional GPCRs which the structures have been resolved, namely 
the human beta2 (β2)-adrenergic receptor and turkey beta1 (β1)-adrenergic receptor. The 
bovine rhodopsin crystal structure would be excluded from the modeling, due to its low 
sequence identity with hA3AR as mentioned earlier. For the turkey β1-adrenergic receptor, 
as such template originated from different species (and A3ARs are known to show 
remarkable inter-species discrepancies), it was deemed inappropriate to be included in the 
multiple template modeling. The 2.4 Å crystal structure of human β2-adrenergic receptor, 
which is the first non-rhodopsin GPCR protein crystallized in 2007 and shares higher 
sequence identity with hA3AR (~26%) than the rhodopsin, 
112
 is considered as a potential 
template in addition to the hA2AAR structure. In fact, a homology model based on the β2-
adrenergic receptor as template for other adenosine receptors, such as A1 and A2A, was 
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already reported by Yuzlenko et al.. 
118 It was shown that β2-adrenergic-based model for the 
A1 and A2A adenosine receptor was more appropriate as compared to the rhodopsin-based 
model, due to its higher sequence identity with the adenosine receptors and its better ability 
to stabilize high affinity antagonists inside the binding pocket. 
118 
The extracellular loop 2 
(ECL2) of β2-adrenergic receptor, which was known to play an important role in ligand 
binding, also differed much less from that of adenosine receptor than the corresponding 
loop in bovine rhodopsin. This allowed a more precise construction of this region and thus 
a more accurate docking of the ligands. 
118
  
             Hence in this study, we investigated on the use of hA2A and human β2-adrenergic 
receptors both as individual and combined (i.e. ‘hybrid’) template for hA3 homology 
modeling. On top of that, a theoretical model of the hA3 adenosine receptor obtained from 
the Protein Data Bank (PDB code: 1OEA) and constructed by homology modeling based 
on the X-ray structure of bovine rhodopsin 
149
 was also included in the study for 
comparison with the other hA3 homology models.  
 
6.2.2     Experimental Methods 
6.2.2.1  Construction of hA3 homology model 
             The protein sequence of human β2-adrenergic receptor 
112
 (PDB code: 2RH1) and 
hA2AAR 
113
 (PDB code:  3EML) templates were obtained from PDB) whereas the protein 
sequence of hA3 receptor (Accession no. P33765) was obtained from Swiss-Prot Database. 
For the construction of both β2-adrenergic receptor- and hA2AAR-based homology models, 
the alignment between each template and the hA3 target sequence was carried out through 
align2d command of Modeller9v6 program 
150
 and counterchecked with alignment from 
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 As for the construction of ‘hybrid’ homology model, the multiple 
sequences alignment was carried out through salign command and again counterchecked 
with alignment from ClustalW program.  Such sequence alignments were guided by highly 
conserved amino acid residues in the TM segments of GPCRs, including LAXAD, DRY 
and NPXXY motifs in TM2, TM3 and TM7 respectively, and the 3 proline residues in TMs 
4, 5 and 6 (Figure A1 (A),   (B) and (C) under Appendix). 
2, 91
 In ClustalW program, the 
alignment was performed using the BLOSUM protein weight matrix, with a gap open 
penalty of 10 and a gap extension penalty of 0.05.  
               Subsequently, the model building was performed through the getmodel-full 
command, and special caution was given to the modeling at the ECL2 to ensure the 
presence of a highly conserved disulfide linkage between the ECL2 (Cys166) and TM3 
(Cys83), which could affect the peculiar fold of the ECL2. A total of 50 independent 
models were built, and each of the models was subjected to ‘slow’ VTFM (variable target 
function method with conjugate gradient) optimization for 500 iterations and ‘slow’ MD 
(molecular dynamics with simulated annealing) optimization by Modeller. The whole 
optimization was repeated for 2 cycles with maximum molpdf set to 1e
6
. The best model 
was then selected based on the Dope assessment score from Modeller program 
150
 and 
Ramachandran Plot from Procheck Program, 
152 
followed by further refinement through 
molecular mechanics minimization with AMBER99 force field using Sybyl7.3. 
143
 The 
energy minimizations were carried out by 200 steps of steepest descent followed by 500 




. The model was 
reevaluated by Ramachandran Plot after the refinement step. All graphical manipulations 
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and visualizations were performed by means of PyMOL Molecular Graphics System. 
153
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6.2.2.2 RMSD calculations for backbone of aligned hA3 models and binding pocket 
residues 
            The Root-Mean-Squared-Deviation (RMSD) among atoms computed by Visual 
Molecular Dynamics (VMD) 
154 
program was used as a measure of similarity among hA3 
models. For the calculations of RMSD of backbone of aligned hA3AR models, only 
backbone atoms were used in the fitting and calculation. To compare the modelled binding 
pocket among the hA3 homology models, the RMSD of binding pocket residue atoms in the 
A2AAR-based model (Model 1) and β2-adrenergic receptor-based model (Model 2) relative 
to the ‘hybrid’ model (Model 3) was computed. The binding pocket residues used are those 
identified by Jacobson and co-workers by site-directed mutagenesis: His95, Lys152, 
Trp243, Leu244, Ser247, Asn250 and His272. 
155 
After loading Model 1 and Model 3  
structures into VMD, a least-squares-fit of Model 1 to Model 3 was performed using 
backbone atoms of transmembrane helices TM1 (Asn12 to Val37), TM2 (Phe50 to Val71) 
and TM3 (Phe80 to Tyr109) with the RMSD Tool. Next, the RMSD of side chain atoms of 
binding pocket residues between Model 1 and Model 3 was computed. The same procedure 
was repeated for Model 2 relative to Model 3.  
 
6.2.3     Results and Discussion 
 6.2.3.1  Secondary structures on ECL2 of hA3 models  
             The results from this investigation indicated that different secondary structures of 
ECL2 were observed among the hA3 models. Such loop has been known to play an 
important role in ligand binding. In the bovine rhodopsin-based hA3AR model 1OEA, 
149
 a 
beta-hairpin linked by anti-parallel strands Lys152-Leu153-Thr154 and Cys166-Glu167-
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Phe168 was present in the middle of ECL2 region, which served as a ‘cap’ at the entrance 
of the binding site. In the β2-adrenegic receptor-based hA3AR model, such beta sheet was 
not present but a α-helix was observed at the ECL2 region (Figure A2 (A) under 
Appendix). On the other hand, no defined secondary structure was seen at the ECL2 of the 
hA2AAR-based hA3AR model. As for the ‘hybrid’ hA3 model, a similar beta-sheet linked 
by anti-parallel strands Thr77-Ile78 and Leu164-Ser165, as well as a small α-helix 
secondary structure at the ECL2 region (Figure A2 (C) under Appendix) was noticed. 
Notably, all the hA3 models had their binding sites opened to the extracellular side, except 
the rhodopsin-based model with a closed binding pocket.  
 
6.2.3.2  Evaluation of hA3 homology models          
            As described before, the overall sequence identity between the bovine rhodopsin 
template and the target sequence of hA3AR is relatively low at less than 20%. In spite of 
such limitation, many bovine rhodopsin-based hA3 models have been reported to-date; for 
example the hA3 model 1OEA 
149
 obtained from the Protein Data Bank, demonstrated 
reasonable stereochemistry parameters in the Ramachandran Plot, with 82.7% of residues 
found in the most favoured region and  a  G-factor  value  of  - 0.16. Besides that, there 
were five residues (1.8%) which fell into the generously allowed regions, namely the Thr77 
(ECL1), Asn150 (ECL2), Arg159 (ECL2), Gln167 (ECL2) and Tyr202 (ICL3). Another 
five residues (1.8%) fell into the disallowed region: His79 (ECL1), Lys119 (ICL2), His124 
(ICL2), Asp175 (ECL2) and Tyr222 (ICL3). All of these residues were found in the loops 
region, which were more flexible conformationally, hence more likely to deviate from the 
rigid orientation as compared to residues located in the TM regions. 
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             In the case of β2-adrenergic receptor (2RH1), the alignment resulted in about 26% 
of identical residues between the β2-adrenergic template and the hA3AR target sequence. 
Based on such sequence alignment, a hA3 homology model was built accordingly (Figure 
A2 (A) under Appendix). Through evaluation of such homology model, we found that the 
model showed relatively high negative Dope Score of about 41,000 and good 
stereochemistry parameters in the Ramachandran Plot (Figure A3 (A) under Appendix), 
with 90.2% of residues in the most favoured region and G-factor value of -0.14. In the 
Ramachandran Plot, there were four residues which fell into the generously allowed 
regions, namely the Thr14 (TM1), Leu208 (IL3), Tyr118 (IL2) and Asn256 (ECL3). One 
of them was from the TM region, and the rest of the residues were found in the loops 
region. None of the residues fell into the disallowed region.  
            For the hA2A adenosine receptor (3EML), the sequence identity with the hA3AR 
target sequence was found to be ~43%. Consistently, the best model based on the hA2AAR 
(Figure A2 (B) under Appendix) has demonstrated slightly higher negative Dope Score of 
about 42,000 and better parameters (% of residues in the most favoured regions = 90.5%; 
G-factor = 0.00) in the Ramachandran Plot (Figure A3 (B) under Appendix)  relative to the 
model based on β2-adrenergic receptor. There were three residues falling into the 
generously allowed regions, namely the Leu208 (IL3), Ser155 (ECL2) and Asn256 
(ECL3); none of the residues was observed in the disallowed region. These observations 
were in agreement with previous studies indicating that for 30-50% of sequence identity, 
more than 80% of Cα-atoms can be expected to be within 3.5 Å of their true positions, 
while for less than 30% sequence identity, the prediction is expected to contain significant 
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 All of these findings suggested that the hA2AAR-based hA3 model was 
stereochemically more precise and accurate. 
           Later, a hA3 ‘hybrid’ homology model based on both hA2AAR and human β2-
adrenergic receptor was constructed (Figure A2 (C) under Appendix). The results showed 
that the best ‘hybrid’ model possessed the negative Dope Score of about 43,000, together 
with 93% of residues in the most favoured region and G-factor value of -0.01 in the 
Ramachandran Plot (Figure A3 (C) under Appendix). Notably, none of the residues was 
found in the generously allowed and disallowed regions of Ramachandran Plot in this 
model. By comparing the respective Dope Scores and evaluation parameters in the 
Ramachandran Plot of the models (Table 8), this ‘hybrid’ homology model indeed showed 
better overall profile than the rest of the models. Based on these findings, it seemed to 
imply that the ‘hybrid’  model  was stereochemically more reliable in relation to the bovine  
 
Table 8. Model evaluation parameters for β2-adrenergic, hA2AAR and ‘hybrid’ template-











































model          




-42,000 268 90.5 25 8.4 3 1.0 0 0 0.00 
‘hybrid’ model -43,000 275 92.9 21 7.1 0 0.0 0 0 -0.01 
a
The published theoretical hA3 model was obtained from the Protein Data Bank (PDB 
code: 1OEA). 
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rhodopsin-, β2-adrenergic- and hA2AAR-based homology models. 
            In fact, the use of the multiple template
 
structures has been reported to be beneficial 
in two aspects: (i) multiple template
 
structures may be aligned with different parts/domains 
of the
 
target, hence eventual absence of structural information in one template can be 
complemented by a second template (thus improving model coverage); (ii) the template 
structures may
 
be aligned with the same part of the target and build the model
 
on the 
template that is the best in a localized area (thus improving model quality). 
158 
This was 
supported by results from the recent CASP6 study, showing that the use of multiple 
templates was often beneficial. 
159
 Besides that, Mobarec et al. also reported that the use of 
multiple templates can provide slightly improved models of the TM region of GPCRs when 
compared to receptor models obtained using single templates. 
160
 
            Through inspection of the multiple sequence alignment (Figure A1 (C) under 
Appendix), it was noticed that additional structural complementarities from 2RH1 template 
alignment relative to the sequence alignment based on 3EML template (Figure A1 (B) 
under Appendix) were mainly found in the TM regions. About 71% (12/17 residues) of 
those identical residues complemented by 2RH1 template were located in the TM regions 
while the remaining ones (5/17 residues) were found in the loop regions (Table 9). These 
structural complementarities have contributed additional 5% in sequence identity (17/318 x 
100%) to the A3AR target sequence. This has summed up to a collective sequence identity 
of about 48% for the ‘hybrid’ model relative to the hA2AAR (moderate sequence identity of 
~43% with hA3AR target sequence). Such structural benefits were postulated to have 
brought about the improved profiles as demonstrated by the Dope Score and evaluation 
parameters in Ramachandran Plot of the ‘hybrid’ model, particularly in the TM regions.  
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Table 9. Residues complemented from 2RH1 template to the hA3AR target sequence in 
multiple sequence alignment. 
Residues on hA3AR  
(residue no. & position) 
Residues on 3EML Residues on 2RH1 
Val (13, TM1) Ser Val 
Leu (24, TM1) Val Leu 
Ile (34, TM1) Cys Ile 
Thr (46, ICL1) Asn Thr 
Ile (51, TM2) Val Ile 
Val (65, TM2) Ala Val 
Leu (74, ECL1) ---- Leu 
Thr (87, TM3) Ala Thr 
Ala (96, TM3) Ser Ala 
Val (106, TM3) Ile Val 
Val (137, TM4) Leu Val 
Leu (140, TM4) Ala Leu 
Glu (156, ECL2) ---- Glu 
Val (191, TM5) Leu Val 
Phe (221, ICL3) Thr Phe 
Lys(227, ICL3) His Lys 
Val (263, TM7) Leu Val 
 
 6.2.3.3 Comparison on TMs position and binding pocket of the hA3 models 
            The RMSDs of the backbone of the aligned hA3 models were computed and 
tabulated in Table 10, in order to examine the relative positions of the helices among the 
constructed hA3 models.  As observed from the RMSD values, the difference in the  helical  
bundle  was  found at the TM1, whereas  the  main  difference  among  the  hA3  models  
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was  in  the  loop  region,  which represented the most variable region of the templates. We 
found that the hA3 ‘hybrid’ model closely resembled the hA2A-based model, as shown by 
the relatively small RMSD values at the TM regions between the two models, except the 
loop regions. In addition, the RMSD values between the ‘hybrid’ and the β2-adrenergic 
receptor-based models were found similar with those computed between hA2A- and β2-
adrenergic receptor- based models. This observation again indicated that the relative 
positions of TM helices of the ‘hybrid’ model were more comparable to the hA2A-based 
model than the β2-adrenergic-based model. Even though there were some deviations in the  
backbones  of  TM helices  and  the  shape  of  binding  pocket  between  the  β2-adrenergic 
 
Table 10. Root mean square deviation (RMSD) of the backbone of the aligned hA3 models. 
 all TM all loops TM1 TM2 TM3 TM4 TM5 TM6 TM7 ECL2 
 
RMSD in Å with respect to human β2-Adrenergic Receptor-based hA3AR model (backbone) 
A3_hybrid 2.16 7.84 2.66 0.92 1.37 1.22 1.63 0.47 0.58 4.00 
 
A3_A2A 2.13 4.97 2.59 0.93 1.41 1.26 1.62 0.52 0.62 4.61 
 
RMSD in Å with respect to human A2A Adenosine Receptor-based hA3AR model (backbone) 
A3_hybrid 0.20 5.89 0.25 0.11 0.12 0.10 0.07 0.11 0.10 2.16 
 
 
receptor and hA2A adenosine receptor, 
161
 the above-mentioned observations have reassured 
that the inclusion of the β2-adrenergic receptor to the construction of the ‘hybrid’ model did 
not cause significant changes to the relative position of TM helices in relation to the hA2A-
based model. In fact, such additional template could potentially improve the structural 
complementarities in the TM regions, as elaborated earlier.  
Chapter 6 Modeling of Binding Site - Homology Modeling 
139 
 
             It is widely known that the accuracy of a homology model is a property of 
the complete structure in terms of the protein stereochemistry and how similar sequences 
map to similar structures. However for docking purposes, the correct orientation of side 
chains within the binding pocket of a model will be the most important criterion 
162
. For 
that reason, the RMSD of representative hA3 binding pocket residues as reported by Gao et 
al., 
155
 such as His95, Lys152, Trp243, Leu244, Ser247, Asn250 and His272 among hA3 
homology models were also computed in this study. The corresponding RMSD values 
obtained were 1.32 Å between A2AAR-based model and ‘hybrid’ model, and 4.25 Å 
between β2-adrenergic receptor and ‘hybrid’ model. The relatively small RMSD (< 2 Å) 
value of binding pocket residues between A2AAR-based model and ‘hybrid’ model 
suggested that ligand binding pockets between these two models was comparable to each 
other, and possibly so for the ligand binding modes and interactions. In view of the close 
resemblance between the hA3 ‘hybrid’ and hA2A-based models in terms of TM helices 
relative position and binding pocket especially, it was deduced that such a ‘hybrid’ model 
built from the dual-template approach could be an alternative to the single template hA2A-
based model for the prediction of ligand binding. Nevertheless, its ability to predict 
comparable binding modes and interactions of ligands as that of the hA2A-based model was 
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6.2.4    Conclusion 
            A dual-template homology modeling approach based on both hA2AAR and human 
β2-adrenergic receptor crystal structures has been applied to construct a ‘hybrid’ homology 
model for the hA3 receptor. The resulting hA3 ‘hybrid’ model showed better 
stereochemistry parameters as evaluated from Ramachandran Plot and Dope Score than the 
rest of the hA3 models. It was mainly attributed to the gain of structural complementarities 
in the TM regions through the inclusion of the β2-adrenergic receptor template in the 
multiple sequence alignment on top of the hA2AAR template. In addition, the relative 
position of helices and binding pocket for the ‘hybrid’ model were found in close 
resemblance to that of the hA2AAR-based model. Such observation implied that the ligand 
binding modes and interactions within the ‘hybrid’ model might be comparable to that of 
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6.3          Molecular Docking Simulations 
6.3.1       Introduction 
               In this section, hypothetical binding modes and interactions of new 2-aryl-PTPs 
(compounds 40-47, 49-51, 53-61, 64-90) and 2-furyl PTPs (compounds 25, 155, 157, 158) 
were examined through the hA3 ‘hybrid’ homology model via Autodock 4.0 receptor-
ligand docking program. 
163
 The same derivatives were also subjected to docking 
simulations through the hA2AAR-based hA3 model and the differences in binding modes 
and interactions with that of ‘hybrid’ model were compared, in order to justify our 
postulation that the prediction of ligands’ binding modes and interactions in both models 
are in fact comparable to each other. On top of that, the binding modes and interactions of 
some representative 2-aryl-PTP derivatives (compounds 40, 69) and the corresponding 2-
furyl-PTP analogues (compounds 25, 155) inside the hA2AAR were also evaluated. 
               For each ligand, highly populated docked conformations with lower energy were 
selected for subsequent interpretation of the ligand’s hypothetical binding motif inside the 
putative binding cavity of hA3 homology models (i.e. ‘hybrid’ and hA2AAR-based models) 
as well as hA2AAR. The interactions between residues on the binding site and the ligands 
were then analyzed and correlated to the results from the pharmacological evaluation. 
Moreover, the findings were also compared with previously reported data from site-
directed mutagenesis experiments that identified residues that were important for hA3 
antagonist recognition. 
               On the whole, this section focused on the hypothetical binding orientation of the 
new 2-aryl- and 2-furyl-PTP derivatives inside the binding pocket of hA3 model and 
hA2AAR, which allowed us to: (i) identify the specific amino acid residues involved in the 
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binding interactions that could be important for hA3 antagonist recognition; (ii) investigate 
the contributing factors that might justify the difference in hA3 affinity between the 2-aryl-
PTP derivatives and the corresponding 2-furyl-PTP counterparts and (iii) justify the 
enhanced selectivity of the 2-aryl-PTPs over the hA2AAR relative to the 2-furyl-PTP 





- and in particular at C
2
-positions of the tricyclic nucleus (that are likely the 
molecular determinants for the ligand recognition) could be identified.  
 
6.3.2       Experimental Methods 
6.3.2.1    Preparation of ligand structures and receptors for docking simulation 
               The structures of 2-aryl-PTPs (compounds 40-47, 49-51, 53-61, 64-90) and 2-
furyl-PTP derivatives (compounds 25, 155, 157, 158) 
84, 87, 90 
were drawn using Sketch tool 
available in SYBYL7.3 program, 
143
 followed by 1000 steps of Powell minimization, until 




. After that, the Gasteiger-Hückel charges were 
added to all the molecules. 
               The molecular docking simulations of all compounds were then carried out using 
AutoDock 4.0 program. 
163 
Polar hydrogen atoms and Kollman charges were added and 
AD4 atoms were assigned to the ‘hybrid’ A3 homology model, hA2AAR-based A3 
homology model and the hA2AAR crystal structure. The quantitative evaluation of free 
energy of binding for the compounds was performed by means of the AutoDock scoring 
function, using the Lamarckian genetic algorithm. The grids of (i) 50, 50, 60 points; (ii) 50, 
48, 50 and (iii) 40, 40, 56 points in the x, y, and z directions were built with the Asn250 
assigned as the central residue within the putative binding site of hA3 ‘hybrid’ model, 
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hA2AAR-based hA3 models and hA2AAR respectively. Each of the corresponding grid 
boxes encompassed the binding pocket surrounded by TM2, 3, 5, 6, 7 and ECL2. The grid 
spacing of 0.503 Å and a distance dependent function of the dielectric constant were used 
for the calculation of the energetic maps. All docked compounds were subjected to 100 
runs of Autodock search. Each run composed of 150 population size and maximum number 
of evaluations set to 25000000. The default values of all other parameters were used. All 





6.3.2.2    RMSD of ligand poses in superimposed hA3 model-ligand complexes 
               In order to compare the differences in binding orientation of ligands inside the 
binding pockets of both ‘hybrid’ model and hA2AAR-based hA3 model, the RMSD of one 
ligand pose from another was computed using the RMSD Tool in the molecular viewer and 
analysis program VMD. After loading the 3D structures of the two hA3 model-ligand 
docked complexes into VMD, a least-squares-fit of the two complexes was performed 
using backbone atoms of residues in transmembrane helices TM1 (Asn12 to Val37), TM2 
(Phe50 to Val71) and TM3 (Phe80 to Tyr109). Next, a refinement of the superposition was 
carried out using atoms of binding pocket residues identified from the binding interactions, 
namely Leu91, Phe168, Asn250, Tyr265 and Ile268. Lastly, the ligand poses were 




Chapter 6 Modeling of Binding Site - Molecular Docking 
Chapter 6 Modeling of Binding Site - Molecular Docking 
144 
 
6.3.3       Results and Discussion 
6.3.3.1 Comparison of ligand binding modes and interactions in ‘hybrid’ and     
hA2AAR-based hA3 models 
               Due to the small RMSD value of binding pocket residues found between the 
A2AAR-based model and ‘hybrid’ model (described in Section 6.2.3.3), the ligand binding 
pockets of these two models are comparable and thus they may also have similar ligand 
binding modes and interactions. To test this concept, we performed docking simulations of 
ligands to both hA3 models and the binding orientation of 2-aryl-PTPs and 2-furyl-PTPs in 
each model was then compared. We found that the binding orientations and interactions for 
ligands within these two models were indeed similar to each other. To further confirm such 
observation, we superimposed the two hA3 model-ligand docked complexes for each ligand 
following the procedures mentioned under Experimental Section. Consistently, all the 
docked ligands of both models were found to be superimposing well to each other, as 
illustrated by compounds 56, 60, 69, 25, 70  (Figures 21 (A)-(E)). Additionally, we also  
measured  the  RMSD  of  ligand  poses  in  these  superimposed  hA3   model-ligand 
complexes, and the values were found to fall within 2 Å. Based on these findings, we 
deduced  that  both ‘hybrid’  and hA2AAR-based models were in fact comparable in terms 
of ligand binding modes and interactions. Hence, the hA3 ‘hybrid’ model can be considered  
as  an  alternative  homology  model  that  is  suitable  for  the  ligand binding prediction 
other than the hA2AAR-based model. In the following sections, we discussed the binding 
modes and interactions of the new 2-aryl-PTP derivatives within the binding pocket of hA3 
‘hybrid’ model in further detail. 
 
 







             
 
   
Figure 21. Superimposition of hA3 ‘hybrid’ model-ligand complex and hA2AAR-based hA3 
model-ligand complex for compounds (A) 56; (B) 60; (C) 69; (D) 25 and (E) 70. hA3 
‘hybrid’ model is coloured blue and hA2AAR-based hA3 model is coloured red. Ligands 
docked in hA3 ‘hybrid’ model and hA2AAR-based hA3 model are both coloured light blue 
and pink, respectively. RMSD values for each pair of hA3 models are shown on top of each 
subfigure. 
 
   C         RMSD = 1.31 Å  D         RMSD = 1.49 Å   E          RMSD = 1.59 Å  
   A           RMSD = 1.81 Å B           RMSD = 1.57 Å 
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6.3.3.2  Binding interactions of 2-aryl-8-(ar)alkyl- (40-47, 49-51, 53-61, 64-74) and 2-
furyl-8-alkyl- (25, 155) PTPs in hA3 ‘hybrid’ model 
               All the 2-aryl- and 2-furyl-PTP derivatives were found to bind at the upper region 
of the hA3 ‘hybrid’ model and were surrounded by TMs 2, 3, 5, 6, 7 and ECL2. All of these 
derivatives but the N
5
-arylcarbamide-2-aryl-8-methyl-PTPs (compounds 79-90, to be 
discussed in Section 6.3.3.3) and N
5
-phenylacetamide-2-aryl-8-phenylethyl-PTPs 
(compounds 75-78, to be discussed in Section 6.3.3.4) shared the similar binding motif 
inside the TM region of the hA3 model. In these derivatives (i.e. compounds 25, 40-47, 49-
51, 53-61, 64-74 and 155), the (un)substituted phenyl ring at C
2
-position pointed towards 
the ECL2, while the free amino and amidic groups at N
5
-position facing to TMs 5 and 6, 
and the substituent at N
8
-position directed to TMs 2 and 3 (Figure 22). The binding 






-positions of these derivatives have 
been elaborated in the following sections.  
 
6.3.3.2.1 Binding interactions at the tricyclic nucleus and C
2
-position 
               The PTP tricyclic nucleus was found to interact mostly with the side chain of non-
polar residues such as Leu246 at TM6 and Phe168 at ECL2 through hydrophobic packing 
and π-π interactions, respectively. Particularly, both the conserved residues Phe168 
(equivalent to Phe171 on hA1 receptor and Phe168 on hA3 receptor) and Leu249 on hA2A 
receptor  (equivalent  to  the  Leu250 on  hA1  receptor  and  Leu246 on  hA3  receptor)  
have been  recently identified as important residues for the hA2A antagonist recognition. 
164
  
               The immediate phenyl ring at C
2
-position of the tricyclic nucleus in N
5
-amine/ 
benzamide-8-(ar)alkyl-2-aryl/furyl-PTP derivatives   (40-47,   49-51,   53-61,   64-68, 155)  




Figure 22. General topology of the hA3 ‘hybrid’ homology model. Compounds 40 
(yellow), 60 (magenta) and 69 (cyan) are docked inside the transmembrane recognition 
site. TM7 is omitted for ease of viewing.  
 
sat inside a hydrophobic pocket surrounded by the side chains of non-polar residues at TMs  
6, 7 and ECL2, such as Ile253, Leu264 and  Val169  (Figure 23).  Nevertheless, the bulky 
side chains of these non-polar residues limited the hydrophobic pocket size around the 
phenyl ring, and only certain substituents with appropriate sizes were tolerable at the para-
position of 2-phenyl ring.  Therefore,  the  introduction  of  bulky  substituents,  such  as  
NO2, CF3 and Ph at the para-position has resulted in relatively low affinity at the hA3 
receptor in compounds 45, 46, 47 and 61 (45, KihA3 = 655 nM; 46, KihA3 = 304 nM; 47, 
KihA3 = 147 nM; 61, KihA3 = 56.4 nM), mainly due to the steric hindrance imposed by 
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Figure 23. Hypothetical binding interactions of (A) compound 155 and (B) compound 40 
within the binding cavity of hA3 ‘hybrid’ homology model. Side chains of some amino 
acids important for ligand recognition are highlighted. Non-polar hydrogen atoms are not 
displayed. Hydrogen bond is represented in dashed line. 
 
hA2B and hA3 adenosine receptors, the non-polar Val169 on ECL2  (which  interacted  with 
the  2-phenyl/furyl  ring)  was  found only  in  hA3  adenosine  receptor. 
2
 In  other receptor 
subtypes, such residue was replaced by a polar glutamate  residue,  which  has  been  
identified  as  important  residue  in  hA2A  antagonist recognition. 
165
 Hence, such non-
conserved and hydrophobic residue was hypothesized to be crucial in the ligand-hA3 
receptor interaction, as well as for the hA3 versus hA2A receptor selectivity.  
               Relative to the 2-phenyl ring of N
5
-benzamide-2-aryl-8-methyl-PTPs (e.g. 
compound 60) (Figure 22), the 2-phenyl ring of N
5
-phenylacetamide-2-aryl-8-methyl-PTP 
derivatives (e.g. compound 69) was found rotated of about 60˚ towards the TM7.  As such, 
the 2-phenyl ring in compound 69 was in proximity of non-polar residues at the TMs 2, 7 
and ECL2, such as Val72, Leu264, Tyr265 and Val169, and interacted with each other 
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Figure 24. Hypothetical binding interactions of (A) compound 25 and (B) compound 69 
within the binding cavity of hA3 ‘hybrid’ homology model. Side chains of some amino 
acids important for ligand recognition are highlighted. Non-polar hydrogen atoms are not 
displayed. Hydrogen bond is represented in dashed line.  
 
hA2B and hA3 adenosine receptors, it was revealed that the same residue was found at the 
equivalent position on hA1 and hA2A receptors, while for the hA2B receptor,  an Asn residue 
was present instead. 
2
 In fact, site-directed mutagenesis of corresponding Tyr271 residue on 
hA2A to Ala has resulted in absence of specific binding to both the agonists and antagonists. 
Conversely, the mutation of this residue into Phe, His or Arg preserved the affinity of either 
agonists or antagonists. 
166
 The mutation of corresponding Asn273 residue to Tyr in hA2B 
receptor has also been shown to increase the affinity of some agonists, which have low 
affinity at hA2B receptor. 
167
 Based on these observations, it was hence deduced that the 
Tyr265 might play an important role in the hA3 antagonist recognition.   
               In addition, van der Waals interactions were also observed between the 2(para-
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residue was previously reported to be important in hA3 antagonist recognition. 
168 
Nonetheless, such interaction was not found in the 2-furyl-PTP counterpart, compound 25 
(Figure 24 (A)). It was postulated that the absence of such interaction with Gln167, might 
partly accounted for the relatively lower hA3 affinity as shown in compound 25 (KihA3 = 
0.81 nM) 
90
 versus compound 69 (KihA3 = 0.108 nM). 
 
6.3.3.2.2 Binding interactions at N
5
-position  
               The free NH2 and -CONH groups (of benzamide and phenylacetamide) at the N
5
-
position could form H-bond with nearby -C=O or HN- group on the side chain of Asn250 
(TM6). This amino acid, highly conserved among all the adenosine receptors, was shown 
to be a crucial residue involved in antagonist recognition at all the adenosine receptors as 
determined from site-directed mutagenesis experiments. 
155, 169 
To reiterate, the loss of one 
H-bond between the NH2 at N
5
 and the -C=O of Asn250 as observed in compound 155 
(KihA3 = 300 nM 
84
) (Figure 23 (A)) might contribute to the decrease in hA3 affinity as 
compared to that of compound 40 (KihA3 = 75 nM), which acquired two H-bonds between 
the NH2 and –C=O of Asn250 (Figure 23 (B)). Furthermore, the side chain of Asn250 was 
also likely to interact with the N
5
-amino or amide group through van der Waals forces. 
Besides that, the HO- side chain of Thr94 (TM3) could also interact with the carbonyl of 
amidic group via dipole-dipole interactions in the N
5
-benzamide-2-aryl-8-(ar)alkyl-PTPs, 
as illustrated by compound 60 (Figure 25). Such residue has also been associated with hA3 
antagonist recognition in the mutagenesis studies. 
2, 169
  
               The phenyl ring of benzamide moiety in compounds 56-61, 64-68 was able to 
form π-π stacking interaction with the Trp243 (TM6) (Figure 25), which is an important 
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residue in adenosine receptor activation and antagonist recognition. 
2, 169 
The corresponding 
phenyl ring also located within the boundary of a hydrophobic pocket formed by a group of 
non-polar residues at TM3 (Leu91) and TM5 (Ile186, Phe182, Met177), and interacted 
with those residues through typical hydrophobic forces. Among these residues, Phe182 and 
Met177 were shown to be essential for the hA3 receptor antagonist recognition. 
169
 On the 
other hand, the phenylacetyl group of N
5
-phenylacetamide-2-aryl-8-methyl-PTPs, such as 
compound 69, has shifted closer towards the extracellular region (Figure 22). Such group 
was surrounded by hydrophobic residues at TM6 (Leu246, Ile253) and ECL2 (Phe168, 
Val169, Met174) (Figure 24 (B)). The presence of the hydrophobic interactions around the 
N
5
-position seemed crucial for the hA3 receptor recognition. This was reflected in the 
binding assay results, in which the hA3 affinity for the N
5
-substituted derivatives was 




Figure 25. Hypothetical binding interactions of compound 60 within the binding cavity of 
hA3 ‘hybrid’ homology model. Side chains of some amino acids important for ligand 
recognition are highlighted. Non-polar hydrogen atoms are not displayed. Hydrogen bond 
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 unsubstituted counterparts (e.g. compounds 40-45). 
 





               The methyl and phenylethyl groups at N
8
-position of the pyrazole ring were 
situated within the boundary of another hydrophobic pocket consisting of a group of 
hydrophobic residues at TM2 (Val65, Leu68, Ala69), TM3 (Leu90) and TM7 (Ile268). On 
top of that, the phenyl ring of phenylethyl group in N
5
-amine- (e.g. compounds 50, 51, 53-
55)/benzamide- (e.g compounds 64-68) 8-phenylethyl-2-aryl-PTPs could also interact with 
neighbouring Tyr265 through hydrophobic interaction as well. Nonetheless, the space 
within this hydrophobic pocket was considerably limited, which imposed a stringent steric 
control around this region. Thus, bulky alkyl chains (e.g. phenylethyl) were not well-
tolerated at this position. Consistently, compounds with a methyl group at N
8
-position (e.g. 
compound 56, hA3Ki = 5.0 nM) generally have higher affinity at hA3 receptor than those 
with a phenylethyl group (e.g. compound 64, hA3Ki = 23.9 nM). At the N
7
-position of 
pyrazole ring, the lone pair of electrons on sp
2
 nitrogen was able to form a H-bond with the 
side chain of His272. This type of H-bond was found in the N
5
-phenylacetamide-2-aryl-8-
methyl-PTPs (e.g. compound 69 (Figure 24 (B)), which might explain the considerably 
high hA3 affinity shown by this group of compounds. Previous studies reported that the 
mutation of this highly conserved residue to glutamate has resulted in the decrease of hA3 
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positions of new 2-aryl-PTPs 40-47, 49-51, 53-61, 64-74 and the corresponding residues in 
hA3 receptor were summarized in the following Figure 26. 
 



















R2 = CH3, CH2CH3, Ph-CH2CH2
R = H, Ph-CO, Ph-CH2-CO











Figure 26. Hypothetical binding interactions of new series of 2-aryl-PTPs 40-47, 49-51, 
53-61, 64-74 with respective residues in hA3AR. 
a






























Val65, Leu68, Ala69 









Asn250 (TM6) Asn250 (TM6) 
Leu246, Ile253 (TM6); 
Phe168, Val169, 
Met174 (ECL2) 
Leu91 (TM3); Ile186, 
Phe182, Met177 (TM5); 
Trp243 (TM6) 
Residue: Involved in H-bonding                                     Residue: Involved in pi-pi interaction 
Residue: Involved in van der Waals interaction              Residue: Involved in hydrophobic interaction 
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6.3.3.3 Binding interactions of N
5
-arylcarbamides-2-aryl- (79-90) and N
5
-
arylcarbamide-2-furyl- (158) 8-methyl-PTPs in hA3 model 
               The N
5
-arylcarbamide-2-aryl-8-methyl-PTPs (79-90) showed a different binding 
mode from the other 2-aryl-PTPs in the hA3 binding cavity. As illustrated by compound 87, 
the 2-aryl ring at C
2
-position and substituent at N
8
-position faced towards the intracellular 
region, while the arylcarbamoyl groups at N
5
-position pointed to the ECL2 (Figure 27 
(A)). Such 180˚ flipping of orientation of 2-aryl ring and N5-substituent relative to other 2-
aryl derivatives (e.g. compounds 60, 69) inside the hA3 binding site was postulated to be 
due to the rigid and bulky arylcarbamoyl chain in compound 87, being intolerable inside 
the intracellular region which is constraint in space. As a result, the arylcarbamoyl moiety 
flipped towards the extracellular side in order to maintain the binding interaction with A3 
receptor. Notably, shorter and less bulky group like benzamide (e.g. compound 60) at N
5
-
position was found relatively tolerable in such intracellular space. On the other hand, a 
bulky yet flexible group like phenylacetamide (e.g. compound 69) was observed to have 
shifted closer towards the extracellular region as mentioned earlier. 
               Two H-bonds between the -NHs on N
5
-arylcarbamide and O=C- on side chain of 
Asn250 (TM6), together with π-π stacking between the pyrimidine ring and Phe168 
(ECL2) were among the interactions found in this group of compounds (Figure 27 (C)). 
The 4-chloro atom at the 2-phenyl ring was also found to engage van der Waals (dipole-
dipole) interaction with the side chain of Ser181 (TM5). Besides that, other hydrophobic 







residues like Ala69 (TM2), Leu90 (TM3), Leu91 (TM3), Thr94 (TM3), (TM6), Ile253 
(TM6), Val259 (ECL3), Leu264 (TM7), Ile268 (TM7) were noticed as well. 




Figure 27. (A) Binding pose of compound 87 inside the binding cavity of hA3 ‘hybrid’ 
homology model. TM7 is omitted for ease of viewing.  
 
      
Figure 27 (cont.). Hypothetical binding interactions of (B) compound 158 and (C) 
compound 87 within the binding cavity of hA3 ‘hybrid’ homology model. Side chains of 
some amino acids important for ligand recognition are highlighted. Non-polar hydrogen 
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              In comparison, similar binding mode and interactions were also observed for the 
2-furyl analogue (compound 158), but with one additional H-bond formed between N
1
 on 
triazole ring and HN- on side chain of Asn250 (Figure 27 (B)). Such additional H-bond 
was postulated to have brought about the higher hA3 affinity in the 2-furyl analogues 
(compound 158, KihA3 = 0.20 nM) 
84, 91
 as compared the 2-aryl derivatives (compound 87, 
KihA3 = 1.33 nM). 







positions of new 2-aryl-PTPs 79-90 and the corresponding residues in hA3 receptor were 

















R = H, F, OCH3
 
 
Figure 28. Hypothetical binding interactions of new series of 2-aryl-PTPs 79-90 with 
respective residues in hA3 ‘hybrid’ homology model. 
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Ser181 (TM5) 
Leu91, Thr94 (TM3); 






Ala69 (TM2);  
Ile268 (TM7) 
Leu249, Ile253 (TM6); 
Leu264 (TM7); Val169, 
Met174 (ECL2); Val259 
(ECL3) 
Residue: Involved in H-bonding                                     Residue: Involved in pi-pi interaction 
Residue: Involved in van der Waals interaction              Residue: Involved in hydrophobic interaction 
157 
 
6.3.3.4 Binding interactions of N
5
-phenylacetamide-2-aryl- (75-78) and N
5
-
phenylacetamide 2-furyl- (157) 8-phenylethyl-PTPs in hA3 model 
               The N
5
-phenylacetamide-2-aryl-8-phenylethyl-PTPs (75-78) also presented a 
different binding motif within the hA3 binding pocket. As illustrated by compound 75, the 
2-aryl ring shifted to the intracellular region in proximity of TM3, TM5 and TM6; the 
phenylethyl at N
8
-position oriented closer to the extracellular region and was surrounded 
by TM5, TM6 and ECL2, while the N
5
-phenylacetyl chain pointed towards TM2 (Figure 





-phenylethyl chain seemed intolerable within the limited space surrounded 
by TM2 and TM3, a region where the N
8
-substituents of the other PTP derivatives were 
commonly situated in. To overcome such steric hindrance and therefore sustain the binding 
with the receptor, the N
8
-phenylethyl shifted to the extracellular side, which was relatively 
more spacious. In turn, the 2-aryl ring moved towards intracellular region, whereas the N
5
-
phenylacetamide switched closer to the TM2. 
               In terms of binding interactions (Figure 29 (C)), a H-bond between N
4
 on triazole 
ring and HN- on side chain of Asn250 (TM6), as well as π-π stacking interaction between 
pyrimidine ring and Phe168 (ECL2) were observed.  The C=O group on N
5
-position could 
also engage some forms of van der Waals interaction with the neighbouring side chain of 







-phenylethyl) and residues like Val65 (TM2), Leu68 (TM2), Ala69 
(TM2), Val72 (TM2), Met86 (TM3), Thr87 (TM3), Leu91 (TM3), Thr94 (TM3), Val169 
(ECL2), Met177 (TM5), Trp243 (TM6), Leu246 (TM6), Ile253 (TM6), Leu264 (TM7), 
Ile268 (TM7) were also noted.  




Figure 29. (A) Binding pose of compound 75 inside the binding cavity of hA3 ‘hybrid’ 
homology model. TM7 is omitted for ease of viewing.  
 
       
Figure 29 (cont.). Hypothetical binding interactions of (B) compound 157 and (C) 
compound 75 within the binding cavity of hA3 ‘hybrid’ homology model. Side chains of 
some amino acids important for ligand recognition are highlighted. Non-polar hydrogen 































Chapter 6 Modeling of Binding Site - Molecular Docking 
159 
 
             On the other hand, the 2-furyl analogue (compound 157) seemed unable to fit 
properly within the binding pocket in which compound 75 was situated and failed to 
interact with corresponding residues as mentioned above (Figure 29 (B)). Particularly, the 
H-bond and hydrophobic packing with neighbouring residues were absent in such 2-furyl 
analogue. It was suggested that the loss of these interactions could have contributed to the 
lower hA3 affinity of the 2-furyl derivative (compound 157, KihA3 = 45 nM) 
87
 relative to 
the 2-aryl counterpart (compound 75, KihA3 = 3.02 nM).    







positions of new 2-aryl-PTPs 75-78 and the corresponding residues in hA3 receptor were 


















Figure 30. Hypothetical binding interactions of new series of 2-aryl-PTPs 75-78 with 
respective residues in hA3 ‘hybrid’ homology model. 
Residue: Involved in H-bonding                                     Residue: Involved in pi-pi interaction 







Leu91, Thr94 (TM3); 





Val65, Leu68, Ala69, 
Val72 (TM2); Met86, 
Thr87 (TM3)  
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6.3.3.5  Binding interactions of 2-aryl- (40, 69) and 2-furyl- (25, 155) PTPs in hA2A 
receptor  
               The hypothetical binding poses of N
5
-unsubstituted 2-furyl-PTP (e.g. compound 
155) 
84
 and 2-aryl-PTP derivatives (e.g. compound 40) inside the cavity of hA2A receptor 
(Figure 31 (A)) were observed to be different from each other. At the hA2A receptor, 
compound 155, with the 2-furyl ring in vicinity of TMs 5 and 6, formed two H-bonds with 
Asn253  (TM6)  and  another  H-bond  with  Glu169  (ECL2)  (Figure 31 (B)). These two 
residues have been indicated to play an important role in ligand binding at the hA2AAR. 
165, 
166
 On the other hand, compound 40 only formed two H-bonds with Asn253 (Figure 31 
(C)). The different orientation of such ligand inside the A2A receptor, with the 2-phenyl 
ring pointed towards the TM2, has resulted in the loss of a H-bond with Glu169. This could 
have justified the fact that compound 40 possessed much lower hA2A affinity (KihA2A = 
121nM) as compared to the 2-furyl-PTP analogue (compound 155, KihA2A = 2.80nM 
84
).  
In  addition,  π-π stacking  interaction  between  the  triazole  ring  and  Phe168  (ECL2)  
were  noticed  in  both compounds 40 and 155. The hydrophobic interactions with some 
residues of  the  binding  site,  including  Met177  (TM5),  Trp246  (TM6),  Leu249  
(TM6), His250 (TM6), Met270 (TM7) and Ile274 (TM7) were also observed for compound 
155, while compound 40 were surrounded by hydrophobic residues like Met177 (TM5), 
Leu249 (TM6), Met270 (TM7) and Tyr271 (TM7). The comparatively less hydrophobic 
packing by neigbouring non-polar residues in compound 40 might have also resulted in low 
affinity at hA2AAR relative to the compound 155. 
                For both N
5
-substituted 2-furyl- (e.g. compound 25) 
90
 and 2-aryl- (e.g. compound 
69)  PTPs,  the binding pose inside the binding cleft of the hA2A receptor was similar to each 




Figure 31. (A) Binding poses of compound 155 (purple) and 40 (yellow) inside the binding 
cavity of hA2A receptor. TM7 is omitted for ease of viewing.  
       
Figure 31 (cont.). Hypothetical binding interactions of (B) compound 155 and (C) 
compound 40 within the binding cavity of hA2A receptor. Side chains of some amino acids 
important for ligand recognition are highlighted. Non-polar hydrogen atoms are not 
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other (Figure 32 (A)). The 2-furyl and 2-phenyl ring were surrounded by TM2 and TM3, 
while the N
5
-subtituents were pointed towards the extracellular region. In both compounds, 
only one H- bond was formed between N
7
-position of ligand and the side chain of Asn253 
(TM6) (Figure 32 (B) and (C)). Because of the presence of N
5
-substitution, the derivative 
could not form the H-bond with Glu169 (ECL2) as observed for N
5
-unsubstituted analogues. 
This finding justified the low hA2A affinity as seen in majority of the N
5
-substituted 2-aryl-PTP 
derivatives. The π-π stacking interaction between the pyrimidine ring and the Phe168 (EL2) 
and hydrophobic interactions with residues, including Ala63 (TM2), Ile66 (ECL1), Ile80 
(TM3),  Ala81  (TM3),  Val84  (TM3),  Met177  (TM5),  Trp246  (TM6),  Leu249  (TM6), 
Ile274 (TM7) and Tyr271 (TM7) were also noticed. Furthermore, at the hA2A receptor, the 
hydrophobic side cleft delimited by TM2 and TM3 could well accommodate the 2-furyl ring of 
compound 25, but hardly accommodate the 2-phenyl ring of the 2-aryl PTPs. This steric effect 
could be the reason for the difference in affinity between the 2-aryl and the 2-furyl analogues at 
this receptor subtype. For the same reason, the presence  of  para-substituents  on  the  phenyl  
ring  led  to  a drastic decrease of affinity at hA2A receptor, up to complete  loss  of  affinity  for  
bulkier  substituents  (compound 25,  KihA2A  =  432nM 
90
 versus compound 60, KihA2A > 
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Figure 32. (A) Binding poses of compound 25 (orange) and 69 (cyan) inside the binding 
cavity of hA2A receptor. TM7 is omitted for ease of viewing. 
                                    
Figure 32 (cont.). Hypothetical binding interactions of (B) compound 25 and (C) 
compound 69 within the binding cavity of hA2A receptor. Side chains of some amino acids 
important for ligand recognition are highlighted. Non-polar hydrogen atoms are not 
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6.3.4     Conclusion 
             The similar binding orientation of ligands found in both binding pockets of 
‘hybrid’ and hA2AAR-based hA3 models, as well as comparable binding interactions with 
nearby residues substantiated our inference that the hA3 ‘hybrid’ model could be a reliable 
alternative for ligand binding prediction in docking studies. Through the docking 
simulations based on the hA3 ‘hybrid’ model, all the experimental SAR findings of 2-aryl-
PTP derivatives have been successfully rationalized.  
            Depending on the length of substituents at the N
5
- and (or) N
8
-positions of the PTP 
scaffold, different binding modes inside the hA3 model and hA2AAR were observed for 
both the 2-aryl- and 2-furyl-PTP derivatives. Generally, the binding interactions found 







-substituents and non-polar residues deemed crucial 











 on pyrazole ring in engaging H-bond with nearby residues; (iii) 
aromatic moiety like triazolo/pyrimidine ring on the tricylic nucleus and phenyl ring of 
benzoyl group at N
5
 to form π-π interaction with the nearby aromatic residues; (iv) van der 
Waals interaction (e.g. dipole-dipole) between the polar moiety (such as amidic group at 
N
5
, polar substituents at para-position of 2-phenyl ring) and the polar residues in vicinity. 
For the binding interactions at hA2AAR, it was deduced that the loss of H-bonding, as well 
as steric hindrance imposed by the 2-aryl ring within the small binding pocket surrounded 
by TM2 and TM3 could account for the decrease in hA2A affinity observed for the new 2-
aryl-PTPs, which resulted in subsequent increase of selectivity against this particular 
receptor subtype. 
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Chapter 7 Concluding Remarks and Future Perspectives 
               In this thesis, we tested the hypothesis that the replacement of existing 2-furyl 




-positions of the 
PTP scaffold, would result in an improved pharmacological profile towards the hA3 
receptor subtypes. We also tested the other hypothesis, for which the application of 
theoretical studies (such as QSAR, homology modeling and molecular docking studies) in 
tandem would be useful in rationalizing the experimental results obtained from the 
pharmacological assays through identification of important structural features and binding 
interactions responsible for the hA3 affinity of such new 2-aryl-PTPs. 
               A new series of 2-[(para-(un)substituted)-phenyl]-pyrazolo[4,3-e]-1,2,4-triazolo-
[1,5-c]-pyrimidines has been designed and synthesized successfully in this project. The 
bioisosteric replacement of the furan ring with a phenyl ring at the C
2
-position has led to 
the identification of such new series of 2-aryl-PTP derivatives as hA3AR antagonists with 
good hA3 affinity and remarkably improved selectivity profile towards the other adenosine 
receptor subtypes in comparison to the 2-furyl-PTP derivatives. Particularly, the 2-aryl-
PTP derivatives bearing a N
5
-amine/benzamide/phenylacetamide (e.g. compounds 69 and 
73) showed approximately 3-15 folds increase of hA3 affinity and significant improvement 
in selectivity of 2-3 orders of magnitude relative to the 2-furyl counterparts. Furthermore, 
the substitution of 2-furyl with an aryl group in the new PTP derivatives is also expected to 
overcome the metabolic instability due to the C
2
-furan ring. In the subsequent series of 2-
aryl-PTPs bearing a N
5
-arylcarbamoyl chain, even though the same bioisosteric 
replacement of existing furan ring with an aryl ring has caused significant decrease of 
affinity towards the A3 receptor as compared to the 2-furyl analogues, these derivatives still 
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possess good hA3 affinities in the low nanomolar range. Besides that, the selectivity over 
other adenosine receptor subtypes of such series of 2-aryl-PTPs was also noticed to have 
considerably improved relative to that of 2-furyl derivatives. 
               Additional functional assay (adenylyl cyclase activity assay), which was 
performed to determine the effect on the hA3 agonist-inhibited cAMP production upon 
administration of some representative compounds (e.g. compound 73), has confirmed that 
these new derivatives were indeed functional antagonists and showed equivalent IC50 
trends with that of  hA3 binding affinity results. Based on the experimental data from both 
the binding and functional assays, a detailed structure-affinity relationship profile for the 
new 2-aryl-PTP derivatives as hA3AR antagonists has been successfully derived.  
               Among the molecular modeling investigations executed in this project, the 
CoMFA-based QSAR study has provided new insights on the steric and electrostatic 
controls that are crucial for modulating hA3 affinity in the new series of 2-aryl-PTPs, 
particularly at the unprecedentedly explored C
2
-position of the tricyclic nucleus. Notably, 
the steric effect of substituents on the PTP scaffold seems to play a more important role for 
the antagonist recognition towards the hA3 receptor. Such ligand-based QSAR model has 
ameliorated the pharmacophore elucidation for the PTP derivatives as potent hA3AR 
antagonists. 
               The receptor-based computational approach, such as molecular docking 
simulations was performed based on a hA3 ‘hybrid’ homology model. This dual template-
based hA3 model demonstrated improvement in the stereochemistry parameters relative to 
the hA2A-based hA3 model and was able to predict comparable binding modes and 
interactions for the PTP derivatives. Through the docking studies, the experimental SAR 
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and selectivity over hA2AAR of the 2-aryl-PTPs have been successfully rationalized. 






-positions, H-bond acceptor at the 
N
5
-amide, as well as π-π stacking with the tricyclic nucleus were considered crucial for the 
hA3 affinity. Moreover, the loss of H-bonding and steric hindrance imposed by the 2-aryl 
ring within the small binding pocket surrounded by TM2 and TM3 of hA2AAR, was 
deduced to be the reason for the decrease in hA2A affinity of the 2-aryl-PTPs and 
subsequent increase of selectivity against such receptor subtype. 
              In summary, the rational design and synthesis of this new series of 2-[(para-
(un)substituted)-phenyl]-pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidines have given rise 
to a class of potent and highly selective hA3AR antagonists. Overall, the combination of 
experimental and theoretical approaches applied in our study has provided new insights on 
the structural features and binding interactions responsible for the hA3 affinity of such new 
PTP derivatives. 
               Nevertheless, additional work is considered worthwhile to be followed up in 
future investigations. Particularly, there is one important issue which should be addressed, 
that is the water solubility profile of the new series of 2-aryl-PTP derivatives.  These 
compounds are in fact, practically insoluble in water. This could be due to the highly 
lipophilic, pseudoplanar and aromatic characteristics of these derivatives, which has 
resulted in low water solubility. In order to overcome such limitation, the same approach 
applied in the synthesis of previously reported potent, selective and water-soluble 
compound 31 can be adopted in this case, by substituting the phenyl ring at N
5
-position 
with a pyridinium salt. Alternatively, a pyridinium ring can also be introduced at the C
2
-
position to achieve the same purpose. In this way, such simple bioisosteric replacement 
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might improve the water solubility, without imposing further steric hindrance within the 
hA3 binding pocket. Besides that, it might be worthwhile to conduct appropriate in vitro 
assay to detect the formation of reactive metabolites from the biotransformation of 2-furyl-
PTP analogues versus that of the 2-aryl-PTP counterparts in order to justify the point that 
the new series of 2-aryl-PTPs can indeed overcome the metabolic instability due to the 2-
furyl ring of the 2-furyl-PTPs. From the pharmacological perspectives, in vivo bioassays to 
evaluate the anti-inflammatory or anti-tumor properties of the compounds should also be 
designed and performed using some of the 2-aryl-PTP derivatives identified as potent and 
highly selective hA3AR antagonists, such as compounds 69 and 73. Other modeling studies 
such as molecular dynamics simulations to simulate the dynamic environment for receptor-
ligand docked complex and further refine the binding mode and interactions between the 
ligand and receptor residues could also be attempted. Last but not least in importance, the 
significance of the 2 residues (Val169 and Tyr265) in antagonist recognition as proposed 
from the molecular docking simulations is deemed necessary for other biological 
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Table A1. Binding affinities of reported PTP derivatives at A1, A2A, A2B and A3 adenosine 
receptors. 
Compounds 

























 ND ND [77,78] 




 ND >10,000 [78-80] 




 ND >10,000 [78-80] 
12, [
3










 ND >10,000 [79] 
15, SCH 442416 1,111 0.048 >10,000 >10,000 [81] 
16, MRS 5346 -- KD = 16.5 nM -- -- [82] 
17 4,927 4.63 >10,000 >10,000 [80] 
18 190 100 >10,000 >10,000 [80] 
19 2,160 0.22 >10,000 >10,000 [80] 
20 1 0.34 5.1 280 [83, 84] 
21 >960 0.6 ND ND [85] 
22, SCH 420814 >1,000 1.1 >1,700 >1,000 [85] 
A2B adenosine receptor antagonist 
23 2 0.8 9 700 [86] 
24 1.6 54 27 65 [86] 
25 702 423 165 0.81 [87] 
26 1,100 800 20 300 [87] 
A3 adenosine receptor antagonist 
28 1,026 1,040 245 0.6 [83] 
29  594 381 222 0.16 [84,90-92] 
30, [
3
H]MRE-3008-F20 -- -- -- KD = 0.8 nM [93] 
31 350 100 250 0.01 [96] 
32 150 21 37 17 [97] 
33 70 3.1 24 212 [97] 
ND: Not determined. 
a,b,c,d 
binding affinity assay determined using recombinant cells 
expressing human A1AR, A2AAR, A2BAR and A3AR, unless noted. 
e
 binding affinity assay 
determined at A1AR in rat brain membranes. 
f
 binding affinity assay determined at A2AAR 




Table A2. Combustion analysis data of the newly synthesized compounds (40-90). 
Compd. Formula MW 
Theoretical values Experimental values 
% C % H % N % C % H % N 
40 C13H11N7 265.27 58.86 4.18 36.96 58.80 4.33 36.75 
41 C13H10N7F 283.26 55.12 3.56 34.61 55.36 3.37 34.53 
42 C13H10N7Cl 299.72 52.10 3.36 32.71 52.19 3.15 32.79 
43 C13H10N7Br 344.17 45.37 2.93 28.49 45.66 2.47 28.32 
44 C14H13N7O 295.30 56.94 4.44 33.20 57.20 4.39 33.10 
45 C13H10N8O2 310.27 50.32 3.25 36.11 50.44 3.18 36.25 
46 C14H10N7F3 333.27 50.45 3.02 29.42 50.63 3.00 29.80 
47 C19H15N7 341.37 66.85 4.43 28.72 66.94 4.18 28.94 
48 C14H12N7Cl 313.74 53.59 3.86 31.25 54.00 3.74 31.13 
49 C14H12N7Cl 313.74 53.59 3.86 31.25 53.76 3.91 31.67 
50 C20H17N7 355.40 67.59 4.82 27.59 67.64 4.86 27.76 
51 C20H16N7F 373.39 64.33 4.32 26.26 64.36 4.34 26.36 
52 C20H16N7Cl 389.84 61.62 4.14 25.15 61.69 4.16 25.23 
53 C20H16N7Cl 389.84 61.62 4.14 25.15 61.75 4.12 25.34 
54 C20H16N7Br 434.29 55.31 3.71 22.58 55.40 3.76 22.76 
55 C21H19N7O 385.42 65.44 4.97 25.44 64.49 4.53 25.36 
56 C20H15N7O 369.38 65.03 4.09 26.54 65.21 4.34 26.61 
57 C20H14N7OF 387.37 62.01 3.64 25.31 61.88 3.59 25.67 
58 C20H14N7OCl 403.82 59.48 3.49 24.28 59.02 3.65 24.35 
199 
 
Compd. Formula MW 
Theoretical values Experimental values 
% C % H % N % C % H % N 
59 C20H14N7OBr 448.28 53.59 3.15 21.87 53.74 3.01 21.47 
60 C21H17N7O2 399.41 63.15 4.29 24.55 63.55 4.18 24.32 
61 C20H14N8O3 414.38 57.97 3.41 27.04 58.01 3.68 27.13 
62 C28H21N7O3 503.51 66.79 4.20 19.47 67.01 4.33 19.44 
63 C27H18N7O2Cl 507.93 63.85 3.57 19.30 64.00 3.67 19.35 
64 C27H21N7O 459.18 70.57 4.61 21.34 70.68 4.59 21.50 
65 C27H20N7OF 477.17 67.91 4.22 20.53 68.06 4.38 20.53 
66 C27H20N7OCl 493.14 65.65 4.08 19.85 65.18 4.13 20.02 
67 C27H20N7OBr 537.09 60.23 3.74 18.21 60.44 3.68 18.65 
68 C28H23N7O2 489.53 68.70 4.74 20.03 68.42 4.55 20.18 
69 C21H17N7O 383.41 65.79 4.47 25.57 66.02 4.62 25.42 
70 C21H16N7OF 401.40 62.84 4.02 24.43 62.34 4.17 24.31 
71 C21H16N7OCl 417.85 60.36 3.86 23.46 60.71 3.49 23.98 
72 C21H16N7OBr 462.30 54.56 3.49 21.21 54.63 3.57 21.15 
73 C22H19N7O2 413.43 63.91 4.63 23.72 64.02 4.88 23.81 
74 C21H16N8O3 428.40 58.88 3.76 26.16 59.03 3.61 26.10 
75 C28H23N7O 473.20 71.02 4.90 20.71 71.54 5.26 20.17 
76 C28H22N7OF 491.19 68.42 4.51 19.95 69.11 4.94 20.62 
77 C28H22N7OCl 507.16 66.20 4.37 19.30 66.79 4.52 18.73 
78 C28H22N7OBr 552.42 60.88 4.01 17.75 61.51 4.39 17.32 
200 
 
Compd. Formula MW 
Theoretical values Experimental values 
% C % H % N % C % H % N 
79 C20H15N8OCl 418.84 57.35 3.61 26.75 57.26 3.40 27.12 
80 C20H15N8OBr 463.29 51.85 3.26 24.19 51.39 3.14 24.36 
81 C21H15N8OF3 452.39 55.75 3.34 24.77 55.71 3.80 24.33 
82 C26H20N8O 460.49 67.81 4.38 24.33 67.79 4.33 24.26 
83 C20H14N8OFCl 436.83 54.99 3.23 25.65 55.10 3.43 25.88 
84 C20H14N8OFBr 481.28 49.91 2.93 23.28 49.81 2.49 23.68 
85 C21H14N8OF4 470.38 53.62 3.00 23.82 53.97 2.78 23.86 
86 C26H19N8OF 478.48 65.26 4.00 23.42 65.64 3.78 23.11 
87 C21H17N8O2Cl 448.87 56.19 3.82 24.96 56.65 3.51 24.37 
88 C21H17N8O2Br 493.32 51.13 3.47 22.71 51.58 3.18 22.66 
89 C22H17N8O2F3 482.42 54.77 3.55 23.23 55.10 3.68 23.51 













H NMR spectroscopic data of synthesized intermediates 119-132, 149, 151, 152. 
 
2-(phenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (119): 
Yield 60%, pale yellow solid, 
1
H NMR (300MHz, DMSO-d6) δ: 4.03 (3H, s, Me), 7.54-
7.57 (3H, m, aromatic H), 8.22 (2H, d, aromatic H, 
3
JHH = 7.5 Hz), 8.93 (1H, s, pyrazolo-
H), 9.45 (1H, s, pyrimidino-H). 
2-(4-fluoro-phenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (120):  
Yield 60%, pale yellow solid, 
1
H NMR (300MHz, DMSO-d6) δ: 4.02 (3H, s, Me), 7.40 
(2H, dd, aromatic H, 
3
JHH = 8.7 Hz, 
3
JHF = 8.7 Hz), 8.25 (2H, dd, aromatic H, 
3
JHH = 8.7 
Hz, 
4
JHH = 5.7 Hz), 8.92 (1H, s, pyrazolo-H), 9.46 (1H, s, pyrimidino-H). 
2-(4-chlorophenyl)-8-methylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (121): 
Yield 62%, yellow solid, 
1
H NMR (300 MHz, DMSO-d6): δ 4.21 (3H, s, CH3), 7.64 (2H, d, 
aromatic H, 
3
JHH = 8.7 Hz), 8.23 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.92 (1H, s, pyrazolo-
H), 9.46 (1H, s, pyrimidino-H). 
2-(4-bromophenyl)-8-methylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (122): 
Yield 64%,  yellow solid, 
1
H NMR (300 MHz, DMSO-d6): δ 4.21 (3H, s, CH3), 7.78 (2H, 
d, aromatic H, 
3
JHH = 8.3 Hz), 8.16 (2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.92 (1H, s, 
pyrazolo-H), 9.46 (1H, s, pyrimidino-H). 
2-(4-methoxy-phenyl)-8-methyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (123): 
Yield 61%,  pale yellow solid, 
1
H NMR (300 MHz, DMSO-d6): δ 3.84 (3H, s, OMe), 4.19 
(3H, s, CH3), 7.12 (2H, d, aromatic H, 
3
JHH = 8.7 Hz), 8.16 (2H, d, aromatic H, 
3
JHH = 8.7 




Yield 57%,  yellow solid, 
1
H NMR (300 MHz, DMSO-d6): δ 4.04 (3H, s, Me), 8.42 (2H, d, 
aromatic H, 
3
JHH = 9.0 Hz), 8.47 (2H, d, aromatic H, 
3
JHH = 9.0 Hz), 8.95 (1H, s, pyrazolo-
H), 9.49 (1H, s, pyrimidino-H). 
2-(4-chloro-phenyl)-7-ethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (125):  
Yield 34%, yellow solid, 
1
H NMR (300MHz, CDCl3) δ: 1.57 (3H, t, CH3,  
3
JHH = 7.2 Hz), 




JHH = 7.2 Hz), 7.47 (2H, d, aromatic H, 
3
JHH = 8.4 Hz), 8.23 (2H, d, 
aromatic H, 
3
JHH = 8.4 Hz), 8.37 (1H, s, pyrazolo-H), 9.07(1H, s, pyrimidino-H).  
2-(4-chloro-phenyl)-8-ethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (126):  
Yield 58%, yellow solid, 
1
H NMR (300MHz, CDCl3) δ: 1.62 (3H, t, CH3,  
3
JHH = 7.2 Hz), 




JHH = 7.2 Hz), 7.48 (2H, d, aromatic H, 
3
JHH = 8.4 Hz), 8.22 (2H, d, 
aromatic H, 
3
JHH = 8.4 Hz), 8.35 (1H, s, pyrazolo-H), 9.08 (1H, s, pyrimidino-H).  
2-(phenyl)-8-phenylethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (127):  
Yield 56%, yellow solid, 
1
H NMR (300MHz, DMSO-d6) δ: 3.32 (2H, t, Ph-CH2, 
3
JHH = 7.2 




JHH = 7.2 Hz), 7.17-7.28 (5H, m, aromatic H), 7.55-7.59 (3H, m, 
aromatic H), 8.25 (2H, d, aromatic H, 
3
JHH = 7.5 Hz), 8.53 (1H, s, pyrazolo-H), 9.30 (1H, s, 
pyrimidino-H). 
2-(4-fluorophenyl)-8-phenylethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine 
(128): Yield 55%, pale yellow solid, 
1
H NMR (300MHz, DMSO-d6) δ: 3.32 (2H, t, Ph-
CH2, 
3




JHH = 7.2 Hz), 7.13-7.28 (5H, m, aromatic H), 
7.39 (2H, dd, aromatic H, 
3
JHH = 9.0 Hz, 
3





JHF = 5.7 Hz), 8.53 (1H, s, pyrazolo-H), 9.30 (1H, s, pyrimidino-H). 
2-(4-chlorophenyl)-7-phenylethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine 
(129): Yield 26%, pale yellow solid, 
1









JHH = 7.2 Hz), 7.18-7.26 (5H, m, aromatic H), 
7.60 (2H (d, aromatic H, 
3
JHH = 8.4 Hz), 8.17 (2H, d, aromatic H, 
3
JHH = 8.4 Hz), 8.53 (1H, 
s, pyrazolo-H), 9.30 (1H, s, pyrimidino-H). 
2-(4-chlorophenyl)-8-phenylethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine 
(130): Yield 54%, orange solid, δ: 3.32 (2H, t, Ph-CH2, 
3





JHH = 7.2 Hz), 7.19-7.29 (5H, m, aromatic H), 7.64 (2H, d, aromatic H, 
3
JHH = 8.4 
Hz), 8.21 (2H, d, aromatic H, 
3
JHH = 8.4 Hz), 8.53 (1H, s, pyrazolo-H), 9.30 (1H, s, 
pyrimidino-H). 
2-(4-bromophenyl)-8-phenylethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine 
(131): Yield 60%, beige solid, 
1
H NMR (300MHz, DMSO-d6) δ: 3.32 (2H, t, Ph-CH2, 
3
JHH 




JHH = 7.2 Hz), 7.19-7.29 (5H, m, aromatic H), 7.77 (2H, d, 
aromatic H, 
3
JHH = 8.4 Hz); 8.14 (2H, d, aromatic H, 
3
JHH = 8.4 Hz), 8.53 (1H, s, pyrazolo-
H), 9.30 (1H, s, pyrimidino-H). 
2-(4-methoxyphenyl)-8-phenylethyl-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine 
(132): Yield 53%, pale yellow solid, 
1
H NMR (300MHz, DMSO-d6) δ: 3.32 (2H, t, Ph-
CH2, 
3




JHH = 7.2 Hz), 7.10 (2H, d, 
aromatic H, 
3
JHH = 8.7 Hz), 7.14-7.26 (5H, m, aromatic H), 8.14 (2H, d, aromatic H, 
3
JHH = 
8.7 Hz), 8.53 (1H, s, pyrazolo-H), 9.30 (1H, s, pyrimidino-H). 
[(2Z)-2-benzylidenehydrazino]methylene}malononitrile (A) and [(2E)-2-
benzylidenehydrazino]methylene}malononitrile (B) (4:1) (149) 
Yield 82%, yellow solid,
 1
H NMR (300 MHz, DMSO-d6): δ 7.43-7.52 (3H, m, aromatic 
HA+B), 7.64-7.73 (2H, m, aromatic HB), 7.76-7.84 (2H, m, aromnatic HA), 7.86 (1H, s, 





Yield 50%, pale yellow solid 
1
H NMR (300 MHz, DMSO-d6): δ 4.21 (3H, s, CH3), 7.95 
(2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.43 (2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.94 (1H, s, 
pyrazolo-H), 9.50 (1H, s, pyrimidino-H).  
2-(4-biphenyl)-8-methylpyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (152): 
Yield 50% pale yellow solid, 
1
H NMR (300 MHz, DMSO-d6): δ 4.21 (3H, s, CH3), 7.42 
(1H, t, aromatic H,  
3
JHH = 7.2 Hz), 7.52 (2H, t, aromatic H, 
3
JHH = 7.5 Hz), 7.78 (2H, d, 
aromatic H, 
3
JHH = 7.5 Hz), 7.89 (2H, d, aromatic H, 
3
JHH = 8.3 Hz), 8.32 (2H, d, aromatic 
H, 
3



















Figure A1. (A) Sequence alignment between hA3 receptor target sequence (AA3R) and 
human β2-adrenergic receptor template (2RH1). T4 lysozyme is removed from the protein 
sequence. The highly conserved pattern of LAXAD motif, DRY motif, Prolines in TMs 4, 
5, 6 and the NPXXY motif are marked with box in magenta. The conserved residues are 

















Figure A1. (B) Sequence alignment between hA3 receptor target sequence (AA3R) and 
hA2AAR template (3EML). T4 lysozyme is removed from the protein sequence. The highly 
conserved pattern of LAXAD motif, DRY motif, Prolines in TMs 4, 5, 6 and the NPXXY 


















Figure A1. (C) Sequence alignment between hA3 receptor target sequence (AA3R) and the 
‘hybrid’ template (3EML & 2RH1). T4 lysozyme is removed from the protein sequences. 
The highly conserved pattern of LAXAD motif, DRY motif, Prolines in TMs 4, 5, 6 and 
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Figure A3. (A) Ramachandran Plot for human β2-adrenergic receptor-based hA3 homology 
model ([A,B,L]: most favoured regions; [a,b,l,p]: additional allowed regions; [~a,~b,~l,~p]: 
generously allowed regions). 
 
 
Figure A3. (B) Ramachandran Plot for hA2AAR-based hA3 homology model ([A,B,L]: 
most favoured regions; [a,b,l,p]: additional allowed regions; [~a,~b,~l,~p]: generously 








Figure A3. (C) Ramachandran Plot for ‘hybrid’ template-based hA3 homology model 
([A,B,L]: most favoured regions; [a,b,l,p]: additional allowed regions; [~a,~b,~l,~p]: 
generously allowed regions). 
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